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ABSTRACT 
 
New Strategies in the Localization of Natural Product Biosynthetic Pathways and 
Achieving Heterologous Expression. (December 2009) 
Eun Jin Kim,  
B.S., M.S., Korea National University of Education;  
M.S., Texas A&M University, 
Chair of Advisory Committee:  Dr. Coran M. H. Watanabe 
 
Natural products have long furnished medical science playing a significant role in 
drug discovery and development. Their importance notwithstanding, it is estimated that 
less than 1% of microorganisms can be cultivated from environmental sources using 
standard laboratory techniques. It is therefore necessary to develop biochemical and 
genetic techniques to access these uncultivable genomes.   
Here as a point of departure toward this goal, two cDNA libraries of two 
microorganisms were constructed along with five fosmid libraries with DNA isolated 
from marine environmental samples. We describe the construction of cDNA libraries 
from marine microbial species and detail experiments to exploit these libraries for their 
natural product biosynthetic pathways and other metabolic enzymes they harbor. 
However, no useful biosynthetic pathways were detected within the cDNA libraries.  
 Genetic selection by complementation was additionally explored as a method to 
identify and localize biosynthetic gene clusters within marine microbial DNA libraries.  
Genetic selection is a fast and economic method which utilizes selection of a part of a 
  
iv 
pathway to represent the presence of an entire pathway for the complementation of 
known mutant strains.  We describe genetic selection to localize biotin biosynthetic 
pathways of Hon6 (Chromohalobacter sp.) as a proof of principle experiment for the 
identification and localization of biosynthetic pathways in general.  
Instead of developing purification methods or manipulating cultivation conditions, 
large fragments of non-culturable bacterial genomes can be cloned and expressed using 
recombinant DNA technology. A strong transcriptional promoter to control high-level 
gene expression is required in recombinant expression plasmids. We aimed to develop 
new tools to control gene expression through the use of riboswitches.  Riboswitches are 
metabolite-sensing ribonucleic acid (RNA) elements that possess the remarkable ability to 
control gene expression. The thiamine pyrophosphate (TPP) riboswitch system was 
chosen as it will enable use of E. coli as a suitable host strain. This system is particularly 
attractive because it has one of the simplest structures among the riboswitches elucidated 
to date. The use of the TPP riboswitch will also enable modulation of pathway gene 
expression by varying the TPP coccentration as many gene products are toxic. The 
violacein gene cluster from Chromobacterium violaceum was selected and placed under 
the control of this riboswitch. We describe modulation of heterologous gene expression 
by the ThiC/Riboswitch and detail experiments to investigate the expression and 
manipulation of the gene cluster under various promoters.   
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CHAPTER I 
 
INTRODUCTION 
 
 
Natural products are chemicals made by living organisms involving primary 
metabolites (such as encoded amino acids, nucleotides, protein, enzyme, 
oligonucleotides, compounds used for energy supply or cell homeostasis, lipids, 
hormones, pheromones) and secondary metabolites („unnatural‟ amino acids and 
nucleotides, glycosides, compounds used for defense mechanisms). Many of the 
currently used pharmaceutical agents are natural products or were derived from natural 
product leads (1). For example, many natural products play a significant role in the 
treatment of the cancer and infectious disease (2-4).  Many secondary metabolites are in 
use today as antibiotics, antitumor agents, antifungals, immunosuppressive agents, 
antivirals, and enzyme inhibitors. Indeed, approximately 60% of new drugs were derived 
from natural products and their structural analogs over the past 26 years as shown in 
Scheme 1 (4, 5). One of the most successful anti-cancer agents is Taxol, shown in Figure 
1, which is produced by the Pacific Yew tree. Another natural product, vancomycin, 
isolated from Amycolaptosis orientalis, is used for the treatment of drug-resistant 
Staphylococcus aureus infections. 
 
 
 
______________  
This dissertation follows the style of Biochemistry. 
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Scheme 1: All new chemical entities, 1981-2006, by source (N=1031) after Newman (5).  
S=Totally synthetic drug; N= Natural product, ND=Natural product derivative, usually semi-
synthetic, S*=Made by total synthesis but pharmacophore is a natural product, NM=Natural 
product mimic  
 
Both drugs have each generated $1 billion in pharmaceutical sales per year (6, 7). 
Therefore, natural products are very important not only as a primary source of drug leads 
but also as an economic source for the pharmaceutical market.  
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Figure 1: Structure of Taxol and Vancomycin. 
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THE HISTORY OF NATURAL PRODUCT FOR DRUG DESIGN 
 
What are the origins of drugs? Where did they originate?  Evidence suggests that they 
originated tens of thousands of years ago. Research discoveries indicate that the 
medicinal use of natural products has been in use long since man evolved (6, 9). 
Palaeoanthropological studies have revealed pollen deposits in one of the graves at the 
cave site of Shanidar in Iraq where Neanderthals lived more than 60,000 years ago. This 
suggested that the Neanderthals might have been aware of the medicinal properties of 
numerous plants (8). We can find many examples of natural medicines that were used 
for human diseases and/or disorder in the traditional Ayurvedic and Chinese herbal 
treatments (9). The ancients took medicine for pain relief from the bark of trees, leaves, 
fruits, the extract of the seeds and many other sources in nature. People in Asia are still 
using these natural sources for treatments. Some over-the-counter drugs were started 
from extraction of natural sources. One famous example is Aspirin, which was extracted 
from willow bark containing salicyclic acid. The extract of willow bark has been used 
for mild to severe pain relief until the French chemist Charles Frederic Gerhardt 
synthesized acetylsalicylic acid (shown in Figure 2)  in 1856 (10).  The first semi-
synthetic pure drug based on the natural product, aspirin, was synthesized by Bayer in 
1899 (10, 11). Morphine and Quinine are also plant extracts that have been used in 
medicine for a long time. Morphine was discovered as the first active alkaloid extracted 
from the opium poppy plant in 1804 (12). The first commercial pure natural product, 
morphine, was available by E. Merck in 1826 (11). Quinine was only obtained from 
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Cinchona trees and was used as a muscle relaxant until American chemists 
R.B.Woodward and W.E. Doering synthesized the products in 1944 (13). 
 
 
                   A                                       B                                             C 
Figure 2: Structure of aspirin (A), morphine (B) and quinine (C). 
 
The “Golden age” of antibiotic discovery was from 1945 to 1960. Many antibiotics of 
natural product origin were discovered  such as daptomycin, erythromycin, 
chloramphenicol, vancomycin, the penicillins, the cephalosporins, the carbapenems, 
ramoplanin, tetracycline, streptomycin, ceftrizxone, and azithromycin (9, 14).   The first 
ten antibiotic structures are shown in Figure 3. Daptomycin is a novel lipopeptide 
antibiotic used in the treatment of certain infections caused by Gram-positive organisms 
(15, 16). Erythromycin is a macrolide antibiotic (17). Chloramphenicol is a bacteriostatic 
antimicrobial originally derived from the bacterium Streptomyces venezuelae, isolated 
by David Gottlieb, and introduced into clinical practice in 1949 (18). It was the first 
antibiotic to be manufactured synthetically on a large scale, and is considered the 
prototypical broad-spectrum antibiotic (19). Vancomycin is a glycopeptide antibiotic 
used in the prophylaxis and treatment of infections caused by Gram-positive bacteria 
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(20). The penicillins are a group of antibiotics derived from Penicillium fungi (21, 22). 
Cephalosporins are a class of β-lactam antibiotics originally derived from Acremonium, 
which was previously known as "Cephalosporium" (23).  Carbapenems are also a class 
of  β-lactam antibiotics with a broad spectrum of antibacterial activity (24, 25).  
Ramoplanin is a glycolipodepsipeptide antibiotic drug derived from  Actinoplanes strain 
ATCC 33076  (26). Tetracycline is a broad-spectrum polyketide antibiotic produced by 
the Streptomyces genus of Actinobacteria (27). Streptomycin is an antibiotic drug, the 
first of a class of drugs called aminoglycosides to be discovered, and was the first 
antibiotic remedy for tuberculosis (28, 29).  Ceftriaxone is a third-generation 
cephalosporin antibiotic; it possesses broad spectrum activity against Gram positive and 
Gram negative bacteria (30). Azithromycin is an azalide, a subclass of macrolide 
antibiotics (31).  
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Figure 3:  Structures of antibiotics of natural product origin. 
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Microbiologists developed assays for the identification and characterization of the 
antibacterial activity of natural products (14).  Natural products can be derived from 
bacteria, fungi, marine organisms, terrestrial plants and other sources. A crude extract 
from any one of these sources contains novel, structurally diverse chemical compounds. 
Chemical diversity in nature is based on biological and geographical diversity. 
Researchers therefore travel around the world to obtain samples which may contain 
novel compounds. Plants are particularly interesting because they have the broadest 
spectrum of biosynthetic capability and produce a wide variety of compounds.  Plants 
use simple starting materials such as water, carbon dioxide, nitrogen, phosphorus 
compounds and salts. Animal samples are not as easy to extract. There are still many 
potential sources of natural products in nature, even though 10,000 bioactive substances 
have been isolated from bacteria, 450 from mollusks and about 250 from insects and 
worms.(4, 11, 12) The latest version of “The Dictionary of Natural Product” has just 
over 214,000 entries (DNP; http://dnp.chemnetbase.com) (6).  Even though there are 
many possible sources of natural products in nature, marine metabolites have not been 
rapidly utilized as clinical agents because of poor metabolite production. For example, 
bryostatin which has 20 different known structures has antineoplastic activity (the 
structure is shown in Figure 4), so this class of compound can be used chemotherapeutic 
cancer drug. However, we can only obtain about 1.5g of bryostatin1, 2g of bryostatin2, 
0.0056g of bryostatin 8 and 0.0086g of bryostatin 15 from about 1,000kg of damp 
Bugula neritina (collection from the Southern California Coast) (32).  
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Figure 4: Structure of bryostatin. 
 
Moreover, the vast majority of sponge species can only be found in small quantities. 
While these amounts might be sufficient to determine bioactivity, it is not typically 
adequate for structure determination studies. For the limited sample supply, researchers 
attempt to cultivate or synthesize the natural product source. Unfortunately, less than 
1.0% of the marine microorganism can be cultivated shown in Table 1 (33, 34). 
Therefore, there has been wide interest in the development of new methodologies and 
culture techniques for the production of marine-derived natural products to obtain new 
drug sources or drug leads. 
 
Table 1:  Culturability of bacteria from different habitats.  From Amman, et al. (34) 
                     Habitat Culturability (%) 
                 
                 Seawater 
 
0.001 to 0.1 
                 Freshwater 0.25 
                 Mesotrophic lake 0.1 to 1 
                 Unpolluted estuarine 0.1 to 3 
                 Activated Sludge 1 to 15 
                 Sediments 0.25 
                 Soil 0.3 
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 As the field of combinatorial chemistry emerged in the early 1980‟s (5), the interests 
in natural products moved from extraction of natural sources to synthesis of the natural 
products. Borman described combinatorial chemistry as a mainstream tool in drug 
discovery to advance synthesis, purification and analysis (35). New characterization 
methods using modern chromatography and spectroscopy, including one of the only 
available comprehensive treatments of the use of nuclear maganetic resonance (NMR) 
spectroscopy for the characterization of natural products, made great impetus on the 
synthetic endeavors to make the natural products with already-known biological activity, 
antimicrobial and antiviral properties or anticancer activity. Researchers attempted to 
find lead compounds which contain bioactivity. A lead compound can be produced by 
total synthesis or a precursor from a semisynthetic compound. It can serve as a template 
for a structurally different synthetic compound. As mentioned earlier, natural products 
from secondary metabolites often have very complex structures. Its complex structure 
makes it unique but may also be difficult to synthesize. The next popular technique was 
diversity-oriented synthesis (DOS) which is a strategy for quick access to molecule 
libraries with an emphasis on skeletal diversity (5). It was used in Schreiber group in the 
late 1990‟s (5, 36).  In the time frame from 2000 to date, over 300 articles have been 
published with the DOS approach.    
In the late 1990‟s, synthetic chemists realized that the synthetic compounds, such as 
nucleosides, peptides, and carbohydrates, lacked the complexity normally related to 
bioactive natural products which have multiple chiral centers, polycyclic structures and 
heterocyclic substituents (5). To discover and develop new drugs, multidisciplinary 
approaches can be combined with total, diversity oriented synthesis approach and 
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combinatorial synthetic methodologies (4) according to the development of 
characteristic methods. In the case of drug discovery efforts, structure elucidation of all 
components that are active in vitro is typically the end goal. Therefore, the structures of 
natural products were elucidated and characterized by modern spectroscopy; UV 
(ultraviolet 1930‟s) IR (infrared 1940‟s), NMR (nuclear magnetic resonance 1950‟s), 
MS (mass spectrometry 1960‟s) and ESR (electron spin resonance), and by other 
methods; ORD (optical rotator dispersion), CD (circular dichroism), acidity and basicity 
measurements (pK), advanced synthetic and biosynthetic technology and x-ray 
crystallography. Modern methods reduce the necessity of chemical degradation methods, 
so much less material is required to elucidate the structure.  Classical structural 
eludication is done by determination of functional groups, determination of the carbon 
skeleton and the location of the functional groups, degradation to smaller fragments, 
elemental analysis and stereochemistry, synthesis of the smaller fragments and the entire 
molecule, and classification of the compound into a biogenetic family of compounds. 
Natural products can be classified by origin of biosynthetic pathways. A few 
biosynthetic pathways will be discussed to introduce the origin of natural products 
briefly. 
 
NATURAL PRODUCT BIOSYNTHETIC PATHWAYS 
 
Isolated natural products contain a wide variety of structural features, yet the origin of 
these molecules flows from basic pathways related to primary metabolism.  Metabolism is 
the set of chemical reactions occurring in living organisms involved in normal growth, 
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reproduction, maintenance of their structures, and response to their environments.  
Primary metabolites include amino acids, nucleotides, fatty acids, and vitamin 
complexes which produce proteins, nucleic acids, and cell membranes required for the 
survival of the organism.   Secondary metabolites are typically classified upon the basic 
origin of their construction from both the metabolic building blocks and the molecular 
machinery that assembles the units.  These natural products are produced by a few 
pathways including the fatty acid synthases (FAS), the polyketide synthases (PKS), the 
non-ribosomal peptide synthetases (NRPS), as well as using the terpene and alkaloid 
biosynthetic pathways. Polyketide synthases (PKS) are similar to fatty acid synthases 
(FAS), producing carbon chains of repeating units in various states of oxidation.  NRPS 
pathways provide a route for the formation of polypepetide units from natural and 
unnatural amino acids.   PKS pathways are constructed with structurally diverse starting 
units with subsequent two carbon (C2) extension units also called acetate units.  
Alkaloids are organic, nitrogenous bases found mostly in plants, but also to some extent 
in microorganisms.   
 
THE ACETATE PATHWAYS: FATTY ACIDS AND POLYKETIDES 
 
Fatty Acids. Fatty acid biosynthesis is catalysed by a fatty acid synthase by the 
polymerization of subunits through a thio-Claisen condensation reaction. Figure 5 
depicts the processive nature of fatty acid biosynthesis. Fatty acid construction begins 
with an acetate unit (keto starting unit) bound to the fatty acid synthase enzyme giving 
enzyme-bound thioesters (SEnz). After decarboxylation of a malonyl unit, the C2 unit is 
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added via attack of the carbonyl carbon on the starter unit creating a β-ketothioester by 
the keto synthase (KS) domain. The starter unit, which is enzyme-bound, is released 
from the enzyme. The extended unit is converted to a β-hydroxy thioester by the 
ketoreductase (KR) domain. The loss of a water molecule by the action of the 
dehydratase (DH) domain, turns the alcohol the α,β-unsaturated thioester. The final 
product of fatty acid biosynthesis can be obtained after reduction by the enoyl reductase 
(ER) domain resulting in the saturated product. The process is repeated until the desired 
lenghth is obtained after transfer of the molecule to the enzyme from the 
phosphopantetheinyl arm. As shown in Figure 5, path B releases the fatty acid by way of 
the thioesterase domain (TE) while further extension can occur through path A. 
 
 
Figure 5: Fatty acid biosynthesis. Fatty acid biosynthesis proceeds through a cyclic mechanism, 
beginning with a Claisen condensation-like carbon-carbon bond forming reaction, then 
proceeding through a reduction, dehydration, and a second reduction to generate a saturated 
chain.   KS - ketosynthase, KR - ketoreducatse, DH - dehydratase, ER -enoyl reductase, SPP - 
phosphopantetheine thiol, SEnz - enzyme bound cysteine.  Path A adds additional 2 carbon units 
to the growing chain.  Path B releases the fatty acid by way of the TE – thioesterase domain.  
Adapted from Dewick, 2002 (37). 
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Polyketides. Polyketides are the building blocks for secondary metabolites from a 
variety sources. Polyketides are biosynthesized by the polymerization of propionyl and 
acetyl subunits by a thio-Claisen condensation similar to that seen in fatty acid 
biosynthesis. Polyketides have diverse structures with a variety of biological activities 
and pharmacological properties. Polyketides are produced by the enzyme known as 
polyketide synthases (PKS). PKSs are an important source of naturally-occurring small 
molecules used for chemotheraphy (38) like epothilone B (39). Many antibiotics such as 
tetracycline and the macrolides are also produced by PKSs (39).  Polyketide synthases 
can be divided into three classes: Type I, Type II and Type III. Type I PKSs are further 
subdivided into iterative PKSs and modular PKSs. Type I polyketide synthases are large 
and highly modular proteins. If the PKSs repeat domains in a cyclic fashion, it belongs 
to the iterative Type I PKSs class. If the PKS does not reuse domains and contains a 
sequence of discrete separate modules, it is classified as a modular Type I PKS. Type II 
polyketide synthases are aggregates of monofunctional proteins and Type III polyketides 
synthases do not use the acyl carrier protein (ACP) domains. Type III PKSs do not share 
domains with fatty acid synthease, so it is a unique polyketides synthase. Type I and 
Type II are illustrated in Figure 6. 
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Figure 6: Comparision of Type I and Type II PKSs and FASs. (A) In Type I PKS/FAS systems, 
protein domains are connected in cis, (B) In Type II PKS/FAS systems, protein domains interact 
in trans. After Walsh et al., 2006 (40).  
 
The domains typically found in PKSs are the AT, ACP, KS, KR, DH, ER and TE 
domains;  AT: Acyltransferase, ACP: Acyl carrier protein with an SH group on the 
cofactor, a serine-attached 4'-phosphopantetheine, KS: Keto-synthase with a conserved 
cysteine residue, KR: Ketoreductase, DH: Dehydratase, ER: Enoylreductase, and TE: 
Thioesterase. Starting modules typically consist of only on AT and ACP domains while 
the TE domain is involved in the termination or release module. Elongation or extending 
modules are combinations of -KS-AT-[DH-ER-KR]-ACP- domains.  As an example, six 
different modules were used for the elongation to synthesize 6-deoxyerythronolide 
(DEBS). The modular structure of DEBS is shown in Figure 7. Each module consists of 
several domains with defined functions. 
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Figure 7: Modular structure of DEBS (6-Deoxyerythronolide) synthetase.  After Staunton, et al.  
(41). 
 
Polyketides are initiated by loading a starter unit, usually acetyl-CoA or malonyl-
CoA, onto the ACP domain of the starter module catalyzed by the AT domain of the 
starter module. The polyketide chain is transferred from the ACP domain of the 
initiation module to the KS domain of the module I. The elongation group, usually 
malonyl-CoA or methylmalonyl-CoA, is loaded onto the ACP domain of module I, a 
reaction catalyzed by the AT domain of module I as shown in Figure 7. The ACP-bound 
elongation group reacts in a thio-Claisen condensation with the KS-bound polyketide 
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chain under CO2 evolution, leaving a free KS domain and an ACP-bound elongated 
polyketide chain. The reaction takes place at the desired number (n) of KSn-bound end of 
the chain, so that the chain moves out one position and the elongated group becomes the 
new bound group. The fragment of the polyketide chain can be altered stepwise by the 
action of additional domains. The KR domain reduces the β-keto group to a β-hydroxy 
group, the DH domain eliminates water and the resulting α-β-unsaturated alkene can be 
further reduced by the ER domain. It is important to note that these modification 
domains actually affect the previous addition to the chain, not the component recruited 
to the ACP domain of the module containing the modification domain. This cycle is 
repeated for each elongation module with different combination of the domains. 
The TE domain hydrolyzes or cyclizes the completed polyketide chain from the ACP-
domain of the previous module. 
  
Non-Ribosomal Peptides. Another class of peptide secondary metabolites produced 
by microorganisms is the nonribosomal peptides (NRPs). NRPs are synthesized by one 
or more nonribosomal peptide synthetases (NRPS) enzymes which are independent of 
messenger RNA. NRPs are often dimers and trimers of identical sequences chained, 
cyclized, or even branched structures (42). NRPs are a very diverse family of natural 
products with an extremely broad range of biological activities and pharmacological 
properties. Many antibiotics (vancomycin, bacitracin, actinomicin and etc) and 
immunosuppressants (cyclosporine A) are produced from nonribosomal peptides. The 
modular structure of the bacitracin synthetase complex is shown in Figure 8 (43).   
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Figure 8: Modular structure of the bacitracin synthetase complex.  After Schwarzer, D., et al.  
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The make up of an NRPS consists of initiation, elongation, and termination modules. 
The initiation module contains an adenylation domain (A) and thiolation domain (T or 
PCP). The T domain, also called peptide carrier protein (PCP), is required in a module 
for thiolation. Elongation modules contain condensation domains (C) in addition to A 
and T domains. Termination modules typically contain a thioesterase domain (TE). 
Besides required domains (42), many optional domains are available; F (formylation), 
Ox (Oxidation), Red (Reduction of thiaolines or oxazolines to thiazolidines or 
oxazolidines), NMT (N-methylation), R (Reduction to terminal aldehyde or alcohol), Cy 
(Cylization) and E (epimerization domain). The biosynthesis of NRPs shares 
characteristics with fatty acid biosynthesis and polyketide biosynthesis. Due to these 
structural and mechanistic similarities, some NRPS contain polyketide synthase modules 
for the insertion of acetate or propionate derived subunits into the peptide chain.   
 
Terpen. Terpenes are derived biosynthetically from isoprene units as one of nature‟s 
building blocks.  Terpenes are multiple linked isoprene units. The isoprene units may be 
linked "head to tail" or “tail to tail” to form linear chains or they may be arranged to 
form rings as shown in Figure 9 (37). 
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(a) 
 
 
(b) 
 
 
 
 
 
Figure 9: Head-to-tail and tail-to-tail condensation of isoprene units.  After Dewick (37). (a)  
Head-to-tail condensation of dimethylallyl pyrophosphate and isopentenyl pyrophosphate to 
produce geranyl pyrophosphate.  (b)  Tail-to-tail condensation of geranylgeranyl pyrophosphate 
to generate squalene and phytoene. 
 
 
Isoprene (C5H8) itself does not undergo the building process, but rather activated 
forms, isopentenyl pyrophosphate (IPP or also isopentenyl diphosphate) and 
dimethylallyl pyrophosphate (DMAPP or also dimethylallyl diphosphate), are the 
components in the biosynthetic pathway  as shown in the first step of  (a) and (b) of 
Figure 9.  
Terpenes are classified sequentially by size as hemiterpenes (C5H8,, isovaleric acid, 
prenol), monoterpenes (C10H16, geraniol, camphor, limonene, menthol), sesquiterpenes 
(C15H24, patchoulol, pentalenolactone, farnesol, farnesenes), diterpenes (C20H32, taxol, 
retinal, retinol, phytol), sesterterpenes (C25H40, geranylfarnesol), triterpenes (C30H48, 
squalene, lanosterol, cycloartenol), tetraterpenes (C40H64, acyclic lycopene, the 
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monocyclic gamma-carotene, the bicyclic α-carotenes, the bicyclic β-carotenes), and 
polyterpenes which consist of long chains of many isoprene units such as rubber (44). 
The biosynthesis of Lanosterol, a tetracyclic triterpenoid which is a precusor compound 
from which all steroids are derived, is shown in Figure 10 (44). 
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Figure 10: Polyene cyclization cascade of oxidosqualene to produce lanosterol.  After Davis, et 
al. (44)  
 
Alkaloids. Alkaloids are naturally occurring secondary metabolites containing basic 
nitrogen atoms defined by in International Union of Pure and Applied Chemistry 
(IUPAC).  Many alkaloids are toxic to other organisms and have pharmacological effects 
so they can be used as medications or recreational drugs. Caffeine, nicotine, cocaine, 
morphine, and quinine belong to the alkaloid classification. Alkaloids are found in 
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plants, animals and fungi such as potatoes, tomatoes, shellfish and mushrooms. The 
biosynthesis of the plant derived alkaloid cocaine is shown in Figure 11 (45). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: The biosynthesis of the plant derived alkaloid cocaine. The biosynthesis of cocaine 
from the coca plant, Erythroxylon coca . 
 
METABOLITES TO GENES 
 
DNA Library. As already mentioned, only a small portion of microbes are culturable 
by present methods and it is assumed that 90-99% of the metagenome is not being 
sampled (14, 34, 46). Even marine microbial communities, including the cyanobacteria, 
have not been systematically collected and fully evaluated for bioactive compounds. 
Instead of developing purification methods or manipulating cultivation conditions, large 
fragments of non-culturable bacterial genomes can be cloned and expressed using 
recombinant DNA technology (47-51). The main scheme of the technique is that the 
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DNA of the coding region is extracted, inserted into a vector and this is transfected into a 
culturable bacterium or other host that expresses biosynthetic genes or clusters.  
Construction of recombinant DNA molecules by simply ligating vector DNA and a 
fragment of interest is a straightforward process as described in Current Protocols in 
Molecular Biology (52). Often, however, molecular biologists do not yet posess the 
particular DNA they are interested in - they must isolate it from a large pool of DNA 
molecules. To do this, a modified form of the DNA cloning scheme is utilized, called 
„the DNA library‟. DNA libraries are mixtures of different restriction enzyme-digested 
DNA molecules ligated into vectors. Libraries are constructed using the same general 
approach, except that instead of inserting one type of DNA fragment into the vector, 
there are thousands or even millions of different DNA fragments inserted into vector 
molecules. There are essentially two types of DNA libraries, based on the source of the 
DNA: Genomic DNA libraries made from genomic DNA, all of the DNA found in the 
organism‟s nuclei and complementary DNA (cDNA) libraries which are made from 
DNA copies of mRNA molecules. 
Genomic DNA molecules are very large (each chromosome in the nucleus is one such 
DNA molecule), so they must be fragmented into small enough pieces to insert into 
vectors. This is typically done through digestion with one or more appropriate restriction 
endonucleases, mechanical shearing, or a combination of the two processes. The DNA is 
then ligated into the vector, which could be a plasmid, but is more often a cosmid or a 
viral chromosome.  
To generate cDNA, mRNA is isolated from a tissue or whole organism, and DNA is 
copied from the mRNA template using reverse transcriptase. This enzyme functions like 
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a DNA polymerase, except that is uses RNA as a template instead of DNA. The resulting 
cDNA molecules are then engineered so that they have restriction enzyme recognition 
sites at each end of every molecule, which allows them to be digested and inserted into a 
vector. 
 The difference between these two libraries is the nature of the DNA found in the 
library. Therefore, the choice of library type depends on what type of DNA sequence a 
researcher wishes to study. 
 
cDNA Libraries. cDNA libraries are a pool of complementary DNA that are 
synthesized from the messenger RNA (mRNA) population of an organism. “Directional” 
cDNA expression libraries (DNA fragments are cloned in one specific direction) will be 
constructed from marine microorganisms for the purpose of mining biosynthetic genes 
of a pathway. The primary advantage of the approach is that no prior knowledge of the 
natural product‟s structure or origin (e.g. polyketide, terpene, non-ribosomal peptide, or 
alkaloid subclass identification) is necessary, nor does the method rely upon the host 
machinery to recognize foreign promoters. While cDNA library expression could 
support production of all enzymes of a biosynthetic pathway necessary for natural 
product production, identification of the actual gene sequences is important for future 
manipulation of the pathway genes in the production of second-generation compounds 
with modified structures and enhanced activities or simply for the improvement of 
natural product yields. In this regard, identification of a single biosynthetic gene by our 
cDNA  library approach will be sufficient for identification of the remainder of the gene 
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cluster (except in plants, most biosynthetic genes have been found to be clustered) by the 
screening of a genomic fosmid or a bacterial artificial chromosome (BAC)  library (53). 
 
Fosmid or BAC Libraries. Fosmid and BAC libraries both allow for the cloning of 
large segments of DNA. BAC vectors are capable of carrying insert sizes ~100 kb in size 
while fosmid clones house fragments within the 30 - 50 kb range (54, 55). In many 
instances, their primary use is to fully represent the genomic DNA of an organism. In 
this regard, BAC libraries of genomic DNA have been constructed from a variety of 
plant, animal, and fungal species and have been used to facilitate large-scale sequencing 
projects (56). Both vectors also have, in principle, the means to house an entire 
biosynthetic cluster(56). In this respect, great strides have been made with the 
randomized cloning of soil bacterial genomes giving rise to natural product expression 
without further manipulation (primarily through the use of fosmid libraries: (57-61). The 
antibiotics turbomycin A and B (Figure 12) for example, were both isolated and 
produced from a 24,546-member fosmid library (61).           
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Figure 12: Chemical structures of turbomycin A and turbomycin B. 
 
Similarly, violacein and deoxyviolacein (Figure 13) were also isolated from an 
environmental fosmid library (58). Fosmid and BAC libraries will now be employed for 
the harnessing of natural product biosynthetic pathways from the marine environment. 
 
 
 
 
 
 
           
                         Violacein                                                        Deoxyviolacein 
Figure 13: The structures of violacein and deoxyviolacein. 
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Pathway-based Screening: Genetic Selections of the Biotin Biosynthetic Pathway. 
Traditional approaches to natural product discovery involve cell-based screening of 
natural product extracts followed by compound isolation and characterization. Their 
importance notwithstanding, continued mining leads to depletion of natural resources 
and the reisolation of previously identified metabolites. Metagenomic strategies aimed at 
localizing the biosynthetic cluster genes and expressing them in surrogate hosts offers 
one possible alternative. A fundamental question that naturally arises when pursuing 
such a strategy is, how large must the genomic library be to effectively represent the 
genome of an organism(s) and the biosynthetic gene clusters they harbor? Such an issue 
is certainly augmented in the absence of expensive robotics to expedite colony picking 
and/or screening of clones. The Watanabe group has developed an algorithm, named 
BPC (biosynthetic pathway coverage), supported by molecular simulations to deduce the 
number of BAC clones required to achieve proper coverage of the genome and their 
respective biosynthetic pathways. The strategy has been applied to the construction of a 
large-insert BAC library from a marine microorganism, Hon6 (isolated from 
Honokohau, Maui) thought to represent a new species. The genomic library is 
constructed with a BAC yeast shuttle vector pClasper lacZ paving the way for the 
culturing of libraries in both prokaryotic and eukaryotic hosts. Flow cytometric methods 
are utilized to estimate the genome size of the organism and BPC implemented to assess 
P-coverage or percent coverage. A genetic selection strategy is illustrated, applications 
of which could expedite screening efforts in the identification and localization of 
biosynthetic pathways from marine microbial consortia, offering a powerful complement 
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to genome sequencing and degenerate probe strategies. Implementing this approach, we 
report on the biotin biosynthetic pathway from the marine microorganism Hon6.  
Modulation of Gene Expression by Riboswitches. Natural product biosynthetic 
pathways requiring further genetic manipulation to achieve enzymatic expression will be 
modified utilizing two independent but complimentary approaches. In the first strategy, 
we will put genes under the control of a riboswitch. Such an approach is attractive as E. 
coli could be utilized as a heterologous expression host, which eases genetic 
manipulations and future biochemical studies, where high levels of protein expression 
might be achieved.   
 
 
Figure 14:  Riboswitch domains. A: a metabolite-binding „aptamer‟ domain B: an 
„expressionplateform‟ for gene regulation. These two activities are accomplished by two 
functionally separate domains on the RNA.  
 
Riboswitches are metabolite-sensing RNA elements that possess the remarkable 
ability of controlling gene expression. A variety of riboswitches have been identified in 
nature responding to such metabolites as purines (adenine and guanine), glucosamine-6-
phosphate, as well as the co-factors TPP (thiamine pyrophosphate), FMN (flavin 
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mononucleotide), SAM (S-adenosylmethionine), and B12 (62-72). Each riboswitch is 
typically comprised of an aptamer domain and an expression platform that either 
activates or disrupts gene expression transduced through ligand binding that causes 
allosteric changes in both the aptamer and expression domains (66, 68). Because of the 
modular nature of RNA structures, different types of   expression platform can be linked 
to the conserved aptamer domain and leads to variations in the riboswitch mechanism. 
The structure is shown in figure 15 (73).   Riboswitches are frequently located within the 
5‟-untranslated region (UTR) of mRNAs and interface with transcriptional and 
translational molecular machinery to modulate gene expression (68). Like proteins, 
riboswitches also demonstrate high specificity and can discriminate against other small 
molecules that display subtle variations on the natural ligand. 
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Figure 15: The known ribowitch aptamers. After Soukup and Soukup (73). 
 
Crystal structures have been reported on a variety of riboswitch systems including the 
purine riboswitch, the TPP riboswitch, and the SAM riboswitch (74) as shown in figure 
15.  The guanine and adenine variants of the purine sensing riboswitch consist of three 
paried regions (P1, P2, and P3), which are arranged as an inverted „h‟ forming three 
helices. The purine ligand binds via hydrogen bonding interactions at the three-way 
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junction of the riboswitch. The TPP riboswitch resembles that of the purine riboswitch, 
with an inverted h-architecture, but the helices are more tightly compressed. Docking of 
the TPP ligand bridges the two parallel helices as opposed to burying within the helical 
junction. In contrast to both of these systems, the SAM riboswitch adopts a completely 
different structural motif. The riboswitch consists of a pseudoknot coupled to a kink-turn 
where SAM binds at the interface of the minor grooves of P1 and P3(75). In at least all 
of these cases, riboswitch regulated gene modulation results from sequestration of a 
switch segment into either a metabolite-bound or a metabolite-free conformational fold. 
The model of the coupling between TPP binding and structural rearrangements in the 
TPP riboswitch is shown in Figure 16. Transcription is completed when metabolite is 
limited, while metabolite is abundant, transcription will be terminated via structural 
rearrangement. The metabolite is thiamine pyrophosphate (TPP) in TPP riboswitch. 
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Figure 16: Model of the coupling between TPP binding and structural rearrangements in the TPP 
riboswitch. Upon TPP binding (1), bulges J2/3 and J4/5 rearrange, thereby closing the sensor 
helix clamp and forming new hydrogen bonds at the tip of loop L5. The TPP-induced parallel 
positioning of the sensor helices stabilizes the three-way junction with A72 at the core of the 
interaction platform (2) and promotes the formation of the switch helix P1 (3), which turns the 
riboswitch "off." After Thore, S. et al. (76). 
 
Traditional methods for the identification of natural products are: isolation and 
purification, characterization, optimization of culture conditions to maximize metabolite 
production, direct inquiry of the pathway with isotopically labeled precursors, fishing 
experiment with protein extracts from DNA libraries using Ni-NTA column, sequencing 
with degenerate DNA primers such as NRPS, PKS, and etc, construction and screening 
of the genomic libraries including BAC, FOS or COS and cDNA libraries, genetic 
selection (pathway-based screeing) and commercial organism sequencing which is 
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available now due to low cost for genome sequencing. In the watanabe group, most of 
these methods have been in use for the identification of natural products or genes of 
biosynthetic pathways.  
 
STATEMENT OF PURPOSE   
 
The overall aim of my research is to develop new strategies in the localization of 
natural product biosynthetic pathways and achieving heterologous expression. 
The specific aims of my research are:  (1) creation of cDNA expression libraries from 
pup14A/B and Hon6 for the identification of the natural product(s) biosynthetic genes; 
(2) construction of a fosmid library from environmental samples; (3) genetic selection of 
the biosynthetic pathways; (4) genetic manipulation of the production of natural product; 
(5) modulation of gene expression by ThiC/riboswitch promoter 
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CHAPTER II 
 
CONSTRUCTION AND ANALYSIS OF COMPLEMENTARY DNA LIBRARIES 
OF HETEROGENEOUS MARINE ORGANISMS AND  
CHROMOHALOBACTER SP.  
 
INTRODUCTION 
 
There are two general sources of genetic information for the construction of 
expression libraries of an organism; genomic DNA and messenser RNA (mRNA). The 
genomic content is the same in all tissues, so it does not matter which tissue is used to 
isolate the genomic information. However, the coding region for a gene of interest may 
be interrupted by one or more intron regions, and thus the complete coding region could 
be quite long. Introns are spliced out of mRNA which thus contains a contiguous coding 
region. Another advantage of mRNA is that tissue specific expression of the protein of 
interest may allow isolation of the appropriate mRNA at enhanced levels. Bacterial 
Artificial Chromosome (BAC) libraries can be constructed from genomic DNA (77), and 
complementary DNA (cDNA) libraries from mRNA in DNA form.  
A general overview for the cDNA approach is as follows. Isolated mRNA serves as 
the template for reverse transcriptase, which synthesizes a strand of cDNA. The mRNA 
template is then destroyed, leaving a single–stranded cDNA molecule. The cDNA is 
then used as a template by DNA polymerase to synthesize a complementary strand. The 
net result is the formation of a double - stranded DNA molecule that contains the same 
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genetic information as the mRNA. In effect, a gene has been made using the information 
from the mRNA. 
Chapter II will focus on the construction and use of cDNA expression libraries for the 
identification of the biosynthetic genes of a pathway. Construction of a BAC library was 
accomplished by one of the Watanabe members, Scott Angell. BAC libraries enable the 
cloning of large DNA fragments (≥100 kb) or gene clusters but relies very heavily on the 
host to recognize foreign promoters. Conversely, cDNA libraries express only a single to 
a few genes at a time, but involve the use of artificial promoters, for example, promoters 
that are specifically designed for that host strain. In other words, the method does not 
rely on the host machinery to recognize a foreign promoter. So, we can use a commercial 
vector which has its own promoter recognized by E. coli. 
The primary advantage of a cDNA library approach for expressing genes for 
synthesis of natural products is that does not necessitate prior knowledge of the natural 
product‟s structure or biogenetic origin, for example, fatty acids, polyketide, non-
ribosomal peptide, terpene, or alkaloid subclass identification. Indeed, to know what the 
actual gene sequences are is important for future applications. We can manipulate the 
sequences and modify the structures for enhancing the bioactivities or improvement of 
natural product production yield. In this regard, our cDNA library approach will give 
sufficient information for identification of a single biosynthetic gene and the remainder 
of the gene cluster by the screening of a genomic BAC library.  
The appeal of the approach is the ability to identify natural product genes of a 
pathway without having prior knowledge of the biosynthetic origins of the metabolites. 
Moreover, as it is estimated that less than 1% of marine microorganisms can be 
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cultivated in the laboratory, (33, 34) these methodologies might offer the means to 
access previously untapped resources.  
Once the cDNA libraries were successfully generated, they were not only screened 
for the natural product biosynthetic pathway genes they harbor, but also for metabolic 
enzymes that could “neutralize” the deleterious effects of acid crude oil (78-81). Crude 
oil corrosivity is a central issue that plagues the oil refinement industry presenting a 
significant economic burden and challenge. Acid crude oils are found in many parts of 
the world resulting from microbial decomposition within the reservoir. While the 
resulting crude oils are cheaper, they are generally more viscous and high in naphthenic 
or terpenoid acids (Figure 17). 
 
COOH
C21 tricyclic terpenoid acid C24 tricyclic terpenoid acid
COOH
COOH
(    )n
Pentacyclic hopanoid acid
 
Figure 17:  Examples of naphthenic acids. 
 
 The compounds react with metal surfaces leading to corrosion of refinery pipework 
and vessels. Given this problem, we aim to identify biosynthetic or metabolic enzymes 
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from the marine environment that could be employed to degrade these acids (78-81). To 
complement these experiments, offering an orthogonal approach, a fosmid library of 
environmental DNA will be generated and diversely screened for natural product 
production. 
   
EXPERIMENTAL PROCEDURES 
  
General. The SuperScriptTM Choice System for cDNA Synthesis kit was obtained 
from Invitrogen life technologies. E.coli cells were routinely grown in LB medium 
containing 1% Bacto Tryptone (Difco, Sparks, MD), 0.5% yeast extract (Difco, Sparks, 
MD), and 0.5% NaCl with antibiotics at 50μg/ml for ampicillin. RNeasy Mini Kit, 
Quiapep Spin Mini Kit, QIAGEN plasmid kit, QIAquick Nucleotide Removal kit, and 
QIAquick Gel Extraction Kit were obtained from QIAGEN Inc (Valencia, CA).  
Restriction enzymes and alkaline phosphatase enzymes were obtained from New 
England Biolabs (Ipswich, MA). 
 
Organisms.  All marine microorganisms utilized in these experiments were obtained 
from field collections by Watanabe‟s group (Table 2) (82).  Hon6 (isolate 6) was 
acquired from Honokohau, Maui, Pup16 (isolate 16) from Pupukea, Oahu. Pup14A and 
Pup14B were also obtained from Pupukea (sample 14).  The identity of each of the 
microorganisms was assigned by the Centralbureau voor Schimmelcultures (CBS) in the 
Netherlands.  E. coli Zappers was obtained from Novagen (Gibbstown, NJ 08027), and 
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EC100 was from Epicentre (Madison, WI).  pETBlue-2 was obtained from Novagen 
(Gibbstown, NJ 08027), and pYES2/CT/LacZ from Invitrogen (Carlsbad, CA) 
 
Table 2: Bacterial strains and plasmids used in Chapter II 
Strain or Plasmid                                    Description 
a
                                        Reference/Source 
Strains   
 EC100                         Host strain for DNA manipulations                             Epicentre 
 NovaXG
TM
 Zappers   Host strain for DNA manipulations                                        Novagen 
   Pup14            Marine microbial assemblage isolated in Pupukea, HI       This study (82) 
   Pup14A            Identified as Pseudomonas aeruginosa by CBS              This study (82) 
   Pup14B            Identified as Enterobacter sp. by CBS                           This study (82) 
   Hon6                         Identified as Chromohalobacter sp. by CBS              This study (82) 
   Pup16                      Identified as Rhodotorula mucilaginosa by CBS                 This study 
Plasmids 
   pETBlue-2                    Amp
r
                                                                                   Novagen 
   pYES2/CT/LacZ          Amp
r
                                                                                   Invitrogen 
 
 Field Collection of Marine Microbial Samples. This work was done by Dr. Scott 
Angell, a  former member of the Watanabe group (82). Marine agar plates were prepared 
with slight modification to a standard literature protocol (83). Yeast extract (2 g), 
bactopeptone (2 g), glucose (4 g), and bacto-agar (Difco, 20 g) were combined in 1 liter 
of seawater, prepared by mixing Instant Ocean (38 g, Petco) with deionized distilled 
water.  The marine agar plates were further supplemented with either 10 mg/L of 
miconazole or a combination of chloramphenicol (10 mg/L) and kanamycin (10 mg/L) 
for the culture of bacteria or fungi, respectively.  Culture swabs (Becton Dickinson, 
supplier VWR International; West Chester, PA) were used to swab submerged rocks, 
and autoclaved vials were used to collect ocean floor sediments.  Samples were applied 
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to both types of marine agar plates and incubated at room temperature for one week.  
Single colonies were generated by repeated streaking of microorganisms onto fresh 
plates. To generate marine microbial populations, cell scrapers (Costar, West Chester, 
PA) were applied to the original plates, and the cells resuspended and cultured in marine 
broth. 
 
Preparation of Total RNA from Marine Sources. Pup 14 cultures were prepared by 
inoculating the salt-based medium with equal amounts of Pup14A and Pup14B. 
Following 72 hours of growth and induction of the blue phenotype, the cells were 
harvested by centrifugation and the cell pellets subsequently flash frozen in liquid 
nitrogen. Total RNA was extracted by hot phenol extraction and purified with a Qiagen 
RNeasy Kit as described in reference (84). Hon6 and Pup16 were also prepared with a 
traditional method (83). Hon6 glycerol stocks streaked on a marine agar plate as shown 
in Figure 18. Hon6 was inoculated into Marine broth containing bacto pepetone 1g, 
bacto Yeast Extract 1g, glucose 2g, and sea salt 19g (83). 
 
 
 
 
 
 
 
Figure 18:  Photograph of the Hon6 strain cultured on a marine agar plate. 
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Preparation of DNA Samples. DNA samples of pETBlue-2 and pYES2/CT/LacZ were 
prepared by transformation into EC100 electrocompetent cells. After growing on agar 
plates containing ampicillin, they were inoculated in media for amplification. Plasmid 
purification was performed with a Qiagen plasmid purification kit followed by gel 
extraction to get the desired DNA. pYES2/CT/LacZ was sequentially digested with XhoI 
and Hind III and pETBlue-2 with EcoRI and HindIII  respectively.  Dephosphorylation 
was performed with Shrimp Alkaline Phosphatase (SAP) or Calf intestinal Alkaline 
Phosphatase (CIAP) after gel extraction of double digested DNA. 
 
Preparation of the Random Hexamers for Priming First Strand Synthesis. Dr. 
Watanabe ordered random hexamer oligonucleotides from SIGMA GENOSYS (The 
Woodlands, TX) 
For pYES2/CT/LacZ (HindIII/XhoI) system (used with Pup16) 
                 DAG HEXAMER: AGNNNNNN 
                 HindIII XhoI ARMS: CGAGAAGCTTCTCG 
For pETBlue-2(EcoRI/HindIII) system (used with Hon 6 and Pup14) 
                 DTT HEXAMER: TTNNNNNN 
                 EcoRI HindIII ARMS: GCTTGAATTCAAGC 
 
cDNA libraies were prepared with a slight modification to the standard Invitrogen 
instruction manual of the SuperScriptTM Choice System for cDNA Synthesis kit. 
Detailed protocol flow diagram shown in Scheme 2 (85). 
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Scheme 2: Detailed protocol flow diagram of cDNA synthesis (after Invitrogen manual p13) 
(85). 
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Preparation of the First Strand cDNA to Optimize First Strand Primer 
Concentration. 10μg of Hon6 mRNA was mixed with either10ng, 25ng, 50ng, 100ng, or 
150ng of DTT Hexamer oligonucleotide, and then heated at 70C for 10min. After 
incubation on ice for 5min, a quick spin was done to get the samples to the bottom of the 
tubes. First strand reaction mixture (4μl 5x first strand buffer, 2μl 0.1M DTT, 1μl 10mM 
dNTP, and 1μl [α-32P] dCTP (1μCi/μl)) was added to each tube and mixed. After 2 min 
at 37C, 1 μl superscriptTM II RT (reverse transcriptase) was added to each tube and 
mixed well. A 1 hr incubation at 37C was performed after a quick centrifugation. After 
analysis of the reaction by agarose gel electrophoresis and phosphoimaging, optimal 
conditions for the first strand reaction were used for further reactions. Samples of Pup14 
and Pup16 were processed indentically to Hon6 except the DAG Hexamer 
oligonucleotide was substituted for the DTT Hexamer oligonucleotide in Pup16. After 
first strand synthesis, a nucleotide removal kit was used to purify the first strand cDNA 
and to remove 
32
P. After running the gel, the dried gel was developed with 
Phosphorimage plate for 2 hrs to overnight depending on the intensity of the signal to 
optimize the concentration random Hexamer oligonucleotides used in the reactions. 
Once optimized conditions were determined, second strand synthesis was followed.  
 
Preparation of the Double-Strand cDNA via Second Strand Reaction. For second 
strand synthesis, the following reagents were added on ice to the first-strand reaction 
tube in the order shown: 89μl DEPC-treated water, 30μl 5x second-strand sysnthesis 
buffer, 3μl dCTP mixture (CH3-dCTP:dCTP, used 1:0, 1:1, 1:3, 3:1), 1μl [γ-
32
P] dCTP 
(1 μCi/ μl), 1μl E. coli DNA ligase (10units/μl), 4μl E. coli DNA polymerase I 
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(10units/μl), and 1μl E. coli RNase H (2units/μl). All tubes were gently vortexed to mix 
and then incubated at 16C for 2 hours. After that 2μl (10units) of T4 DNA polymerase 
was added and incubation was continued for an additional 5 min at 16C.  The same 
procedure was performed to optimize the dCTP concentration by analysis with 
phophorimage reader. The phosphorimage is attached in Appendix A. 
 
EcoRI HindIII Adapter Addition. First-strand and second-strand synthesis with 
optimized conditions was repeated, and the cDNA extracted with phenol: chloroform: 
isoamyl alcohol (25: 24: 1). Prepared cDNA was dried at 37C for 5 min. The following 
reagents were added to the cDNA: 18μl DEPC-treated water, 10μl 5x adapter buffer, 
10μl EcoRI HindIII adapters, 7μl 0.1M DTT, and 5μl T4 DNA ligase. The Adapter 
addition reaction was incubated at 16C for a minimum of 16 hrs.  After precipitation 
with EtOH, sequential digestion with HindIII followed by EcoRI was performed and the 
cDNA precipitated again. 
 
 Column Chromatography. A scintillation counter (facility of Biology Department at 
Texas A&M University) was used for checking specific activity after running a cDNA 
fractional column, which was provided with kit. All procedures were performed as 
described in the manual (85). Each fraction was evaluated for Cerenkov Counts (CPM) 
by Scintillation counter. The amount of double strand cDNA was calculated with 
equation (1) after inserting the SA value calculated with equation (2). 
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 Ligation of cDNA. After column chromatography, the desired amount of double 
strand cDNA was precipitated with EtOH. The ligation reaction consisted of the 
following: 4μl 5x T4 DNA ligase buffer, 2μl plasmid (dephosphorylated), 8μl cDNA, 
5μl DEPC-treated Water, and 1μl T4 DNA ligase.  Dephosphorylated 
pET/HindIII/EcoRI plasmid was used for Pup14 and Hon6 and dephosphorylated 
PYES2/HindIII/XhoI plasmid for Pup16. The reaction was performed at 4C overnight.  
Electroporation of cells was carried out with a BioRad MicroPulser.  Electroporation for 
the transformation into competent cells (NovaXG
TM
 Zappers and EC100) was performed 
after desalting the ligation reactions. The cells were plated on LB agar +Ampicilin, and 
then incubated for 16 hrs at 37C.  
 
 Analysis of cDNA Library. Colonies were inculated in 5ml of LB media containing 
Ampicilin and incubation for 16 hrs at 37 C. Grown cells were harvested and then 
purified with QIAprep mini-prep.  EcoRI, NotI, XhoI and NcoI restriction enzymes were 
used for analysis of cDNA libraries to check insertion size. 
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Screening of cDNA Library.  We calculated that the number of colonies we need to 
collect from the agar plates using equation 3. 
 
 
GS for Pup14 or Pseudomonas pathway site = 1.96Mb = 1.96× 10
6
 
P = 99% = 0.99 
Insertion size = 1.5kb = 1.5 × 10
3 
 
Explanation of the derived equation is described in Chapter IV. For Pup14, 10,000 
colonies were required while for Hon6 12,000 colonies were required based on the blue 
and white screening and insertion size.  Transformants were collected and stored at -
80C (All 40 tubes for Pup14 and 60 tubes for Hon6 each tube contains 250 colonies). 
 
Screening of cDNA Libraries for Naphthenic Acid Converting Enzymes. Using NCBI 
BLAST search, primers of SAM-dependent methyltransferase and Carboxylic Acid 
Reductase were designed (86).  Eight organisms were used to design the primers of 
Carboxylic Acid Reductase: Nacardia farcininca IFM 10152, Nocardia sp NRPL 5646, 
Mycobacterium avium subsp, Paratuberculosis str. K10, Mycobacterium tuberculosis 
H37Rv, Mycobacterium bovis AF2122/97, Mucobacterium tuberculosis CDC155, and 
Mycobacterium lepraae TN. Thirteen organisms were used to design the primers of  
SAM-dependent Carboxylic Methyltrasferase: Salmonbella enteric subsp, Enterica 
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Serovar choleraesuis str. SC-B67, Salmonella typhimurium LT2, Enterica serovar Typhi 
Ty2, Enterica serovar Typhi str. CT18, Enterica serovar Paratyphi A. str. ATCC9150, 
Escherichia coli K12, Escherichia coli, Yjhp from E. coli, Geobacter sulfurrecucens 
PCA, Anaeromyxobacter dehalogenans 2CP-C, Geobacter metallireducucens GS-15, 
and Rhodosprillum rubrum. 
 
RESULTS AND DISCUSSION 
 
Isolation of Pup14 (82). Samples were collected from the north shore of Oahu, 
Hawaii.  Ocean floor sediments (up to a depth of 40 ft) were obtained as well as culture 
swabs of submerged rocks.  The microorganism specimens were plated on bacterial or 
fungal plates employing standard literature protocols (83).  Microbial communities were 
inoculated into liquid media and cultured in shake flasks.  Among the microorganism 
samples examined, Pup14 (Pupukea sample 14, bacterial plate) gave an unusual green 
phenotype following ~72 hr of culturing; while the cells remained white, the medium 
turned green (Figure 19).  Extraction of the medium resulted in an aqua blue color.  The 
Pup14 sample showed that cells propagated from single colonies and grown in culture 
could not generate the green phenotype, suggesting that natural product production was 
in some way coupled with microbial interactions.    
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                                        A                                                            B 
 
 
   
                                                                  
 
                                        C                                                             D 
Figure 19: Induction of pyocyanin production.  (A) Uninduced co-culture of Pup14A and 
Pup14B after 24 hours of growth. (B) Induced co-culture after 72 hours of growth.  (C) 
Methylene chloride extract of induced co-culture. (D) Pyocyanin Structure 
 
Pup14 A and B, two marine microorganisms were retrieved from the north shore of 
Oahu, Hawaii. Pup14 or Pseudomonas aeruginosa is a bacterium that was identified 
through examination of mixed cultures of marine microbial populations for bioactivity.  
The bacterium was shown to produce a blue metabolite, pyocyanin, when activated with 
another microorganism, identified as Enterobacter (Figure 19D).  In 2005, the paper was 
published that addresses the synergistic role of the microorganisms in the production of 
the blue metabolite, pyocyanin.   
N
N
O
CH3
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As the techniques employed were quite general, they can be easily applied to address 
synergism observed with other organisms. Full characterization for the compound is also 
provided, including missing structural information, 2D-NMR data, X-ray analysis, and 
DNA microarray analysis, which suggest that the compound promotes oxidative damage 
and stress (82).    
 
Construction of cDNA Libraries from Marine Microorganisms. cDNA libraries have 
been successfully generated from both Hon6 and the synergistic microorganisms Pup14 
A/B.  The directional libraries were constructed as follows. Total RNA was isolated by 
hot phenol extraction and subsequently purified with a Qiagen RNeasy Kit (Figure 20) 
(5).    
 
            
                          
Samples From Left to Right 
[1] 1 kb DNA ladder (NEB) 
[2]Yeast total RNA control 
[3]  Gal 2PB 
[4]  Gal 1 PC 
[5]  Pup 16 
[6]  Hon 17 
[7]  Hon 1B 
    
     
Figure 20: Total RNA isolated from a variety of marine bacteria and fungi. 
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cDNA synthesis is initiated by employing an RNA-dependent DNA polymerase.  Since 
these enzymes are not capable of initiating cDNA synthesis de novo, primers were used 
to which the nucleotides can add. Current priming strategies include the use of poly-dT 
primers or random hexamers. While oligo-dT primed synthesis should theoretically 
result in full length cDNA, in practice the yield of such reactions are typically less than 
50%, also resulting in significant 3‟-end bias (87).  In contrast, with random priming 
control over the average cDNA size can be achieved by adjusting primer template ratios.  
At low ratios, priming events become a lot less frequent and larger cDNA sequences are 
produced. Therefore, we selected to construct our libraries with random hexamers 
(Figure 7, optimization of primer concentration with the marine microorganism Pup14). 
More specifically, directionality of the library could be achieved by using directional 
random hexamer primers that consist of a random hexamer sequence preceded by two 
defined bases at the 5‟-end (Figure 21) (88).  Having only two bases at this position 
allows proper priming while defining the 5‟-end of the first strand to allow directional 
cloning of the cDNA. 
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Figure 21: Directional cDNA cloning strategy with tethered random hexamers. Modified from 
Morris et al.(88).  
 
In the configuration shown here, the two defined bases are d(TT). Directional cloning 
of the cDNA is achieved upon ligation with an EcoRI/HindIII directional linker 
[5‟d(GCTTGAATTCAAGC)] including an internal EcoR I flanked on each side by four 
of the six bases defining a Hind III site followed by digestion with EcoRI and HindIII. 
Since HindIII can only cut the linker if it ligates next to a d(AA):d(TT) dinucleoside 
base pair, heterogeneous ends are produced and cloning achieved in a unidirectional 
manner.  To protect internal EcoRI and HindIII sites upon digestion, 5-methyl dCTP is 
mRNA (A)n     3'
Synthesize cDNA
CH3 CH3
cDNA
cDNA
AA     3'
TT     5'
CH3 CH3
Ligate Directional
Linkers
CH3 CH3
cDNA
cDNA
AAGCTTGAATTCAAGC     3'
TTCGAACTTAAGTTCG     5'
CH3 CH3
Hind III Eco RI
Digest with
EcoRI + HindIII
5'     GCTTGAATTCAAGC
3'     CGAACTTAAGTTCG
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CH3 CH3
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A               3'
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CH3 CH3
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used in both first strand and second strand syntheses and the resulting cDNA clones 
propagated in a non-methylating host so that their methylation patterns are no longer 
retained (88).   
First strand cDNA was obtained after optimization of the random hexamer 
concentration. 100ng DTT Hexamer was used with 10μg of Pup14 after analysis of the 
phophrous image as shown in Figure 22. 50ng DTT hexamer was used with 10μg of 
Hon6 and 50ng DAG hexamer was chosen for Pup16 by a phosphrous image analysis, 
more data is attached on AppendixA (Figure A.1). 
 
 
 
 
 
 
 
 
 
 
Figure 22: Optimization of cDNA synthesis of Pup14A/B by varying the concentration of the 
random DTT Hexamer. 
 
 Double strand cDNA was prepared via 2
nd
 strand reaction. Second strand reaction 
was performed with a different ratio of methyl-dCTP to dCTP. After analysis of 
3.0 kb 
 
2.0 kb 
1.5 kb 
 
1.0 kb 
0.5 kb 
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phosphrous image, one to one ratio of methyl-dCTP to dCTP was employed for the 
second strand reaction. (Shown in Figure 23) 
 
 
Figure 23: Phosphrous image of second strand cDNA with Pup14A/B.  
 
After fractionating the cDNA using a fractional column, 4 to 5 fractions were 
combined to get about 10ng of cDNA at a concentration of ≥1ng/μl for use in the 
ligation reaction. DNA was precipitated following the ligation reaction and 
transformated into EC100 or NovaXGTM Zappers competent cells as described in the 
experimental procedure. Base on blue and white screening the first fraction group after 
column appeared to give the best results. The selected group was subjected to check 
insertion size with different restriction enzymes. As shown in Figure 24, more than 80% 
of selected clones of Pup14 A/B and Hon6 cDNA libraries have bigger than 3 kb size 
insertion after digestion with EcoRI.  Pup16 cDNA library showed about 30% clones 
with an insert larger than 3 kb. More detailed results are attached at Appendix A (Figure 
A.2).  
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By the approach described above, a cDNA library was successfully generated from 
the marine microorganism Pup14A/B and Hon6 (Figure 24, representative clones of the 
libraries).  Generated clones were collected and stored as described in experimental 
procedures. The resulting cDNA library in E. coli strain NovaXGTM Zappers was 
subdivided into 40 pools of 10,000 clones for Pup14A/B and 60 pools of 15,000 clones 
for Hon6.  Frozen glycerol stocks of each pool also were prepared. 
 
   A                                                                B 
 
 
 
 
 
 
 
 
 
Figure 24: Representative clones from the Pup14 cDNA library (A) and Hon 6 cDNA library (B) 
cut with the restriction enzyme EcoRI. Each clone contains an insert greater than 3kb size.  
Ladder is 1kb DNA ladder from NEB. More data as attached on Appendix A. 
 
Screening of cDNA Libraries for the Identification of Natural Product Biosynthetic 
Genes. Directional cDNA expression libraries offer an attractive complement to BAC 
library expression cloning (overview of approach Figures 20 to 23).  Partial purification 
Pup14 
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of crude protein extracts can offer whole genome representation of proteins.  Coupled 
with a selection strategy involving the use of rare enzyme cutters, the procedure could 
find general use for bio-prospecting of natural product biosynthetic pathways. A protein 
extract of the cDNA library was prepared and the expressed proteins purified with a Ni-
NTA column. The protein extract was incubated with radio-labeled acetate or radio–
labeled S-adenosylmethionine in addition to co-factors (NADPH, SAM, FAD) and other 
cellular components (prepared by filtration of a crude protein extract from E. coli, 
Pup14A/B or Hon6 through a stirred cell apparatus. Following incubation, the extract 
was extracted with organics. The extract was run on the TLC plate in 15 CH2Cl2: 1 
methanol solution and then was exposed on phosphorous image plate. The result was 
analyzed by phosphorous imager. (Shown in Appendix Figure A.3) This approach failed 
to yield any intresting results. Another approach is analysis of the extract by HPLC. All 
peaks will be collected and analyzed for radioactivity with a scintillation counter.  
Identification of the natural product biosynthetic genes will be achieved by using rare 
enzyme cutters to deplete the library while not disturbing vector sequence (refer to 
Figure 25). The depleted library will be re-introduced into E. coli. If natural product 
production is affected, cut sequences can be distinguished from the remainder of the 
library population by ligating and cloning them into a vector containing a different 
selectable marker, the DNA will be isolated and sequenced. Finally, the identified 
sequences could then be used to probe a BAC library of the organism for elucidation of 
the remainder of the pathway genes. We however realized that it would require 
significant resources to complete the screening. Therefore, the prepared samples have 
been stored at -20 C until more funds are available for sequencing and MS analysis 
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Figure 25: cDNA library depletion approach with rare enzyme cutters.  
 
Screening of cDNA Libraries for Naphthenic Acid Converting Enzymes. The cDNA 
libraries were also screened for metabolic enzymes that can neutralize the effects of 
naphthenic acids (Figure 17). Degenerate oligonucleotide probes generated through 
sequence comparisons will be employed to identify S-adenosylmethionine dependent 
methyltransferase genes (converting carboxylic acids to esters), reductases (transforming 
carboxylic acids to aldehydes), and decarboxylases (89, 90). 
To identify enzymes from the marine environment to “neutralize” the deleterious 
effects of High Acid Crude (HAC), cDNA libraries from marine sources will be 
screened with degenerate oligonucleotide probes to identify appropriate metabolic 
enzymes. SAM-dependent methyltransferase primers were as following; M1F: 5‟ GAY 
TTY AAY CAR ATY TTY CA-3‟; M2F: 5‟-AAY CAN GRN CAY TTY TTY CA-3‟; 
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M2R: 5‟-TGR AAR AAR TGN CAN GTR TT-3‟; M3F: 5‟-GAR AAR GAY GAY TTY 
ATG CAR TT-3‟; M3R: 5‟-AAY TGC ATR AAR TCY TTY TC-3‟; M4R: 5‟-CAR-
TAD ATN GGR ATR TTR AA-3‟.  To get optimized conditions for PCR, M1F-M2R 
(252bp), M1F-M3R (540bp), M1F-M4R (948bp), M2F-M3R (258bp), M2F-M4R 
(666bp), and M3F-M4R (378bp) primer sets were performed with Pup14A, Pup14B and 
Hon6 genomic DNA.   
Carboxylic acid reductase primers are R1F: 5‟-CCN AAR GGN GCN ATG TAY 
AC-3‟, R2F: 5‟-TTY GAY GAR GAY GGN TTY TA-3‟, R2R: 5‟- TAR AAN CCR 
TCY TCR TCR AA-3‟, R3F: 5‟-TAY GCN AAY GGN RAY GGN AA-3‟, R3R: 5‟-
TTN CCR TAN CCR TTN GCR TA-3‟ and R4R: 5‟-ARC CAR TCN ACR AAN GTR 
TC-3‟. For the optimization of PCR condition, the following primer sets were used for 
PCR reaction; R1F-R2R, R1F-R3R, R1F-R4R, R2F-R3R, R3F-R4R and R3F-R4R. 
Even though Carboxylic acid reductase primers were designed with conserved region by 
multiple alignments, there are significant variations of non-conserved regions observered 
in different organisms.  Any clear PCR product therefore was subjected for sequencing 
analysis. Degenerate oligonucleotide probes have been designed as shown in Table. 3.                         
 
Table 3: Designed degenerate primers of metabolic enzymes 
Carboxylic acid reductase                                              SAM-dependent carboxylic acid methyltransferase 
5‟- CCN AAR GGN GCN ATG TAY AC-3‟                  5‟- GAY TTY AAY CAR ATY TTY CA-3‟ 
5‟- TTY GAY GAR GAY GGN TTY TA-3‟                  5‟- AAY CAN GRN CAY TTY TTY CA-3‟ 
5‟- TAR AAN CCR TCY TCR TCR AA-3‟                   5‟- TGR AAR AAR TGN CAN GTR TT-3‟ 
5‟- TAY GCN AAY GGN TAY GGN AA-3‟                 5‟- GAR AAR GAY GAY TTY ATG CAR TT-3‟ 
5‟- TTN CCR TAN CCR TTN GCR TA-3‟                    5‟- AAY TGC ATR AAR TCY TTY TC-3‟ 
 5‟- ARC CAR TCN ACR AAN GTR TC-3‟                  5‟- CAR TAD ATN GGR ATR TTR AA-3‟ 
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PCRs were performed with genomic DNA of Pup14A, Pup14B, and Hon 6 to 
optimize PCR conditions and primer sets for each reaction as described in expreimetal 
procedure. The PCRs were analyzed using an agarose gel. To screen SAM-dependent 
methyltransferase primer sets, the reaction M1F-M2R, M2F-M3R and M3F-M4R with 
Pup14A resulted in PCR products of the expected size and the reaction with M2F-M3R 
primer set resulted in a product of the correct size from Pup14B. However, no PCR 
product of the expected size was found with Hon6.  Detailed results are shown in 
Appendix Figure 4. For Carboxylic acid Reductase screening, all primer sets generated 
PCR product with Pup14A (Figure 26) and M1F-M2R, M1F-M4R and M3F-M4R 
reaction gave PCR product with Pup14B. Hon6 gave no PCR product with Carboxylic 
acid Reductase primiers.             
                                      
   
                        A                                                   B                                                 C 
 
Figure 26: Gel analysis with PCR product of carboxylic acid reductase on Pup14A.  Ladder is 
1kb DNA ladder from NEB. A: top R1F-R2R primer bottom: R1F-R3R; B: top R1F-R4R 
bottom: R2F-R3R; C: top R2F-R4R bottom: R3F-R4R primer set was used. 
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In conclusion, cDNA libraries of Pup14 A/B and Hon6 were successfully constructed. 
We attempted to find a desired clone for indentification of a natural product biosynthetic 
pathway with various methods. However, no useful biosynthetic pathways were detected 
with cDNA libraries so far. Screening of the cDNA libraries involved lots of sequencing 
with different primer sets. I did not include a chromosome walking experiment we used 
to identify valuable clones which was not completed due to lack of funds. Sequencing is 
quite expensive because numerous samples are required to obtain desired sequences.  
Ideally, the identified clone of the cDNA libraries can be utilized as a probe for 
identification of the remainder of the pathway genes of a genomic library.   
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CHAPTER III 
 
CONSTRUCTION AND ANALYSIS OF FOSMID LIBRARY OF 
ENVIRONMENTAL DNA IDENTIFICATION AND SCREENING OF 
NATURAL PRODUCT OF BIOSYNTHETIC PATHWAYS 
 
INTRODUCTION 
 
Traditional approaches to natural product discovery involve cell-based screening of 
natural product extracts followed by compound isolation and characterization. Their 
importance notwithstanding, continued mining leads to depletion of natural resources 
and the reisolation of previously identified metabolites. Metagenomic strategies aimed at 
localizing the biosynthetic cluster genes and expressing them in surrogate hosts offers 
one possible alternative. Environmental libraries have been extremely valuable as a 
source of information about microbial diverisity in natural ecosystems, even though little 
information about the physiology of unknown organisms (91).  The construction of 
fosmid libraries from uncultured organisms is one method that theoretically can yield 
more insight into the metabolism and genetics from the sample (91, 92).   
Great strides have been made with the randomized cloning of soil bacterial genomes 
giving rise to natural product expression without further manipulation (primarily through 
the use of fosmid libraries) (57-61). Antibiotics turbomycin A and B,were both isolated 
and produced from a 24,546-member fosmid library (61).                    
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The most popular systems for less than 50 kb-insert libraries are cosmid libraries 
containing cos sites (cohesive ends) which are recognized by the viral proteins for 
packaging. A fosmid library is a modification of the cosmid with an F-factor origin of 
replication to lower the copy number of the generated plasmid, increasing its stability. 
Because the minimal DNA sequence to encode these functions requires about 10kb, 
these vectors are capable of carrying approximately 40 kb of foreign DNA. Construction 
of -bacteriophage-based libraries is a popular technique for molecular biologists (93-
95). A wide variety of vector systems have been constructed based on this system which 
primarily differ in the amount of the original viral genome and function still contained in 
the DNA fraction of the system (93). The viral head, which carries the DNA construct, is 
limited by volume to contain no more than 50 kb of DNA, so the less viral sequence 
contained in the DNA the larger the foreign insert can be. While the fosmid cannot 
compete with the BAC (bacterial artificial chromosome) library or YAC (yeast artificial 
chromosome) library in terms of the size of the insert it can propagate, the fosmid gives 
wider information in fewer samples than a cDNA library. Fosmids are commonly used 
for preparing genomic libraries when a smaller insert size is desired. The inserts have an 
average size of 40 kb and are produced by random shearing, yielding more uniform 
coverage of the genome than other library types. Fosmids are excellent candidates for 
closing gaps in a whole genome sequence and physical maps due to their uniform 
coverage. Additionally, they are popular for metagenomic and expression studies (53, 
58, 91, 96) . The entire 40 kb insert can be shuttled into an expression vector more easily 
than a larger insert (92) and the inducible high copy number per cell allows for easier 
  
60 
manipulation and cheaper downstream applications. Because of these advantages, we 
attempted to construct fosmid libraries from environmental samples. 
 
  
Microbial 
Sample
Isolate/Purify 
Genomic DNA
Genomic DNA
Shear, End-
Repair, Size 
Select
30-40 Kb Inserts Vector
cos site
Mix & Ligate
Viral Protein Extract
Viral Chromosome 
Concatamer Mimic
Mix & 
Package
Packaged ViroidsE. coli Clones
Infect
 
Figure 27: Overview of the fosmid library construction. 
 
 
 
I described the method used to construct a fosmid library of CD151 and CD179 in the 
shuttle cosmid vector pOJ446. This included (A) preparation of pOJ446 vector (B) 
preparation of Genomic DNA from CD151 (C) preparation of Recombinants (D) 
isolation and analysis of the clones. Each of these is discussed in detail below. 
 
  
61 
EXPERIMENTAL PROCEDURES 
 
 General. Cells were routinely grown in LB medium containing 1% Bacto Tryptone 
(Difco), 0.5% yeast extract (Difco), and 0.5% NaCl with 50μg/ml for ampicillin. 
UltraClean Mega Prep Soil DNA Kit was purchased from MO BIO Laboratories, Inc. 
(Carksbad, CA). Qiaprep Spin Mini Kit, QIAGEN plasmid kit, QIAquick Nucleotide 
Removal kit, and QIAquick Gel Extraction Kit were obtained from QIAGEN Inc 
(Valencia, CA).  Restriction enzymes and alkaline phosphatase enzymes were obtained 
from New England Biolabs (Ipswich, MA 01938-2723). Pulsed Field Gel 
Electrophoresis (PFGE) was performed on a BioRad CHEF DR II apparatus (Hercules, 
CA).  Electroporation of cells was carried out with a BioRad MicroPulser (97).  The E. 
coli strain DH10B was obtained from Prof. Dennis Gross, Texas A&M University, 
Department of Plant Pathology. 
  
Constructions of Fosmid Libraries from Environmental DNA with pCCIFOS Vector 
(eDNA, Biofilm). A fosmid library has been constructed from the samples collected from 
Galveston Beach. Sheared DNA of approximately 40 kb was isolated, end-repaired, 
packaged, titered, and plated (Figure 1). The CopyControl™ pCC1FOS™ cloning vector 
for CopyControl Fosmid library production is supplied linearized at its Eco72 I (blunt) 
site and then dephosphorylated and is ready for cloning end-repaired (blunt end) 
genomic DNA of approximately 40 kb (Epicentre).  End- repaired eDNA is shown in 
Figure 28. Biofilm was obtained from a field collection by Dr. Dan Thornton, 
Department of Oceanography, Texas A&M University, in the Gulf of Mexico. The 
  
62 
biofilm was initially washed with 19g/L instant ocean seawater to remove dirt and 
debris, and then cut with a razor blade into small pieces. The pieces were flash frozen in 
liquid nitrogen, then ground with a mortar and pestle. (This part was performed by Dr. 
Angell)  The Biofilm fosmid library was also constructed as described in manual 
provided by Epicentre (98). 
 
Figure 28: End- repaired eDNA ready for size selection on pulsed field electrophoresis (CHEF 
gel).   
 
 
Constructions of Fosmid Libraries from Environmental Samples with pOJ446 Vector 
(C3, Bahama, CD151, CD179). Fosmid libraries were constructed with pOJ446, which 
is a cosmid shuttle vector for cloning (99) (shown in Figure 29) instead of Copycontrol 
pCC1FOS vector provided from EPICENTRE. pOJ446 can be maintained in both E. coli 
and Streptomyces. pOJ446 vector has Apramycin–resistance as an antibiotic selectable 
marker. In this study we also used methylation-deficient strain dam
-
/dcm
-
 from NEB. In 
wild-type E. coli, dam methylase transfers a methyl group to the adenine in the sequence 
GATC, and dcm methylase does to internal cytosine in the sequences CCAGG and 
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CCTGG (100). The strain dam-/dcm- was employed for transformation in streptomyces 
for future experiments.  
 
Figure 29:  pOJ446 vector map. After Bierman, M. et al (99). 
 
Isolation of pOJ446 Vector DNA from E. coli.  pOJ446 in strain DH10B was grown 
in 5ml of LB+Apramycin (50μg/ml) for overnight then inoculated in 500ml LB + 
Apramycin media for about 16hrs. The cells were spun down at 9000 rpm for 10 min 
then purified with a QIAGEN Plasmid Maxi kit. The purification procedure was 
followed as described in the protocol provided in kit. 
 
Cleavage of Vector DNA and the Preparation of Linearized DNA. Double digestion, 
which is cleaving a DNA substrate with two restriction enzymes simultaneously, was 
performed to obtain linearized vector DNA. HpaI and EcoRV were chosen as restriction 
enzymes to get the blunt end site for pOJ446 vector DNA. The remaining two cos sites 
of pOJ446 vector would make it possible to package into bacteriophage λ particles. The 
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restriction digestion included EcoRV (20units), HpaI (5units), NEB buffer#4, 100X BSA 
(10mg/ml), pOJ446 vector DNA, and water was performed at 37°C for 1.5hr, and then 
heat inactivation at 80C was followed to kill the enzyme. Linearized pOJ446 vector was 
purified by agarose gel electrophoresis (shown in Figure 30 (A)).  ~9 kb fragment was 
cut from the gel and isolated using QIAquick Gel Extraction Kit. Final concentration of 
linearized pOJ446 vector is 0.5μg/μl shown in Figure 30(B). After 1st elute obtained, the 
column was eluted 4 times more with deionized water to improve the yield of DNA 
recovery. 5
th
 elute was detected on 1% agarose gel (Figure 30(B)). 
       
 
Figure 30: (A) After double digestion of pOJ446 vector DNA. (B) Recovered DNA after gel 
extraction.  (1: 1
ST
 elution 2: 5
th
 elution 3: total) 
 
 
Dephosphorylation of Blunt–Ended pOJ446 Vector. DNA 10μg of double digested 
pOJ446 vector DNA was dephosphorylated with 5units of CIP in NEB buffer #3 for 15 
min at 37°C, then another 5units of CIP was added into the mixture to ensure complete 
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dephosphorylation. After another 45 min incubation at 55°C, the reaction was terminated 
by adding 4μl of 0.5 M EDTA and heat inactivation at 75°C for 10 min. 
Dephosphorylated pOJ446 vector DNA was concentrated with isopropanol precipitation 
followed by washing by 80% ethanol. Final concentration of pOJ446 vector DNA was 
0.5μg/μl shown in Figure 31. 
 
Figure 31: Dephosphorylated pOJ446 vector DNA with two arms. Lane 1:1kb ladder (NEB), 
lane 2: 33μg/μl,   lane 3: 5μg/μl. 
 
 
Preparation of Genomic DNA from CD151. CD151 sample was obtained from 
Arabian Sea, Pakistan Margin by RRS Charles Darwin. The core was taken on 
September, 27, 2003 from actual depth 263m. PowerMax Soil DNA Isolation kit from 
MO Bio Laboratories, Inc was used to extract sample DNA of CD151. After obtaining 
~20μg purified DNA, we performed end repair reaction, which converts 3‟ and 5‟ 
overhangs into blunt ends with DNA terminator End Repair kit from Lucigen 
Corporation to get blunt ended CD151 DNA. We were interested in DNA bigger than 
10kb size. Pulsed Field Electrophoresis (CHEF gel) was run for size selection shown in 
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Figure 32. We usually performed Gel elution using Pulsed Field Elctrophoresis, but the 
yield was quite low. In this study, we used gel extraction kit from QIAGEN to get the 
size selected DNA after running the CHEF gel. After gel extraction, we got the size 
selected DNA with ~7ng/μl. Isopropanol precipitation was performed to get 20ng/μl for 
ligation reaction. 
 
 
Figure 32: (A) Pulsed field electrophoresis of CD151 end-repaired DNA. (B) Pulsed field 
electrophoresis of CD179 end-repaired DNA CD151 from Arabian Sea, Pakistan Margin and 
CD179 from Nazare canyon, Portuguese magargin. 
 
 Preparation of Recombinants. Ligation reaction was performed with following 
condition; 1 μl 10X ligation buffer, 1 μl 10mM ATP, 1 μl pOJ446 (0.5μg/μl), 6 μl insert 
DNA, and 1 μl Fast-Link DNA Ligase in total 10 μl reaction followed by 2 hours 
incubation at room temperature and then heat inactivation at 70C for 10min. Amount of 
insert DNA used was 1:5 and 1:10 ratio of vector to insert DNA. Electroporation instead 
of packaging and titering was chosen for these library constructions (CD151 and 
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CD179). The ligation mixture was desalting using Agar-cone on ice for 1hr, followed by 
electroporation into E. coli EPI300-T1
R
 competent cells provided with the Fosmid 
library construction kit. 
 
Isolation and Analysis of the Clone of the Constructed Library. After transformation 
of the library into E. coli EPI300-T1
R
, ten randomly selected clones were selected from 
1:5 and 1:10 ratio ligation conditions. Plasmid DNA was isolated by alkaline lysis using 
QIAGEN Plasmid mini kits according to standard procedures (101). The plasmids were 
digested with EcoRI and analyzed by PFGE (Figure 33 and 34). Colonies were selected 
and arrayed on 384-well plates. In total, thirteen plates were arrayed for each 
environmental library, giving a total of 4992 members in each library. 
 
Smaple Preparation for the Ames Test. CD151 and CD179 libraries were used for the 
Ames test. Each plate was grown in 500 ml LB+Apramycin (10μg/ml) media. The 
supernatant was removed by centrifugation, the cell pellet was resuspend in 50ml of 1:1 
(Methanol: Dichloromethane) mixture. After 4 hrs stirring, the cell debris was removed 
by filtration. The filtrate was dry out with Rotory vaporizer and then purged with 
nitrogen gas to completely dry out. The sample was dissolved in 500µl of DMSO, 
ethanol can be used in the case of the sample does not completely dissolved in DMSO.  
For the Ames test, E. coli WP2 (CGSC#5378) and AB2437(CGSC#2437) strain were 
used. 
 
 
  
68 
RESULTS AND DISCUSSION 
  
Isolation of DNA from Environmental Samples. DNA purification from 
environmental samples was the most difficult, because the yield is too low and the DNA 
is susceptible to degradation by many enzymes and microbes present in the environment 
(97).  After we evalutated several methods to isolate DNA from environmental samples, 
the UltraClean Mega Prep Soil DNA Kit was determined to be the best method. DNA 
was isolated by following the protocol provided with the UltraClean Mega Prep Soil 
DNA Kit. Some representative isolated samples are shown in Figure 33. 
 
 
                              A                            B                          C                     D  
Figure 33: Isolated DNA from environmental samples. All lane 1 is 1kb DNA ladder (NEB) A: 
lane 2: control DNA (1μg/μl) lane 3: eDNA, B: lane 2: control DNA (1μg/μl) lane 3: Sittee river, 
C: lane 2: control DNA (1μg/μl) lane 3:C3, D: lane 2: CD179 
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Construction of the Fosmid Library from Environmental Samples. Fosmid library 
construction was attempted with 13 different samples. (12687, 12704, 12723, Biofilm, 
eDNA from Galveston beach (Texas), A: Mouth of Mississippi, B: Atchafalaya Bay, C3: 
Louisiana/Texas border Jones lagoon, M: Mystery cay, BH: Bahamas, SR: Sittee River, 
CD151, CD179).  
 Fosmid libraries were successfully constructed with traditional packaging method 
from the following samples: the Biofilm from Gulf of Mexico, eDNA from Galveston 
beach at Texas, C3 from Louisiana/Texas border, and “Bahamas” from the Bahamas.  
However, we did not obtain enough clones of eDNA fosmid library from Galveston 
beach. The first 7 clones from eDNA forsmid library after digestion have bigger than 
35kb size insertion as shown in Figure 34.  Control DNA is 35kb size. Unfortunately, 
purification of eDNA resulted in low DNA yield and ligation efficiency is not enough to 
get many colonies. The number of clones obtained was insufficient to produce a library. 
The number of colonies is required to achieve sufficient coverage of putative 
biosynthetic pathways within the library. 
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Figure 34: Pulsed field gel electorphoresis (PFGE) sizing of fosmid library of eDNA after 
digestion with EcoRI. Control DNA size is 35kb.  Lane 1, 13: NEB midrange II PFG marker.  
Lane 2, 14: control DNA. Lane 3-9: EcoRI digests of fosmind clones. Lane 10,11: undigested 
lane 3 and 5. 
 
 
CD151 fosmid library and CD179 library were constructed with a slightly different 
method. A Streptomyces - E. coli shuttle vector was used in place of a fosmid. I tried a 
packaging method and a transformation with electroporation method. Based on the 
investigation of insertion size, I decided to use the transformation method.  The method 
had been successfully applied to different systems in our lab. Sample CD151 and CD179 
were obtained from the Pakistan margin in Arabian Sea and the Portuguese margin in the 
Atlantic Ocean respectively. These 2 samples originate in the earth of deep depth under 
the ocean which may contain different microorganisms than the surface and terrestrial 
soil.   
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To get the clones with bigger insertion size, ligation reaction was performed with 
different ratio of the vector and insert DNA. CD179 fosmid clones were ramdomly 
chosen to check the insertion size with various enzymes. The pulsed field gel 
electrophoresis was performed after digestion with EcoRI of the representative clones as 
shown in Figure 35. 60% of greater than 10kb size insertion was found in 1:5 and 40% 
from 1:10 ratio of the ligation. The ligation from the ratio of 1:5 (vector to insert) has 
large-size inserts compare to from 1:10 ratio ligation.  However, 1:10 has better variation 
of the insertion size. Therefore, 4600 clones were selected from the ligation of 1:10 ratio 
and 2300 clones were selected from the 1:5 ratio. 
 
Figure 35: PFGE sizing of fosmid inserts (CD179). Lane 1,14-NEB 10kb markers. Lane 3-12 – 
EcoRI digests of CD179 fosmid clones. 1:5 (vector: insert) has large-size inserts, so using this 
ratio 6 plates of clones were selected. 12 plates of clones were selected from 1:10 which has 
better variation of the size. 
 
Screening of an Environmental Fosmid Library. The Construction of fosmid library 
has been performed with many environmental samples obtained from the various 
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locations as described above. A total of ~5,000 clones was collected and screened for 
natural product production. Metabolite production was assayed by two independent 
methods including zone of inhibition assays and metabolic profiling by LC/MS spec 
analysis. An overview of the entire approach is shown in Scheme 3. 
Zone of Inhibition Assays. Fosmid libraries were examined for natural product 
production by assaying for growth inhibition against a lawn of cells such as B. subtilis or 
yeast (53). Two strategies could be employed. Either the cells could be plated with pins 
in a 96–well format on a lawn of cells, or the fosmid library clones could be cultured and 
extracted with methanol or dichloromethane, and the organic extracts applied to filter 
disks and laid on the cultured lawn of cells (Kirby-Bauer technique,(102)).  Inhibition 
would be observed by the presence of a halo around either the cell colony or filter disk. 
We chose the second method for screening of fosmid libraries (Biofilm, CD151, and 
CD179); methanol or dichloromethane extracted sample was dried with rotor vaporizer 
and then resuspended in however no interesting results were obtained.   
Metabolomics Approach. The metabolic “blue prints” of the fosmid library colonies 
will also be compared to control colonies harboring the vector alone. The fosmid library 
colonies were grown, pooling sixteen colonies at a time, which will subsequently be 
extracted with ethyl acetate. The extracted colonies will be directly compared to extracts 
generated from the control colonies utilizing LCMS for analysis. All extracts will be 
examined in duplicate.  16 colonies combined to one sample for the LC/MS analysis. 
312 LC/MS samples from Biofilm fosmid clones were prepared and then stored at -20C 
for the LC/MS analysis. 
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Scheme 3: Overview of fosmid library screening: fosmid libraries are transformed into E. coli,                   
the white colonies picked and cultured in 384-well plates. Clones are then examined in zone of 
inhibition assays or their extracts examined by mass spec (metabolomics approach). The fosmid 
clone is then identified, sequenced and the compound(s) of interest characterized. 
 
Screening with 
32
P Labeled Hybridization Probe. Natural product biosynthetic genes 
are typically clustered in prokaryotic genomes and are often clustered in fungi as well 
(103). Hence, detection of a single gene is often sufficient for the identification of the 
remainder of the gene cluster. Fosmid library screening with radiolabeled degenerate 
probes has thus been extensively utilized to target specific biosynthetic genes, such as 
polyketide synthases (PKS), and non-ribosomal peptide synthetases (NRPS). For the 
screening of the Biofilm fosmid library with hybridization probe, we employed 
nitrocellulose filters which can be used for replica plating and in situ hybridization.  The 
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procedure was followed as described in literature (104). To test a large number of clones 
at one time, the library was spread out on agar plates, and then the clones were 
transferred to filter membranes. The clones could be simultaneously hybridized to a 
particular probe. All 13 plates of Biofilm fosmid library were screened with a 
32
P labeled 
hybridization probe (
32
P dATP). The best hit (#4E10 from Biofilm fosmid library, Plate 
#4, row E and column 10) was chosen by analysis with a Phosporimage reader. Ninety 
positive clones were found, forty clones with the most intense signal selected, then 
sixteen positive colonies were sequenced with PKS primers. PCR reaction results and 
conditions are shown in Appendix B.  After sequencing analysis by NCBI blast search 
(86), 5 PKS (such as PKS type I, Modular PKS, PKS/NRPS), NRPS, and many Biotin 
synthase genes (bioB, bioC, bioF) were found.   On the way of this analysis, we decided 
to try screening for biotin biosynthetic pathways within a fosmid library. Detailed data is 
shown in Appendix B. 
 
Genetic Selection with Environmental Samples.  We identified the biotin biosynthetic 
genes within Hon6 to evaluate the potential use of genetic selection in the elucidation of 
biosynthetic pathways from marine microbial consortia. (Detailed in Chapter IV) As 
mentioned earlier, we constructed many fosmid libraries from environmental samples. 
We employed the strategy in a proof of principle experiment using the Hon6 system. We 
used the genetic selection for the biotin and Ames test. The Ames test is a biological 
assay to assess the mutagenic potential of chemical compounds (105). A positive test 
indicates that the chemical might act as a carcinogen. The test uses Salmonella 
typhimurium strains that carry mutations in genes involved in histidine synthesis, so that 
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they require histidine for growth. The variable being tested is the mutagen's ability to 
cause a reversion to growth on a histidine-free medium. The bacteria are spread on an 
agar plate with a small amount of histidine. This small amount of histidine in the growth 
medium allows the bacteria to grow for an initial time and have the opportunity to 
mutate. When the histidine is depleted, only bacteria will survive which can produce 
histidine by itself with mutation. The mutagenicity of a substance is proportional to the 
number of colonies observed.   
CD151 and CD179 fosmid libraries were screened by Ames test. The plate was 
incubated for at least 48 hours. We used E. coli WP2 (CGSC#5378) and 
AB2437(CGSC#2437) histidine deficient strains. Azinomycin B in ethanol (1μg) and 
Methyl methanesulfonate (MMS, 12.99mg) were used in a serial dilution for positive 
control experiments. Compared to the positive control, we did not get more or an equal 
number of colonies grown on the agar plate. The plasmids from CD151 and CD179 
fosmid libraries were transformed into E. coli WP2 and AB2437 competent cell, no 
survival colony was detected.  CD151 and CD179 fosmid libraries were also screened 
with biotin deficient strains. Many positive results were obtained. Data for biotin 
screening with the Biofilm fosmid library is shown in Appendix B. C3 samples were 
also screened with bioA, bioB, bioC, bioD, bioF, and bioH.  Only bioA, bioB, and bioD 
were detected. Data is shown in Appendix B.  We published the data obtained with 
Hon6, therefore we attempted to find a novel biotin biosynthetic pathway within the 
positive ones.  We did not get desired results for this attempt so far. 
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In conclusion, we successfully constructed 5 different fosmid libraries among 16 
trials. The main issue for the failure to construct libraries from environmental samples is 
poor DNA yield. DNA isolation from environmental samples is a major bottleneck for 
most studies requiring large sample sizes. Specifically, marine environmental samples 
do not contain as much DNA when compared to a sample from surface of the earth. If 
we can improve the method to isolate environmental DNA, the rate of success of 
construction of the DNA library will be dramatically increased. Construction of the 
libraries is labor intensive and also a time consuming procedure; however it is a required 
procedure to screen for the identification of desired clones. We attempted to identify 
NRPS and PKS DNA fragments by 
32
P labeled hybridization probe and PCR.  Based on 
the sequencing results of the identified clone, as I mentioned above, our interest was 
inclined to a genetic selection method to identify a biotin biosynthetic pathway with 
Hon6 library.  The result is shown in Chapter IV. Genetic selection with the Ames test 
was interesting and a fast method mutant clones.  
Clones from the constructed libraries can be screened by genetic selection for several 
other biosynthetic pathway such as thiamine synthase (ThiC), pyrimidine synthase 
(nadA), heme (hemN), lipoyltransferase (LipB), and thiamine biosynthesis (ThiH). 
 
 
 
 
  
77 
CHAPTER IV 
 
ESTIMATING P-COVERAGE OF BIOSYNTHETIC PATHWAYS IN DNA 
LIBRARIES AND SCREENING BY GENETIC SELECTION: BIOTIN 
BIOSYNTHESIS IN THE MARINE MICROORGANISM 
CHROMOHALOBACTER* 
 
INTRODUCTION 
Recent advances in molecular microbial ecology have revealed that microbial 
diversity in nature far exceeds that reflected in laboratory strain collections since the 
majority of naturally occurring species either cannot withstand the conditions imposed 
by traditional culture media, or do not grow sufficiently to produce observable colonies 
under these conditions(106-108). Cultivation-independent analyses such as microbial 
rRNA sequencing have dramatically altered phylogenic definitions of major microbial 
classes and suggest that a large fraction of indigenous microbial communities are 
composed of new but uncultivable microbial groups(34, 109-111). Therefore, improving 
organism culturability could unveil previously untapped resources and natural products 
with novel structural frameworks. Some success has been achieved using high-
throughput culturing  
_________________ 
* Reprinted with permission from “Estimating p-coverage of biosynthetic pathways in 
DNA libraries and screening by genetic selection: Biotin biosynthesis in the marine 
microorganism chromohalobacter” by Eun Jin Kim, Scott Angelle, Coran M. Watanabe 
2008. Mol. BioSyst. 4, 606-613. Reprinted by permission of The Royal Society of 
Chemistry. 
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procedures that utilize the concept of extinction culturing to isolate cells in very low 
nutrient medium and small volumes(112). Moreover, recent work involving microbial 
challenge experiments (82, 113) and small molecule activation studies(114) has yielded 
promising results in the induction of “silent” natural product pathways. 
An alternative strategy would be to “shotgun” clone environmental genomic DNA 
and express these whole genomic bacterial communities within heterologous hosts. 
Recent studies with soil samples and bacterial symbiont genomes are beginning to reveal 
the potential of this technology for both natural product and enzyme discovery (57-59, 
96, 109, 115-117). Molecular screening of recombinant environmental libraries with 
degenerate probes recognizing specific biosynthetic gene sequences have also proved 
quite fruitful in the identification of natural product biosynthetic pathways (96, 118-
120). In some instances, heterologous expression of these clones has resulted in 
metabolite production (121). 
Here we provide details on the construction of a large construct BAC library from a 
previously undescribed species of Chromohalobacter. An algorism is put forth to 
estimate the number of colonies required to achieve sufficient coverage of putative 
biosynthetic pathways within the library, “Biosynthetic P coverage,” where genome size 
of the microorganism is estimated by flow cytometry. Genetic selection by 
complementation is additionally explored as a method to identify and localize 
biosynthetic gene clusters within marine microbial DNA libraries. 
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EXPERIMENTAL PROCEDURES 
 
General. Pulsed Field Gel Electrophoresis (PFGE) was performed on a BioRad 
CHEF DR II apparatus (Hercules, CA). Electroporation of cells was carried out with a 
BioRad MicroPulser. The E. coli strain DH10B was obtained from Prof. Dennis Gross, 
Texas A&M University, Department of Plant Pathology. N. crassa was obtained from 
the lab of Prof. Deborah Bell-Pederson (Texas A&M University, Department of 
Biology). The E. coli bioB (R875, CGSCII 6954), bioC (R878, CGSCII 7087), and bioF 
(Mec5, CGSCII 7261) knockout strains were obtained from Dr Mary K.B. Berlyn at the 
E. coli Genetics Stock Center, Yale University, MCD Biology Department. The E. coli 
bioA (R879, CGSCII 6952) and bioD (R877, CGSCII 6956) strains were obtained from 
OmniGene Bioproducts. Flow cytometry experiments were carried out on a Becton-
Dickinson FACS Calibur flow cytometer (Franklin Lakes, NJ). Molecular simulations 
were performed on a Intel Pentium 4 running Linux 2.4. 
 
Construction of pClasper lacZ. The lacZ multiple cloning site and its promoter were 
amplified from the vector pBeloBAC11 with primers, ASC1LACZF and MLUILACZR, 
tagged with restriction enzyme sites Asc I and Mlu I, respectively. The resulting DNA 
fragment was cloned into the cloning vector pCR 2.1 TOPO (Invitrogen; Carlsbad, CA). 
The plasmid was miniprepped and digested with the enzymes Asc I and Mlu I, 
respectively. The pClasper vector was also digested with Asc I and Mlu I, phosphatase 
treated, and subsequently ligated to the lacZ construct with T4 ligase. The resulting 
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colonies were miniprepped, screened by digestion with AscI and MluI, and the 
respective clone confirmed through sequencing. 
       ASCILACZF: 5′-ACGCGTTTGGCGGGTGTCGGGGCTGGCTTAA-3′                      
      MLUILACZR: 5′-GGCGCGCCAATTTTTTTAAGGCAGTTATTGGTG-3′ 
 
Isolation of Hon6. The Hon6 strain was identified from marine microbial isolates 
obtained from Honokohau, Maui. Seawater and sediment were plated onto marine 
bacterial plates. Marine agar plates were prepared with slight modification to standard 
literature protocols (83). Yeast extract (1g; Difco), Bactopeptone (1g; Difco), glucose 
(2g), and Bactoagar (10g; Difco) were combined in 500 mL of seawater, prepared by 
mixing instant ocean (19g, Petco) with deionized distilled water. The agar suspension 
was autoclaved, cooled to 50°C, to which miconazole (10mg/L) was added. Hon6 was 
identified from single colonies generated through repeated streaking of microorganisms 
onto fresh plates. Taxonomy of the strain was assigned by the Centrallbureau voor 
Schimmelcultures (CBS) in the Netherlands. 
 
Library Construction. DH10B cells containing pClasper lacZ were grown in a 2L 
culture and harvested by centrifugation(122). The plasmid was isolated using a Qiagen 
Maxiprep kit (Valencia, CA). The vector (10μg) was digested and dephosphorylated   
(122). Following dephosphorylation, the vector was further purified by self-ligation and 
electrophoresis (117) and isolated from the surrounding agarose with a Qiagen gel-
extraction kit. 
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Hon6 cultures (500mL; 1L Erlenmeyer flask) were grown for 20 h at 30°C and 250  
rpm. The cell pellet was harvested by centrifugation, washed with TE buffer (97), and 
resuspended in an equal volume of TE. To the suspension was added an equal volume of 
molten agarose (1.5% m/v agarose, 10% m/v sucrose, and 40% v/v glycerol). This 
suspension was streaked out onto a Petri dish cooled on ice and allowed to solidify. The 
solidified agarose was immersed in wash buffer (122) containing 0.15% v/v beta-
mercaptoethanol and incubated on ice for 20 h. The wash buffer was drained and the 
agarose incubated with fresh wash buffer lacking beta-mercaptoethanol for one hour at 
37°C. The wash buffer was replaced with lysis buffer (122) and lysed at 50°C for 48 h. 
The lysed agarose material was embedded in a pulsed field agarose gel and run with 
settings of 15 s initial and final switch times, 6 V/cm, 14°C, and a 12 h run time in 0.5X 
TAE buffer (97). The agarose material was cut out with a razor blade and stored in 0.5 
M EDTA, pH = 8 at 4 °C until use. 
Restriction digest optimization was performed (117). Once optimal conditions were 
established, a preparative digest and double size fractionation was carried out (117) 
employing eight agarose plugs (150 μL), 250 U of Hind III per digest, and 0.5× TAE 
buffer instead of 0.5× TBE. The resulting high molecular weight Hon6 genomic DNA 
was isolated by electroelution with dialysis tubing (122). 
The genomic DNA was ligated to the dephosphorylated pClasper lacZ with T4 ligase 
(two 300ng scale ligation reactions were necessary to produce the required number of 
clones, 1536) and electroporated (2kV; 0.2cm gapped cuvette, BioRad) into 
electrocompetent DH10B cells. Electrocompetent DH10B cells were prepared as 
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described in Current Protocols in Molecular Biology (101). Colonies (1536) were 
arrayed by hand into four 384 well microtiter plates and stored at −80°C. 
 
Insert Size Characterization. Individual clones (24 clones) were cultured in LB broth 
(3mL) supplemented with chloramphenicol (15mg/L) and miconazole (3mg/mL). Clones 
were mini-prepped and the nucleic acid pellet dissolved in TE buffer (101). Samples (10 
μL) were digested with 2 U of I–SceI and analyzed by PFGE (initial switch time: 20 
sec.; final switch time: 6 V cm; 14°C; run time: 12 h). MidRange PFG Marker II from 
New England Biolabs (Beverly, MA) was utilized as a size reference. 
 
FACS Analysis of Genome Size. Overnight cultures (3mL) were prepared for all 
species except Neurospora, which was cultured on an agar slant. E. coli and S. 
cerevesiae were grown for 16 h according to standard procedures in LB and YPD liquid 
media, respectively (97, 101). Neurospora crassa was propagated on an agar slant of 
Vogel's media according to standard procedures (123). Liquid cultures were pelleted by 
centrifugation. Pellets (50μL portions) were resuspended in 1mL of 60% Galbraith 
buffer in EtOH (124). Neurospora multinucleate spores were harvested by scraping the 
surface cultures with a spatula. The cells were resuspended in 60% Galbraith buffer as 
detailed above and filtered through a 20mμm nylon mesh. Samples were incubated at 
4°C overnight, pelleted by centrifugation and resuspended in 500ml Galbraith's buffer. 
The samples were subsequently incubated at 37 °C for 1 h, pelleted by centrifugation 
and resuspended in 500ml of TE buffer containing propidium iodide (0.1mg/mL). 
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Following 1 h of incubation, the cells were again pelleted, resuspended in 500ml of TE 
and analyzed by flow cytometry. 
 
Analysis of Hon6 Biotin Pathway by PCR with Degenerate Probes. The Hon6 BAC 
library was bulk cultured in LB medium supplemented with chloramphenicol (15mg/L). 
Specifically, the BAC library (from glycerol stocks) was stamped onto agar plates with 
384 well pins. Following 24 h of growth, the agar was sliced into pieces and inoculated 
into 1L flasks containing LB medium and chloramphenicol (15mg/L). The cells were 
centrifuged and the DNA isolated using a Qiagen maxiprep kit. The isolated DNA was 
subsequently transformed into the E. coli bioB− strain. Transformed cells were spread 
onto M9 + chloramphenicol (15mg/L) agar plates. The resulting transformants were 
individually cultured in M9 + chloramphenicol (15mg/L) and the DNA isolated with a 
Qiagen miniprep kit. The isolated DNA was employed in PCR reactions with bioB 
degenerate probes. All subsequent PCR reactions employed DNA isolated from bioA−, 
bioC−, bioD−, bioF−, and bioH− E. coli transformants that were generated by isolating 
the bioB− transformant DNA and retransforming them into each knockout strain. The 
PCR cycles were as follows for each of the reactions detailed above: step 1= 95°C for 5 
min; step 2=95°C for 1 min; step 3=annealing temp (−5°C below the melting 
temperature of the oligonucleotide pair) for 1 min; step 4=extension at 72°C for 10 min. 
Steps 2–4 were repeated 50 times and reaction stored at 4°C. The bands were evaluated 
by agarose gel analysis and sequenced. See supplemental information for photos of 
agarose gels and BLAST data. 
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Degenerate primers  
BioA1F: 5′-CAY ATH TGG CAY CCN TAY AC-3′                                                          
BioA2R: 5′-CCR AAN GTR TCN CCR TGR TA-3′                                                            
BioB1F: 5′-GAR GAY TGY AAR TAY TGY CC-3′                                                          
BioB5R: 5′-CCN GCC ATR AAR CAC ATN GCY TG-3′                                                                       
BioC6F: 5′-TNG CNG TNC ART GGT GYG G-3′                                                                   
BioC7R: 5′-GTN GCN CCD ATN CCY TT -3′                                                                         
BioD1F: 5′-GAY ACN GAR GTN GGN AA-3′                                                                          
BioD3R: 5′-GCR TGR TTD ATR CAN CC-3′                                                                                 
BioF10F: 5′-ATG GTN GAY GAY GCN CAY GG -3′                                                                       
BioF11R: 5′-GCY TCN GCN GGN GGC AT-3′ 
PCR conditions  
BioA: 1 μl of Hon6 plasmid DNA, 1 μl of BioA1F primer, 1 μl of BioA2R primer, 0.5 μl 
of Taq polymerase, 5 μl of 10× thermal solution, 0.5 μl of dNTP, 3 μl of MgCl2, and 38 
μl of deionized water. 
BioB: 1 μl of Hon6 plasmid DNA, 1 μl of BioB1F primer, 1 μl of BioB5R primer, 0.5 μl 
of Taq polymerase, 5 μl of 10× thermal solution, 0.5 μl of dNTP, 2.5 μl of DMSO, and 
38.5 μl of deionized water. 
BioC: 1 μl of Hon6 plasmid DNA, 1 μl of BioC6F primer, 1 μl of BioC7R primer, 0.5 μl 
of Taq polymerase, 5 μl of 10× thermal solution, 0.5 μl of dNTP, 2.5 μl of DMSO, and 
38.5 μl of deionized water] 
BioD: 1 μl of Hon6 plasmid DNA, 1 μl of BioD1F primer, 1 μl of BioD3R primer, 0.5 μl 
of Taq polymerase, 5 μl of 10× thermal solution, 0.5 μl of dNTP, 3 μl of MgCl2, and 38 
μl of deionized water. 
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BioF: 1 μl of Hon6 plasmid DNA, 1 μl of BioF1F primer, 1 μl of BioF2R primer, 0.5 μl 
of Taq polymerase, 5 μl of 10× thermal solution, 0.5 μl of dNTP, 2.5 μl of DMSO, and 
38.5 μl of deionized water. 
BioH: 1 μl of Hon6 plasmid DNA, 1 μl of BioH1F primer, 1 μl of BioH2R primer, 0.5 μl 
of Taq polymerase, 5 μl of 10× thermal solution, 0.5 μl of dNTP, 3 μl of MgCl2, and 38 
μl of deionized water. 
Hon6 Extract ELISA. The Hon6 clones (Hon6 #1-1, Hon6 #1-2 and Hon6 #1-3, 
corresponding to plate # and colony #) were each inoculated in M9 minimal salt medium 
supplemented with chloramphenicol (15mg/L). The M9 minimal salt medium (1L) 
consists of 33.9g of Na2HPO4, 3g of KH2PO4, 0.5g of NaCl, 1g of NH4Cl, 20mL of 20% 
glucose, 2mL of 1.0 M MgSO4 and 0.1mL 1.0 M CaCl2. After growth in M9 liquid 
medium for ∼41 h at 37 °C with shaking, 50μL of cells were inoculated again in fresh 
M9 liquid medium with chloramphenicol (15mg/L). After 7 h of growth, they were spun 
down for 5 min at 14 K rpm. The supernatant (50mL) from each sample was used for 
analysis with the vitamin H (Biotin) ELISA kit from MD Biosciences. Analyses were 
performed in duplicate following the manufacture's protocol. Briefly, 50μL of standard, 
serum control or diluted sample was transferred into the wells of the plate and incubated 
for 30 min. The diluted conjugate solution (50μL) was added into each well, and 
incubated for 30 min. After 4 washes with wash solution, 50μL of Chromogen was 
added to each well and incubated in the dark for 30 min. Stop solution (100mL) was 
added to each well and the absorbance of the solution read with a microplate reader 
(μQuant, BIO-TEK instruments, INC) set to 450 nm. All procedures were performed at 
room temperature. M9 medium (with chloramphenicol) was employed as an additional 
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control and showed that the medium contained no biotin. See supplemental information 
for details. 
 
RESULTS AND DISCUSSION 
 
At the outset of constructing a genomic library of a microorganism(s) with the intent 
of mining the biosynthetic genes contained within, one must consider the size of the 
genomic library to effectively represent the genome(s) and their respective gene clusters. 
To address this issue, we have devised the algorism BPC (biosynthetic pathway 
coverage) and apply it to the construction of a BAC library of the marine microorganism 
Hon6.  
 
Achieving “Biosynthetic P Coverage” of the BAC Library (Performed by Dr. Scott 
Angell). The probability of cloning an intact biosynthetic pathway of an organism, 
and/or determining the required number of clones N to ensure proper coverage of the 
genomic library can be calculated from eqn (1),  
  
 
 
where P represents the probability that a given pathway will be represented in its entirety 
by at least one clone in the library, f represents the fraction of G (the genome size of the 
organism) contained within an individual subclone of length I, or f = I/G, and c is a 
coefficient that defines the probability that an insert will contain the sequence of interest 
in its entirety. The eqn (1) is a manifestation of eqn (2),  
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which has been widely employed to calculate the number of clones required to ensure 
that any given gene is represented at least once in a library with probability P(97, 125). 
Eqn (2) is a rearrangement of eqn (3),  
  
  
 which states that the probability of not cloning a fragment, (1 − P), is equal to (1 – f) N. 
Recall that f represents the fraction of the genome contained in I, i.e. it reflects the 
probability that a sequence of interest will be contained in I, and (1 − f) is the probability 
that it will not, where N is the total number of clones. Eqn (2) and (3), however, only 
hold true if the sequence of interest is negligibly small in comparison to the insert size of 
the subclones. In the event that the desired sequence is in the same size range of the 
insert, the probability that the sequence will be cloned intact is considerably less than the 
probability of f. To correct for this scenario we inserted the variable c, where c is defined 
as (eqn (4)),  
  
 
 
where B is the length of the sequence (in our case the biosynthetic pathway) contained 
within the insert I. Hence, as the size of the gene cluster increases, the coefficient c 
decreases lowering the overall probability of cloning the pathway intact, and increasing 
the number of clones required to ensure that the biosynthetic pathway would be 
represented within the library of clones.  
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Hon6 BAC Library Construction (Performed by Dr. Scott Angell). Hon6 was 
identified from marine microbial isolates obtained from the coast of Honokohau, Maui. 
The Centrallbureau voor Schimmelcultures (CBS) in the Netherlands identified the 
strain as a new species, 98% identical to Chromohalobacter. High molecular weight 
genomic DNA was isolated utilizing agarose as a DNA stabilizer. Cultures of Hon6 were 
pelleted by centrifugation, embedded in molten agarose, washed and lysed with 
detergents. DNA degradation occurred to a lesser extent when the embedded cells were 
either streaked in a thin layer or cut into thin sheets prior to lysis. We attribute this to an 
increased surface area, which enhances the diffusion of nuclease inhibitors, detergents, 
and proteases into the agarose matrix. Isolation of megabase DNA was achieved by 
pulsed field gel electrophoresis, which eliminated small fragments of DNA from the gel 
plugs. The agarose plugs containing the megabase DNA were fragmented and digested 
with the restriction enzyme Hind III. A double size selection by pulsed field gel 
electrophoresis was carried out to generate a narrow insert size distribution (see 
supplemental information for representative gels on library construction). 
 
Figure 36: Basic plasmid map of the BAC yeast shuttle vector, pClasper lacZ. 
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The DNA was isol The DNA was isolated and ligated to the vector pClasper lacZ. 
PClasper (126), a vector that can maintain large DNA fragments in both bacteria and 
yeast was modified to install the lacz gene within the multiple cloning site (MCS region) 
of the vector (Figure 36). The lacZ modification allows for blue/white colony selection 
and elimination of empty constructs during library construction. In the long term, the 
vector might allow for the housing and expression of biosynthetic pathways in both  
 
Figure 37: (A) Representative clones from the Hon6 BAC library cut with I-SecI. (B) Graph 
depicting the number of clones with specific insert size ranges (of 24 clones analyzed). 
prokaryotic and eukaryotic hosts.   
 
Following ligation and transformation into DH10B cells the clones were analyzed 
(Figure 37A). Four (16%) were found to contain no insert or an insert of negligible size, 
while those containing inserts, averaged 105 kb. The size distribution shows a large 
percentage of clones in the 100 kb size range with a few scattered individuals at sizes 
below 50 kb and a strong, roughly exponential decrease in the population of clones as 
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the size increases beyond 110 kb (Figure 37B). 
 
Estimation of Genome Size by Flow Cytometric Analysis (Performed by Dr. Scott 
Angell). Calculating the number of clones required to allow good coverage of a genomic 
library requires prior knowledge of the genome size of an organism. We therefore 
measured the genome size of Hon6 by flow cytometric analysis. The nuclear DNA 
content of the Hon6 strain was evaluated by flow cytometry after PI staining relative to 
Neurospora crassa, which served as a standard (Figure 38 (A) and 38 (B)). Genome sizes 
of E. coli and S. cerevisiae were also measured to assess the degree of accuracy. The 
technique can be employed to estimate the genome size of an organism since 
fluorescence intensity is directly proportional to the DNA content of the cells (127, 128).  
A calibration curve was generated resulting in the linear graph shown in Figure 38 (C) 
and was used to calculate the genome size of S. cerevisiae and E. coli, which are also 
plotted on the graph for comparison. Measured values were accurate to within 7% of the 
known standards (Figure. 38 (D)). For example, the genome size of E. coli was 
calculated to be 4.33 Mb while its true genome size is 4.63 Mb. Likewise, the genome of 
S. cerevisiae was measured to be 24.7 Mb while its established genome size is 24.14 Mb. 
The nuclear DNA content of Hon6 was estimated by this flow cytometric approach to be 
3.89 Mb ± 7%. 
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Figure 38: (A) N. crassa cell population. (B) Genome size measurements for N. crassa in its 
various nuclear states. (C) Standardization curve of organisms with established genome sizes. 
(D) Genome size estimates for marine microorganisms based upon N. crassa. 
 
 
 “Biosynthetic P coverage” of the Hon6 Library and Molecular Simulation Analysis 
(Performed by Dr. Scott Angell). Utilizing the BPC algorism, we determined that a 
genome size of ∼3.89 Mb, a library consisting of 1536 colonies or clones, with the vast 
majority of inserts in the 100 kb range (of which ∼86% contain inserts), we can expect a 
greater than 99% probability of cloning an 85 kb pathway intact. This high probability is 
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achieved due to the depth of coverage. Our library contains about 132 Mb of DNA, or 
about 34 fold coverage of this organism. 
To account for the heterogeneity in clone length, a molecular cloning simulation was 
conducted in the Perl programming language. For each step of simulation: a circular 
genome of 3.89 Mb was virtually constructed to contain a randomly-placed pathway of 
85 kb; 1536 clones derived from this genome were simulated by taking a random 
“insert” from the genome, with the insert lengths following the distribution of sizes 
shown in Fig. 38B; the simulation step was scored as a success if at least one of the 1536 
clones contained the pathway in its entirety, in either orientation. The simulation was 
carried out for over 400000 steps (Figure 39) and rapidly stabilized on a success rate of 
99.88%. The success rate increases dramatically for pathways less than 85 kb. The 
simulation does not address bias that could be introduced by differential clonability of 
different genomic regions due to stability or the nonrandom distribution of restriction 
sites. 
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Figure 39: A simulation of cloning success rate on a pathway of 85,000 bases using the empirical 
distribution of clone insert sizes. The success rate is cumulative over previous steps in the 
simulation. The first 100,000 simulation steps are shown. Each marker represents 100 simulation 
steps. 
 
 
Screening by Genetic Selection: Biotin Biosynthesis in Hon6. To explore the potential 
use of genetic selection in the identification and localization of biosynthetic pathways 
from marine microbial consortia, as a proof of principle experiment, we identified the 
biotin biosynthetic genes within Hon6. Biotin (vitamin H, a co-factor involved in CO2 
transfer) biosynthesis has been well characterized in terrestrial bacterial systems, notably 
that of E. coli, B. subtilis, and B. sphaericus (Figure 40) (129-132). In contrast, 
understanding of biotin formation within the marine environment is limited to 
information obtained from a few sequenced genomes (133, 134). The Hon6 library was 
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directly transformed into bioB− E. coli and the clones evaluated by PCR analysis with 
degenerate probes. The cells can only survive if clones contain an expressed gene or 
genes capable of complementing the knockout, i.e. cells cannot survive without some 
mode of CO2 transfer. Sequence analysis of the PCR products revealed the presence of 
the bioB gene. As BioB represents the rate-limiting step in biotin biosynthesis, we 
measured biotin production levels of three representative transformants. Biotin 
production in these transformants ranged from 666ng/L to 753ng/L. While many 
microbes synthesize biotin, it is produced at low levels (135). 
The bioB− containing BAC clones were then individually transformed into bioC−, 
bioF−, bioA−, bioD−, and bioH− E. coli. The resulting transformants were again 
analyzed by PCR with degenerate probes. The genetic selection results revealed the 
presence of bioC, bioF, bioA, and bioD biosynthetic genes. The bioW and bioH genes 
were not detected in either the bioB clones, or Hon6 genomic DNA. Therefore, from an 
evolutionary perspective, the Hon6 biotin biosynthetic pathway is quite similar to that of 
the E. coli bio operon. The results of these experiments additionally suggest that 
complementation analysis might not only be useful in the mining of biotin biosynthetic 
pathways from terrestrial bacterial genomes34 but also in the analysis of marine 
microbial consortia at various depths, locations, and environmental conditions. The 
approach might ultimately lead to the discovery of a novel biotin biosynthetic 
pathway(s) or even better, a new mode of CO2 transfer; the resulting enzymology would 
certainly be of considerable interest. In this regard, genomic clones lacking key genes of 
the canonical pathways would be of principal interest. 
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Figure 40: Schematic diagram depicting biotin biosynthetic pathways in E. coli, B. sphaericus, 
and B. subtilis the bioF, bioA, bioD, and bioB genes are common to all three pathways. The 
Hon6 biotin biosynthetic pathway genes are demarcated by the green underline. The red 
underline specifies genes not common to the Hon6 biotin biosynthetic pathway. 
 
Conclusions. Current research indicates that less than 1% of microbes in the 
environment can be cultured by any given culture method. This suggests that countless 
biosynthetic pathways have escaped analysis for either natural product production, or 
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mechanistic investigations. Metagenomics, which involves the culture-independent 
genomic analysis of a microbial population aims to access this buried but highly valued 
information. 
In this study, we have constructed a large insert BAC library of the marine 
microorganism Hon6, a new species of the genus Chromohalobacter, isolated from 
Honokohau, Maui. The size of the library was constructed on the basis of an algorism 
that we generated, referred to as BPC or “Biosynthetic P-Coverage.” Based on this 
algorism, our library consisting of 1536 clones covering 132 Mb of DNA (34-fold 
coverage), ensures a greater than 99% probability of cloning an 85 kb pathway intact. 
While the approaches described herein focused on a single organism, image 
densitometry (136) might in the future offer the means to estimate genome sizes of 
microbial populations and expansion of the technique to enable genome quantification of 
heterogeneous populations and sizing of their respective libraries. 
Additionally, to evaluate the potential use of genetic selection in the elucidation of 
biosynthetic pathways from marine microbial consortia, we identified the biotin 
biosynthetic genes within Hon6. As the statistical probability of observing heterologous 
expression of a single gene is much higher than that of an entire biosynthetic pathway, 
genetic selection could prove to be an important tool in the localization of novel 
biosynthetic pathways. Coupled with promoter replacement technologies, the approach 
could lead to the discovery of a new generation of bioactive natural products. In this 
regard, we are currently applying genetic selection to reveal novel terpene biosynthetic 
pathways in marine microbial consortia. 
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CHAPTER V 
 
CONTROL OF HETEROLOGOUS GENE EXPRESSION BY THE THIAMIN 
PYROPHOSPHATE RIBOSWITCH 
 
INTRODUCTION 
 
As already mentioned in Chapter I, only a small portion of microbes are culturable by 
present methods and 90-99% of the metagenome is not being sampled (14, 34, 46). Even 
marine microbial communities, including the cyanobacteria, have not been 
systematically collected and fully evaluated for bioactive compounds. Instead of 
developing purification methods or manipulating cultivation conditions, large fragments 
of non-culturable bacterial genomes can be cloned and expressed using recombinant 
DNA technology (47-51). E. coli is the most commonly used host for heterologous gene 
expression (137). A strong transcriptional promoter to control high-level gene expression 
is required in recombinant expression plasmids (138).  
We aimed to develop new tools to control gene expression through the use of 
riboswitches. The strategy could facilitate the functional characterization of biosynthetic 
genes in a facile fashion by effecting gene modulation, thus adjusting natural product 
levels and permitting analysis of natural product flux. While pBAD and lac promoters 
are commonly employed inducible promoters, both promoters exhibit an all-or-none 
activity in wild-type E. coli strains and are not titratable (139-144). There is therefore a 
need for the development of new, enabling methodologies.  
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Figure 41: Crystal structure of TPP-bound sensing domain front view. The RNA is in a stick-
and- ribbon representation, with bound TPP in red. after  Serganov, A. et al. (145). 
 
 
The TPP riboswitch system was chosen to upregulate biosynthetic genes that exhibit 
little to no innate gene expression upon initial analysis in E. coli. This system is 
particularly attractive for these investigations for the following reasons. The TPP 
riboswitch, like the purine riboswitch, adopts a compact inverted h-structure, and is 
among the simplest of riboswitches. The structure of the TPP riboswitch is shown in 
Figure 41(145).  
In a β-galactosidase reporter assay, a translational fusion construct that encompassed 
the 5‟-UTR of ThiC in E. coli exhibited a thiamine-dependent suppression of β-
galactosidase activity of 110-fold when the cells where grown on minimal medium 
(146). Genetic control appears to occur primarily at the level of transcription as a 
transcriptional fusion containing the ThiC leader yields a modest 16-fold effect with 
added thiamine (146). Significant fold change differences are observed between the 
metabolite-bound and unbound states. Moreover, the metabolite-binding aptamer 
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domain of the TPP riboswitch has been shown to be essentially identical in both 
prokaryotic and eukaryotic systems, E. coli and Arabidosis thaliana, respectively (76, 
145, 147). Additionally, not only will the use of the TPP riboswitch enable use of E. coli 
as a suitable host strain, but also as many gene products are toxic, the use of the TPP 
riboswitch will enable modulation of pathway gene expression by varying the TPP 
concentration. Having the ability to control metabolite flux in pathways might result in 
the accumulation of intermediates that could not otherwise be isolated or characterized. 
While inducible promoters such as the popular arabinose-inducible promoter PBAD and  
the isopropyl-β-D-thiogalactopyranoside (IPTG)-inducible promoter Plac come to mind, 
they are subject to all-or-none induction in which intermediate concentrations of IPTG 
or arabinose give rise to subpopulations of cells that are fully induced or uninduced (139, 
140, 144). In contrast, the sensitivity of TPP detection by the RNA riboswitch as 
measured by monitoring the extent of spontaneous cleavage at several ligand-sensitive 
sites within the RNA over a range of ligand concentrations as well as measuring levels 
of β-galactosidase reporter gene expression reveals its dependence on metabolite 
concentration and the tunable nature of these regulatory switches.   
Recently, the violacein operon has been studied in E. coli and other bacteria after 
isolation, sequencing, and heterologous expression of the gene cluster (58, 148-150). 
The biosynthetic pathway, which was mapped to a 5 kb region of DNA, has been 
functionally expressed in E. coli. The biosynthetic pathway was identified from a soil 
environmental library (58). This violacein gene cluster from Chromobacterium 
violaceum was selected to be placed under the control of the ThiC riboswitch.  The 
entire vio operon is shown in Scheme 4 (151).   
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Scheme 4: DNA region encoding violacein biosynthesis from Chromobacterium violaceum 
ATCC12472 including putative transcriptional terminator (Ω) and promoter (P) regions. After 
Sánchez, C. et al. (151) 
 
 Besides evaluating the function of a riboswitch to express violacein in E. coli, the 
system was also applied to the expression of insoluble protein to evaluate the solubility 
change. Many heterologous proteins which are overexpressed lead to the formation of 
insoluble aggregates known as inclusion bodies (152-154). Inclusion body formation 
might potentially be minimized by a riboswitch promoter. The yield and solubility of 
recombinant protein are highly dependent on the specific protein sequences, as well as 
on the vector, host cell, and culture conditions used (154). Predicted flavin reductase 
(RutF) in a novel pyrimidine catabolism pathway and β-lacto-Globulin (BLG) protein 
were employed to verify the improvement of expression and solubility under the ThiC 
riboswitch. 
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EXPERIMENTAL PROCEDURES 
 
Materials and General Methods. Competent Top10, BL21 (DE3) and BL21-
CodonPlus (DE3) RIL E. coli strains were from Invitrogen (Carlsbad, CA). The DH10B 
E. coli strain was obtained from Prof. Dennis Gross, Texas A&M University, 
Department of Plant Pathology. Oligonucleotide primers and linkers were from 
Integrated DNA Technologies (Coralville, IA).  TaKaRa LA TaqTM DNA polymerase 
was from Takara Bio Inc. (Otsu, Shiga, Japan).  Phusion DNA polymerase, restriction 
enzymes, and T4 DNA ligase were from New England Biolabs. Plasmid pETBlue-2 was 
from Novagen, pCCIFOS was from Epicentre, and TOPO XL 2.1 was from Invitrogen. 
DNA sequencing to verify PCR fidelity was performed on double-stranded DNA by the 
Gene Technology Lab Core Facility of Texas A&M University (College Station, TX). 
Plasmid DNA preparation was performed with the Qiaprep kit from Qiagen (Valencia, 
CA). Gel extraction of DNA fragments was done using QIAquick Gel Extraction kit 
from Qiagen. Thiamine Pyrophosphate Chloride (TPP salt) was purchased from Sigma. 
ONPG (o-Nitrophenyl-beta-galactopyranoside) ELISA β-galactosidase substrate was 
purchased from Biocompare. 
Pulsed Field Gel Electrophoresis (PFGE) was performed on a BioRad CHEF DR II 
apparatus (Hercules, CA).  Electroporation of cells was carried out with a BioRad 
MicroPulser. SDS-PAGE gels were from BioRad. High performance liquid 
chromatography (HPLC) purification of violacein was performed on a Gemini 
instrument from Phenomenex using a C18 column (3μm, 110A, 75 x 4.60 mm). 
Preparative HPLC was performed on a Biochrom 1010 ODS instrument from Regis with 
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a C18 column (10μm, 25 x 10.0 mm) and Analytical HPLC was performed on a Gemini 
instrument from Phenomenex using a C18 column (10μm, 150 x 4.60 mm). Liquid 
chromatography mass spectrometry (LCMS) identification was carried out on a Gemini-
NX instrument from Phenomenex using C18 column (3μm, 110A, 150 x 2.00 mm) and 
TIC (ESI-APCI-positive mode) at UV 220 nm. Standard recombinant DNA, molecular 
cloning, and microbiological procedures were performed as described (97).  
  
Cloning of the Violacein Operon by Mediated PCR. The entire violacein operon was 
obtained by PCR amplification of genomic DNA from Chromobacterium violaceum 
ATCC 12472 with LA Taq polymerase.  Mediated PCR reaction (155) was performed 
with the following primers: VioB-R: 5‟- GCC TCT CTA GAA AGC TTT CCA CAA 
GCC AAA TCC AG-3‟ and 3275RLR  4900 bp (Seq: VioBCR: 5‟- GCA GCC CAG 
CGC GTA GTC GTC GTA GCT GCG G-3‟ and 3275RLS) and 3369LFR: 5‟- CGG 
CGA ATC GGC GAC GCC GGA TGT CGC CGG CCT GCT CGA G-3‟ and VioBCF: 
5‟- CCG CAG CTA CGA CGA CTA CGC GCT GGG CTG C-3‟  4450 bp (Seq: VioC-
F: 5‟- GAA AAG AGC AAT CAT AGT CGG AGG CGG G-3‟  and  3269LFS). All 
PCR products which contained the whole operon were digested with MluI and XhoI and 
ligated into dephosphorylated Topo XL vector after digestion with MluI and XhoI 
restriction enzymes.  
Each gene in the cluster (VioA, VioB, VioC, VioD, and VioE) was detected with 
following primers: VioA: 5‟- CGC GGC GAT GCG CTG CAG CAG CAG-3‟ and 5‟- 
GAA GCA TTC TTC CGA TAT CTG CAT TGT CGG-3‟; VioB:  5‟- GCC TCT CTA 
GAA AGC TTT CCA CAA GCC AAA TCC AG-3‟ and 5‟- GCA TTC TGG ATT TTC 
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CAC GCA TCC ATT TCC G-3‟;  VioC: 5‟- TCA GTT GAC CCT CCC TAT CTT GTA 
CC-3‟ and 5‟- GAA AAG AGC AAT CAT AGT CGG AGG CGG G-3‟ ; VioD:  5‟-
TCA GCG TTG CAG CGC GTA GCG C-3‟ and 5‟- ATG AAG ATT CTG GTC ATC 
GGC GCG G-3‟; VioE:  5‟- TAT ATC TAG ACT AGC GCT TGG CGG CGA AG-
3‟and 5‟-ATA TAA GCT TAC TAG TGA GGA GGC CGC ATG GAA AAC-3‟. All 
PCR products were confirmed through DNA sequencing.  Sequencing reactions were 
performed with the Perkin Elmer ABI Bigdye Terminator kit according to the 
manufacturer‟s instructions and analyzed on an ABI31303/Genetic Analyzer by the 
Gene Technology Lab Core Facility of Texas A&M University.   
Initially genomic DNA from C. violaceum ATCC 12462 was digested with MluI and 
XhoI and run on a 1% agarose gel by Pulsed Field Gel Electrophoresis (PFGE) to isolate 
those fragments between 5 kbp and 12 kbp with little modification to the previously 
reported method (149). After gel extraction and purification, end-repaired DNA 
fragments were ligated into linearized pCCIFOS, which was blunt-ended by PmlI 
restriction enzyme. The resulting plasmid was transformed into BL21-Codon plus (DE3) 
RIL E. coli strain. However, we did not get any colored colonies from this construction.  
pETBlue-2 vector was also employed to clone the whole operon using the sized DNA 
fragments. pETBlue-2 was digested with MluI and XhoI and then dephosphorylated 
after gel extraction and purification. The plasmid was transformed  into Top10 and 
DH10B. 
Vector maps for pETBlue-2, pCCIFOS, and TOPO XL are shown in Appendix D. 
The described expression plasmids were transformed into Top10, BL21 (DE3), and 
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BL21-CodonPlus (DE3) RIL competent cells according to the vector used for the each 
construction. 
 
Expression, Extraction, and Purification of Violacein in Heterologous Systems. 
Violacein was extracted from Chromobacterium violaceum ATCC12472 as described in 
references (150, 151, 156-160).  For violacein expression in E. coli, cells were grown at 
28 C in Luria-Bertani (LB) media after transformation into Top10 by electroporation 
and then plated on LB agar plates with appropriate antibiotics. After incubation for 48hrs 
at 28 C, only one purple colony appeared which was confirmed to contain the whole vio 
operon by performing digest screening and sequencing of miniprepped DNA. The 
colony from the construction under Lac/Native promoter was shown in Figure 2.  The 
selected clone was inoculated into LB media with appropriate antibiotics (constructions 
with Topo system used 10μg/ml Kanamycin). The bacterial cultures were spun down by 
centrifugation and then separated to cell and supernatant. Both samples were extracted 
with ethyl acetate or methanol according to previously described methods (151, 157, 
160, 161). The extracted violacein was concentrated in vacuo to dryness.  The dried 
samples were subjected to high performance Liquid Chromatography (HPLC) and mass 
spectrometry (MS) analysis. Crude MS samples were prepared in Methanol.  Crude 
samples from the cell extract and supernatant were confirmed by Electrospray Ionization 
(ESI) in positive mode for mass analysis. Purification was performed with Reverse-
phase HPLC using a C18 column (75mm×4.6mm, 3micron) with Acetonitrile and water 
as solvent according to previously published data (151). The sample was dissolved in 
10% Acetonitrile (ACN). Elution started at 10% ACN for 4 min, followed by a linear 
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gradient up to 88% at 30 min and a final isocratic hold at 100% for 5 min, at a flow rate 
0.5ml/min with 168-575 nm high wavelength detection.  The purified sample eluted with 
ACN was subjected to analyze by MS, ESI data shows only M minus Hydrogen.  
Therefore, the HPLC condition was changed to a gradient 50% MeOH / 50% water to 
100% MeOH in 15 min. For prep-HPLC MeOH/water and Acetone/water were used to 
obtain purified violacein. The change in solvent polarity only results in a difference in 
elution time. Purified violacein was identified based on HPLC/MS, UV-visible 
absorption characteristic, mass spectra and NMR, compared to previously published data 
(148, 151, 156, 157, 161-163). 
 
Characterization and Analysis of Violacein. Violacein was characterized and 
analyzed by proton (
1
H) NMR (300MHz, 500MHz), Carbon (
13
C) and 
13
C DEPT135 
(500MHz) NMR spectra. NMR spectra were acquired on a Bruker ARX 500 instrument 
using a 3mm Broad band (BB)/H probe with WALTZ decoupling for the 
13
C 
experiment. Ultraviolet-visible (UV-Vis) spectroscopy was performed with a 
ThermoSpectronic, model Genesys 2 spectrophotometer, and mass spectrometry with a 
QStar from PE Sciex for ESI and 5Voyager DE-STR from Applied Biosystems (for 
MALDI).  
All primers and linkers used in Chapter V are shown in Table 4. 
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Table 4: Primers and linkers used in Chapter V 
Primer Name                                       Squence                                                                Melting T.           
 
Violacein cluster detection primers 
 
VioA-F  reverse  5‟- GAA GCA TTC TTC CGA TAT CTG CAT TGT CGG-3‟          60.8 
VioA-R forward  5‟- CGC GGC GAT GCG CTG CAG CAG CAG-3‟              71.2 
VioB-F   5‟- GCA TTC TGG ATT TTC CAC GCA TCC ATT TCC G-3‟        63.1 
VioB-R   5‟- GCC TCT CTA GAA AGC TTT CCA CAA GCC AAA TCC AG-3‟       64.2 
VioC-F  reverse  5‟- GAA AAG AGC AAT CAT AGT CGG AGG CGG G-3‟               62.5 
VioC-R forward  5‟- TCA GTT GAC CCT CCC TAT CTT GTA CC-3‟                   59.3 
VioD-F reverse  5‟- ATG AAG ATT CTG GTC ATC GGC GCG G-3‟          63.1 
VioD-R forward  5‟-TCA GCG TTG CAG CGC GTA GCG C-3‟           67.3 
VioE-F reverse     5‟-ATA TAA GCT TAC TAG TGA GGA GGC CGC ATG GAA AAC-3‟ 
VioE-R forward   5‟- TAT ATC TAG ACT AGC GCT TGG CGG CGA AG-3‟  
3269F       5‟- GCC GCT ACC CGG TGG CGA TAG CCG -3‟          69.7 
3275R      5‟-GGC GCA GTC GGC GGT GGC GAA GCA GAC C-3‟          73.2 
VioBCF   5‟ CCG CAG CTA CGA CGA CTA CGC GCT GGG CTG C-3‟        72.2 
VioBCR    5‟- GCA GCC CAG CGC GTA GTC GTC GTA GCT GCG G-3‟         72.2 
3269LFR  5‟- CGG CGA ATC GGC GAC GCC GGA TGT CGC CGG CCT GCT CGA G-3‟ 77.0 
3269RLF  5‟- GCT CGA GCG CCT GGG CGC CGG CCA TGC GCT GGA CGG CCA GCC-3‟       80.9 
3269LFS  5‟- GGA CGG CCA GCC GGG CTA CCA CGG CAA CCT CTC G-3‟                  74.7 
3275RLR  5‟-GTA CGC GTA CTA CAC CGC CCA GGG GCC GCT CAA TCG TTC CGC C-3‟     74.4 
3275RLS  5‟- CGT TCC GCC GAG CTG CGC CTG ATC AAT CAC AGC CG-3‟          72.0 
3275FLR  5‟- GTA CGC GTA CTG GTT GCC CCC CAC GCC GCC CCA CCA GGC-3‟       77.1 
3275FLS  5‟- GGC CCA GAA CCA GCC GGG ACG GTC GGC GCG CTC CAG C-3‟        78.2 
 
TPP/Riboswitch construction primers 
 
F: TPP+P+Ribos 5‟-GCACGCGTTTGA GTT CTG CGC TGT TAA GGC GTA ATT TAC-3‟           66.4 
R:TPP+P+Ribos 5‟-CGACTAGTAGCTC ATT CCA AAA AGT TAA GGA CGT GG-3‟                   62.2 
 
Oligonucleotides for the linkers 
 
F: MluI-T7-SpeI (For Lac+T7)                 5‟- CGC GTT AAT ACG ACT CAC TAT AGG GA-3‟       57.5 
R: MluI-T7-SpeI                                        5‟- CTA GTC CCT ATA GTG AGT CGT ATT AA-3‟        52.8 
F: MluI-T7-MluI (For Lac+T7+Ribos)     5‟- CGC GTT AAT ACG ACT CAC TAT AGG GA-3‟       57.5 
R: MluI-T7-MluI                                       5‟- CGC GTC CCT ATA GTG AGT CGT ATT AA-3‟        57.5 
F: AsnI-T7-SpeI (For T7)                         5‟- TAA TTA ATA GCA CTC ACT ATA GGG A-3‟           50.5 
R: AsnI-T7-SpeI                                        5‟- CTA GTC CCT ATA GTG AGT CGT ATT AAT-3‟      53.0 
F: AsnI-HpaI-HindIII-MluI                       5‟- TAA TGT TAA CAA GCT TA-3‟                                   39.0 
R: AsnI-HpaI-HindIII-MluI                      5‟- CGG GTA AGC TTG TTA ACA T-3‟                             50.1 
F: AsnI-T7-HpaI-HindIII-MluI (For T7+Riboswitch)  
                                         5‟-TAA TTA ATA CGA CTC ACT ATA GGG GTT AAC AAG CTT A-3‟ 58.3 
R: AsnI-T7-HpaI-HindIII-MluI  
                                  5‟- CGC GTA AGC TTG TTA ACC CCT ATA GTG AGT CGT ATT AAT-3‟ 62.4 
F: MluI-HpaI-HindIII-SpeI (For Lac)         5‟- CGC GTG TTA ACA AGC TTA-3‟                             50.5 
R: MluI-HpaI-HindIII-SpeI                         5‟-CTA GTA AGC TTG TTA ACA-3‟                              43.3 
F: MluI-XhoI linker (For pCCIFOS)          5‟- GCA CGC GTC GAT CTC GAG C -3‟                        61.3 
R: MluI-XhoI linker                                    5‟-GCT CGA GAT CGA CGC GTG C-3‟                          61.3 
F: EcoRV+MluI+SpeI (For pETBlue-2)    5‟- CGA TAT CGG ACG CGT CCA CTA GTC-3‟            60.6 
R: EcoRV+MluI+SpeI                                5‟- GAC TAG TGG ACG CGT CCG ATA TCG-3‟           60.6 
F: EcoRV+MluI+SpeI sticky                      5‟- ATC GGA CGC GTC CAC TAG TC-3‟                       58.9 
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Table 4: continued 
Primer Name                                       Squence                                                                Melting T.           
 
R: EcoRV+MluI+SpeI sticky                      5‟- CTA GTG GAC GCG TCC GAT-3‟                             56.8 
 
Riboswitch linker 
 
Ribos1     5‟-CGC GTT AAT TTC TTG TCG GAG TGC CTT AAC TGG CTG AGA CC-3‟              67.3 
Ribos2   
 5‟-GTTTATTCGGGATCCGCGGAACCTGATCAGGCTAATACCTGCGAAGGGAACAAGAGTTAA-3‟    69.9 
Ribos3   
5‟-GTTCCGCGGATCCCGAATAAACGGTCTCAGCCAGTTAAGGCACTCCGACAAGAAATTAA-3‟        70.3 
Ribos4   5‟ –CTA GTT AAC TCT TGT TCC CTT CGC AGG TAT TAG CCT GAT CAG-3‟             64.2 
 
LacZ construction and sequencing primers 
 
             PCR 
LacZ F (SpeI)                              5‟-CGC GAC TAG TGT TTA TCA CAG TTA AAT TG-3‟             56.3 
LacZ R (XbaI)                            5‟- CCC CTC TAG ACT TAC AAT TTC C-3‟                                   52.4 
LacZ F (SacI-pBAD33)              5‟- CGC GGA GCT CGT TTA TCA CAG TTA AAT TG-3‟             59.8 
            Linker 
F: XbaI-Nsil-SpeI                       5‟-CTA GAG CGA TGC ATG CGA-3‟                                               54.9 
R: XbaI-Nsil-SpeI                       5‟-CTA GTC GCA TGC ATC GCT-3‟                                                55.2 
F: XbaI-Nsil-XhoI                      5‟-CTA GAG CGA TGC ATG CGC-3‟                                                56.7 
R: XbaI-Nsil-XhoI                     5‟-TCG AGC GCA TGC ATC GCT-3‟                                                 60.5 
          Sequencing 
T7 pETBlue-2F                           5‟-GTG CGG CGA CGA CCG GTG-3‟                                               64.8 
pETBlue-2 T7up Primer              5‟- TCA TAA CGT CCC GCG AAA-3‟                                              54.1 
FPCRXL-TOPO                          5‟-GCA AAC CGC CTC TCC CCG CGC G-3‟                                  70.0 
RPCRXL-TOPO                         5‟-CGA CGG CCA GTG AAT TG-3‟                                                  54.0 
pET FP                                        5‟-GGA TGT GCT GCA AGG CGA TTA AGT TGG-3‟                    62.0 
pET RP                                        5‟-CTC GTA TGT TGT GTG GAA TTG TGA GC-3‟                        58.1 
 
RutF construction and sequencing primers 
F:RutF (SpeI)                            5‟-GCC ACT AGT ATG AAC ATT GTC GAT CAA C-3‟                  57.6 
R:RutF (XhoI)                           5‟-GGC CTC GAG TTA ACA AGC AGG GCG CAT CAG-3‟           67.2 
 
BLG construction primers 
 
BLGThiCRibo(f)SpeI                 5‟-GCG CAC TAG TAT GAA ATG TCT GCT GC-3‟                       60.0 
BLGThiCRibo(R)XhoI                                                                                                                              68.8 
    5‟- CGC GCT CGA GTT AAT GAT GAT GAT GAT GAT GAA TGT GAC AGT GTT CTT CCA GCT GGG-3‟  
 
 
Bold: inserted restriction enzyme site, underlined: inserted 6-His tagged site 
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Construction of the Violacein Gene Cluster under the Lac/Native, Native and Lac 
Promoter. Lac/Native promoter was constructed first with the mediated PCR product 
which was confirmed by sequencing. The cloned whole operon was digested with MluI 
and XhoI restriction enzymes and then purified by gel extraction. The double digested 
PCR product was inserted into the Topo XL vector which has a Lac operon.  This is the 
p(v4(MluI-XhoI) Topo) vector which contains Lac/Native + vio operon. To construct the 
vector containing Native promoter only, the p(v4(MluI-XhoI) Topo) vector was digested 
with AsnI and MluI restriction enzymes  (removing the Lac promoter) and then treated 
with phosphatase (CIP). Lac operon is located at base pairs 95-216, AsnI cuts at base 
pairs 48 and 107 and MluI cuts at site 248.  All vector maps including manipulating sites 
are shown in Appendix. Gel purified digested vector was ligated to the synthesized 
linker (F: AsnI-HpaI-HindIII-MluI: 5‟- TAA TGT TAA CAA GCT TA-3‟ and R: AsnI-
HpaI-HindIII-MluI: 5‟- CGG GTA AGC TTG TTA ACA T-3‟) with T4 DNA ligase. 
Construction of violacein gene cluster under Lac promoter control was performed with 
ligation of linearlized p(v4(MluI-XhoI) Topo) vector which was digested with MluI and 
SpeI restriction enzymes (removes the native promoter) and then treated with 
phosphatase, and  the linker which was synthesized with F: MluI-HpaI-HindIII-SpeI :5‟- 
CGC GTG TTA ACA AGC TTA-3‟ and R: MluI-HpaI-HindIII-SpeI :5‟-CTA GTA 
AGC TTG TTA ACA-3‟.  All constructions were transformed into Top10 E. coli strain 
except Lac promoter controlled vector which was transformed into Top10 and BL21 
(DE3) E. coli strain.        
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Construction of Violacein Gene Cluster under the Lac/T7 Promoter and T7 Promoter 
in Topo System. The vector containing Lac/T7 promoter was constructed with MluI and 
SpeI double digested p(v4(MluI-XhoI) Topo) vector which was dephosphorylated and 
the linker which was synthesized with F: MluI-T7-SpeI: 5‟- CGCGTTAATACGAC 
TCACTATAGGGA-3‟ and R: MluI-T7-SpeI: 5‟- CTAGTCCCTATAGTGAGTCGT 
ATTAA-3‟.  To construct T7 promoter control vector, pv4(MluI-XhoI) Topo vector was 
linearized by digestion with AsnI and SpeI restriction enzymes. Ligation was followed 
with the linker which was produced with F: AsnI-T7-SpeI: 5‟- TAA TTA ATA GCA 
CTC ACT ATA GGG A-3‟ and R: AsnI-T7-SpeI: 5‟- CTA GTC CCT ATA GTG AGT 
CGT ATT AAT-3‟.  All constructions were transformed into Top10 E. coli strain. 
 
  Synthesis of Riboswitch Linker. The sequences of the TPP riboswitch sequence were 
compared with E. coli str. K12 substr.DH10B (CP000948) of the reference paper Cheah 
et al. (8). The sequence is shown in Appendix D. Riboswitch  was synthesized with 
oligonucleotides as shown in below (Ribos1: 5‟-CGC GTT AAT TTC TTG TCG GAG 
TGC CTT AAC TGG CTG AGACC-3‟; Ribos2 : 5‟- GTT TAT TCG GGA TCC GCG 
GAA CCT GAT CAG GCT AAT ACC TGC GAA GGG AAC AAG AGT TAA-3‟ 
Ribos3 : 5‟-GTT CCG CGG ATC CCG AAT AAA CGG TCT CAG CCA GTT AAG 
GCA CTC CGA CAA GAA ATT AA-3‟;  Ribos4: 5‟ –CTA GTT AAC TCT TGT TCC 
CTT CGC AGG TAT TAG CCT GAT CAG-3‟ ). Reaction conditions for linker 
synthesis are described in Appendix D (Figure A.14).   
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Construction of Violacein Gene Cluster under the Lac/Riboswitch, Lac/T7/Riboswitch 
and T7/Riboswitch Promoter. To construct Lac/Riboswitch controlled vector, a 
synthesized riboswitch linker was ligated to digested p(v4(MluI-XhoI) Topo) vector 
with MluI and SpeI restriction enzymes.  The construction was transformed into Top10 
E. coli strain. This vector was used for manipulation of riboswitch containing vector, 
named as a p(RV8topo) vector. To prepare the Lac/T7/Riboswitch controlled vector, 
p(RV8topo) vector was digested with MluI restriction enzyme and then purified with gel 
extraction kit after dephosphorylation. The linearized p(RV8topo) vector was ligated to 
the linker which was synthesized with F: MluI-T7-MluI: 5‟- CGC GTT AAT ACG ACT 
CAC TAT AGG GA-3‟and R: MluI-T7-MluI: 5‟- CGC GTC CCT ATA GTG AGT 
CGT ATT AA-3‟.  Transformation followed after ligation reaction. Top 10 E. coli strain 
was used for this construction.  Construction of the violacein gene cluster under the 
T7/Riboswitch promoter was performed with ligation of AsnI and MluI restriction 
digested p(RV8topo) vector, which was dephosphorylated, and the linker. The linker 
was synthesized with F: AsnI-T7-HpaI-HindIII-MluI: 5‟-TAA TTA ATA CGA CTC 
ACT ATA GGG GTT AAC AAG CTT A-3‟ and R: AsnI-T7-HpaI-HindIII-MluI: 5‟- 
CGC GTA AGC TTG TTA ACC CCT ATA GTG AGT CGT ATT AAT-3‟.  The 
plasmid was transformed into BL21 E. coli strain (DE3 and CP RIL respectively).  
 
PCR Product of the ThiC/Riboswitch Promoter. The gene sequence of the ThiC 
promoter for thiamine pyrophosphate protein was identified from the region 4291721 to 
4294220 in the DH10B Escherichia coli strain after generation of complementary 
sequence (164, 165).  The sequence was analyzed to design the primers for PCR reaction 
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as shown in Appendix with indication of Riboswitch part in red color, promoter region 
in blue color, start codon in pink italic font, and transcription part in green. Mini-prepped 
DH10B was used as template for PCR to obtain the ThiC/Riboswitch PCR product 
(288bp) with primers; 5‟-GCA CGC GTT TGA GTT CTG CGC  TGT TAA GGC GTA 
ATT TAC-3‟ and 5‟-CGA CTA GTA GCT CAT TCC AAA AAG TTA AGG ACG 
TGG-3‟. Red colored sequence containing MluI restriction site was modified (C to G) to 
protect from digestion with MluI restriction enzyme. PCR conditions are described in 
Appendix D.  After gel extraction, the PCR product was confirmed by sequencing.  
 
Construction of Violacein Gene Cluster under the Lac/ThiC/Riboswitch and 
ThiC/Riboswitch. ThiC+Riboswitch PCR product was digested with MluI and SpeI 
restriction enzyme and then heat inactivation followed at 80C for 20 min.  
Dephosphorylated p(v4(MluI-XhoI) Topo) vector after double digestion with MluI and 
SpeI was employed for construction of the Lac/ThiC/Riboswitch controlled vector.  
Ligation reaction was performed at 16C overnight and then 2 hrs more incubation at 
room temperature. The plasmid was transformed into Top 10 and BL21 E. coli strains.  
Construction including ThiC/Riboswitch promoter was performed with 
dephosphorylated Lac/ThiC/Riboswitch controlled vector after double digestion with 
AsnI and MluI restriction enzymes (removes the Lac promoter portion), and then 
ligation with a linker. The linker was synthesized with following oligonucleotides; F: 
AsnI-HpaI-HindIII-MluI 5‟- TAA TGT TAA CAA GCT TA-3‟ and R: AsnI-HpaI-
HindIII-MluI 5‟- CGG GTA AGC TTG TTA ACA T-3‟.  The construction was 
transformed into Top 10 E. coli strain and BL21 E. coli strains (DE3 and CP RIL). 
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Construction of Violacein Gene Cluster under the T7/Native, T7, Native and 
T7/Riboswitch Promoter in pCCIFOS System.  T7 promoter in pCC1FOS was used to 
manipulate the violacein operon containing vector. pCC1FOS vector map is attached in 
Appendix D. PmlI (an isoschizomer of Eco72 I) was employed to generate linearized 
pCCIFOS vector with a blunt end. HpaI and PmlI were used to remove T7promoter 
region. For the T7/Native promoter system, genomic DNA of Chromobacterium 
violaceum and was digested with MluI and XhoI and then end repaired as described 
earlier. Ligation reaction was performed with fast-link DNA ligase. The resulting 
plasmid was transformed into BL21 E. coli strain (DE3 and CP RIL respectively). Many 
colonies grew after 16hrs, but no violet - colored colonies were observed. An identical 
procedure was performed for construction of the T7 promoter controlled vector with 
SpeI and XhoI digested vio operon fragment which was end repaired after digestion. For 
the Native promoter, pCCIFOS vector was digested with HpaI and PmlI restriction 
enzymes to remove T7 promoter. The linearized vector with HpaI and PmlI was ligated 
with the linker (synthesized with 5‟- GCA CGC GTC GAT CTC GAG C -3‟ and 5‟-
GCT CGA GAT CGA CGC GTG C-3‟). The resulting plasmid was transformed into 
BL21 E. coli strain (CP RIL) and Top 10 E. coli to amplify the vector containing MluI 
and XhoI linker. Mini-prepped plasmid was dephosphorylated after digestion with MluI 
and XhoI restriction enzymes, and then ligated with MluI and XhoI digested DNA 
fragments of violacein operon from different sources, such as genomic DNA, PCR 
product and MluI and XhoI digested DNA fragment of p(v4(MluI-XhoI) Topo) vector.  
An alternative method for construction of native promoter controlled vector containing 
vio operon was usage of end-it repair enzyme mix. After removing the T7 promoter, end 
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repaired insert DNA was ligated to the vector. For preparation of T7/Riboswitch 
controlled vector, p(RV8topo) vector was digested with MluI and XhoI restriction 
enzymes to get riboswitch and vio operon without native promoter. The resulting DNA 
fragment was end repaired to remove sticky ends. pCC1FOS vector was digested with 
PmlI restriction enzyme and dephosphorylated.  Ligation reaction was performed at 
16C overnight and then transformation followed.                                       
 
Construction of Violacein Gene Cluster under the T7/Native, T7, and T7/Riboswitch 
Promoter in pETBlue-2 System. pETBlue-2 vector was manipulated with restriction site 
of EcoRV, MluI, and XhoI in multiple cloning site.  The map of pETBlue-2 vector is 
attached in Appendix D.  For construction of T7/Native promoter controlled vector, 
MluI and XhoI double digested pETBlue-2 vector was prepared as described earlier and 
then ligation was performed with 5-12kbp sized genomic DNA, PCR product and MluI 
and XhoI digested DNA fragment of p(v4(MluI-XhoI) Topo) vector, respectively. The 
resulting plasmid was transformation into Top10 E. coli strain.  After digestion of 
pETBlue-2 vector with EcoRV and XhoI restriction enzyme, the synthesized linker and 
SpeI and XhoI digested DNA fragment of p(v4(MluI-XhoI) Topo) vector were ligated to 
it for construction of T7 promoter controlled vector containing violacein operon without  
the native promoter. The linker was synthesized with following oligonucleotides; 5‟- 
ATC GGA CGC GTC CAC TAG TC-3‟ and 5‟- CTA GTG GAC GCG TCC GAT-3‟.  
For preparation of T7/Riboswitch controlled vector, Lac/Riboswitch promoter, 
p(RV8topo) vector was digested with MluI and XhoI restriction enzyme to obtain 
riboswitch and vio operon without native promoter.  pETBlue-2 was digested with MluI 
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and XhoI restriction enzymes.  Ligation reaction was performed at 16C overnight and 
then transformation followed.                     
 
Construction of ThiC Riboswitch/β-galactosidase System (LacZ+ThiC+Riboswitch) 
and Arabinose/β-galactosidase System (LacZ+pBAD33). The LacZ multiple cloning site 
and open reading frame site were amplified from the plasmid pETBlue-2 with primers, 
LacZF (SpeI) (5‟-CGC GAC TAG TGT TTA TCA CAG TTA AAT TG-3‟, the SpeI site 
is underlined) and LacZR (XbaI) (5‟- CCC CTC TAG ACT TAC AAT TTC C-3‟, the 
XbaI site is underlined),  and were tagged with restriction enzyme sites SpeI and XbaI,  
respectively. The desired PCR product was obtained after gel extraction with QIAquick 
gel extraction kit from Qiagen. The DNA fragment was digested with SpeI and XbaI, gel 
extracted, and subsequently ligated to the ThiC/Riboswitch promoter containing TOPO 
vector, which was linearized with SpeI and XhoI restriction enzymes and then 
phosphatase treated. The phosphatase treated vector was ligated to the liker with T4 
DNA ligase. The sticky end linker was synthesized with F: XbaI-Nsil-XhoI (5‟-CTA 
GAG CGA TGC ATG CGC-3‟, the XbaI site and XhoI site are underlined) and R: XbaI-
Nsil-XhoI (5‟-TCG AGC GCA TGC ATC GCT-3‟ the XbaI site and XhoI site are 
underlined).  The resulting plasmid was transformed into Top10 E. coli strain. The 
resulting colonies were miniprepped, screened by blue and white colony, and the blue 
clone confirmed through sequencing.  
LacZ construct containing LacZ+pBAD33 promoter was performed as described 
above.  The vector pBAD33 was digested with XbaI and SacI and phosphatase treated 
with CIP. The phosphatase treated vector was ligated to the PCR product, which was 
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digested with XbaI and SpeI, and linker with T4 DNA ligase. PCR reaction was 
performed with LacZ F (SacI-pBAD33) (5‟- CGC GGA GCT CGT TTA TCA CAG 
TTA AAT TG-3‟, the SacI site is underlined) and LacZ R (XbaI) (5‟- CCC CTC TAG 
ACT TAC AAT TTC C-3‟, the XbaI site is underlined). This combination did not work 
well; pBAD33 cut with XbaI only due to SacI can not cut properly in the system. The 
DNA fragment for LacZ+ThiC+Riboswitch was also used for pBAD33. The sticky end 
linker was synthesized with F: XbaI-Nsil-SpeI (5‟-CTA GAG CGA TGC ATG CGA-3‟, 
the part of XbaI and SpeI sites are underlined) and R: XbaI-Nsil-SpeI (5‟-CTA GTC 
GCA TGC ATC GCT-3‟, the part of SpeI and XhoI sites are underlined). The insertion 
was confirmed by sequencing. 
 
Construction of RutF Protein Expression Vector containing ThiC/Riboswitch 
Promoter. The PCR product was obtained with F:RutF(SpeI) and R:RutF(XhoI) primers: 
F:RutF(SpeI)    5‟-GCC ACT AGT ATG AAC ATT GTC GAT CAA C-3‟                     
R:RutF(XhoI)  5‟-GGC CTC GAG TTA ACA AGC AGG GCG CAT CAG-3‟    
The desired PCR product was obtained after gel extraction with QIAquick gel extraction 
kit from Qiagen. The DNA fragment was digested with SpeI and XhoI, gel extracted, 
and subsequently ligated with T4 DNA ligase to the ThiC/Riboswitch promoter- 
containing  Topo vector, which was linearized with SpeI and XhoI restriction enzymes 
and then phosphatase treated. The resulting plasmid was transformed into Top10 E. coli 
cells. The resulting colonies were miniprepped and confirmed through sequencing. 
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Construction of β-γ-Globulin Protein Expression Vector containing ThiC/Riboswitch 
Promoter. The PCR product was obtained with BLGThiCRibo(F)SpeI and 
BLGThiCRibo(R)XhoI;                                                                                              
F: 5‟-GCG CAC TAG TAT GAA ATGTCTGCTGC-3‟  
R: 5‟-CGCGCTCGAGTTAATGATGATGATGATGATGAATGTGACAGTGTTCTTCCAGCTGGG-3‟ 
Phusion Taq polymerase and Taq polymerase were employed to produce optimal PCR 
product. The desired PCR product was obtained after gel extraction with QIAquick gel 
extraction kit from Qiagen. The DNA fragment was digested with SpeI and XhoI, gel 
extracted, and subsequently ligated with T4 DNA ligase to the ThiC/Riboswitch 
promoter containing vector which was linearized with SpeI and XhoI restriction 
enzymes and then phosphatase treated. The resulting plasmid was transformed into 
Top10 E. coli strain. The resulting colonies were miniprepped, screened by blue and 
white colony, and the blue clone confirmed through sequencing. 
 
β-Galactosidase Assay. The assay was modified from the protocol of S. Maloy lab by 
J. Boylason. The cells were grown in LB media with appropriate antibiotics in a 37C 
incubator at 250 rpm. After incubation for an appropriate time (see the result part), the 
culture OD at 630 nm was measured. After centrifugation, the cells were resuspended in 
Z-buffer which contained Na2HPO4, NaH2PO4H2O, KCl and MgSO47H2O (pH=7.0) to 
an OD630 = 0.3~0.4. Z-buffer was supplemented with β-mercaptoethanol just before use. 
To permeabilize the cells, 10μl of 0.1% SDS and 20μl of chloroform were added to 
750μl of cells resuspended in Z-buffer. After 15-20 sec vortexing, the cells were 
incubated at room temperature for 15 min. 250μl of permeabilized cells and 250μl of Z-
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buffer were added into epp-tubes in triplicate and then 125μl of 10mg/ml o-nitrophenyl-
β-D-galactopyranoside (ONPG) in Z-buffer was added and incubated until a light yellow 
color developed. To stop the reaction 250μl of 1M of Na2CO3 was added to each 
reaction tube and the time recorded. Centrifugation was performed at 13000 rpm for 10 
min at 4C.  Absorbance was checked at 450 nm. Units of β-galactosidase were 
calculated by following equation. 
 
 
TPP Titrability Test with Constructions Controlled under Lac/Riboswitch, 
ThiC/Riboswitch, LacZ/ThiC/Riboswitch and LacZ/pBAD33. Thianine Pyrophospate 
Chloride (TPP) was used to check titrability of Riboswitch, ThiC/Riboswitch promoter 
with various promoters and operons. TPP was added with following final concentration; 
0.0 mM, 0.5 mM, 1.0 mM, 1.5 mM, 2.0 mM, 2.5 mM, 3.0 mM, and 5.0 mM. After 
appropriate day culture, 100μl of culture was inoculated into fresh LB containing 
appropriate antibiotic and different amount of TPP. For the violacein production level 
with various TPP concentrations, HPLC was employed for the detection. The β-
galactosidase assay was used to check production of β-galactosidase by LacZ with 
ThiC/Riboswitch or pBAD33 promoter. β-galactosidase assay was modified by adding 
additional TPP in Z-buffer. 
 
Solubility Test with SDS-PAGE Gel and Western Blot Gel. To prepare soluble sample, 
1ml of culture was centrifugated for 1min at 13,000 rpm. The supernatant was discarded 
  
118 
and replaced with 1ml of Tris (0.2mM, pH8.0) and 100μl of 10% SDS. After adding a 
small amount of glass beads, the tube was vortexed for 5min. After 10 min 
centrifugation the supernatant containing solubilized protein sample was obtained. After 
washing the cell pellet with Tris solution, 100μl Tris buffer was added to the same 
volume of protein loading dye (2x) and heated for 10min at 90C. The cell sample which 
contained non-soluble protein for the SDS-PAGE gel after centrifugation for 10 min at 
14,000 rpm.  SDS- Polyacrylamide Gel Electrophoresis (SDS-PAGE) gel was run using 
PAGE-SDS Laemmli standard protocol (166). To run Western blot gel proteins were 
resolved on 12% SDS-PAGE gels and electrophoretically transferred to nitrocellulose 
and subjected to western immunoblot analysis using goat anti-mouse IgG/ HisTag 
monoclonal antibody detection system (from Novagen) as previously described (167). 
 
RESULTS AND DISCUSSION 
 
Cloning of the Known Violacein Cluster from Chromobacterium violaceum. The vio 
operon was obtained from PCR products.  As shown in Figure 42, the plasmid with 
Lac/Native promoter was used to induce the violacein production. The vio operon has 
high G+C content (average : 68%) (58, 168). This feature was a major obstacle to 
obtaining the vio operon by PCR.  A PCR product was obtained with LaTaq DNA 
polymerase along with GC buffer I. The entire vio operon (~8.9kb size) was achieved  
by mediated PCR (155). Mediated PCR products were obtained with the primer BR and 
3275RLR (4.9kb) and 3269LFR and BCF (4.45Kb) as described in experimental 
procedures. PCR conditions were the following: 0.5μl of Takara La Taq polymerase, 
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25μl of 2x GC buffer II, 8μl of dNTP, 4μl of Genomic DNA, 1μl of Forward primer, 1μl 
of Reverse primer and 10.5μl of deionized water in total 50μl reaction volume. PCR was 
run at step 1= 94C 1min, step 2=94C for 30sec, step 3=60C for 30sec, step 4=72C 
for 10min step 5= go to step 2, 30cycles step 6=72C for  5min step 7= 4C hold. The 
resulting PCR products were confirmed by sequencing as shown in Appendix D.  
 
 
Figure 42: Violacein expression in E. coli with Lac/ Native promoter. One purple colony showed 
up at 28C on LB+ 10μg/ml Kanamycin agar plate, and then streaked onto new agar plate to 
verify expression. 
 
 
After PCR products were obtained (4.9 Kb (M1) and 4.45 kb (M2) size), gel purified 
PCR products were used as templates to obtain the entire vio operon with 8.9 kb size.   
To run the mediated PCR with M1 and M2, PCR conditions were as follows: 0.5μl of 
Takara LaTaq DNA polymerase, 25μl of 2x GC buffer II, 8μl of dNTP, 4μl of M1 PCR 
product, 4μl of M2 PCR product, 0.4μl of Forward (3269LFR) primer, 0.4μl of Reverse 
(3275RLR) primer and 7.7 μl of deionized water in total 50μl reaction volume.  PCR 
was run utilizing the following conditions: step 1=98C for 1 min, step 2=98C for 20 
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sec, step 3=60C for 30 sec, step 4=67C for 15 min step 5= go to step 2, 30cycles step 
6=72C for  10 min step 7= 4C  hold. Previously reported results, from the Walsh group 
indicated only 2-violet colored colonies were obtained among thousands of colonies with 
the vector pET24b (169).  Another group also reported the vio locus without native 
promoter, the SpeI-XhoI fragment, which expressed violacein under the ermE*p 
promoter in S. albus (151). However, no violacein cluster was obtained with the methods 
under T7 promoter of pCC1FOS and pETBlue-2 in E .coli. Mediated PCR product was 
confirmed by sequencing with several combinations of primers to evolve the product 
contained vioA, vioB, vioC, vioD and vioE genes in their entirety. Only one violet-
colored colony was obtained from the mediated PCR product after ligation with Topo 
vector and then transformation into Top 10 E. coli strain. This construction was used as 
the mother vector, named as pV4(MluI-XhoI) (Scheme 5(A)). 
 
Construction of Violacein Gene Cluster under Various Promoters. All 17 different 
constructions were done by manipulation of the three different vector systems Topo XL, 
pETBlue-2 and pCC1FOS.  The illustration of the constructions is shown in Scheme 5.  
Only six constructions in the Topo system expressed the violacein violet-colored 
colonies: Lac/Native, Lac/Riboswitch, Lac/T7, Lac/ThiC/Riboswitch, ThiC/Riboswitch 
and Lac promoter. T7 promoter failed to express violacein in E. coli but a combination 
of Lac/T7 promoter did.  Because Lac promoter can express violacein by itself, Lac/T7 
promoter construction can be controlled by Lac promoter not the T7 promoter. We 
wondered why the T7 promoter failed to express violacein in 3 different common vector 
systems.  One possible explanation is that the T7 promoter is blocked by unidentified 
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genes. To address this issue, the sequence of the violacein operon was checked for a T7 
terminator. A terminator-like sequence was found in bp7932 to 7978 (170), which is 
located after the native promoter site. As shown in Figure 1, the native promoter is 
located in between an MluI and SpeI site. This means the terminator-like sequence 
remained after removing the native promoter. The sequence could form a hairpin-like 
shape, which is the common shape of the terminator. Detailed data is shown in Appendix 
D. 
Complementary experiments were performed with RutF protein to check expression 
of the protein under a vector in which expression is controlled by T7 promoter. The RutF 
gene was obtained by PCR.  PCR product was purified and digested with XhoI and SpeI. 
Double digested PCR product was ligated with linker (MluI-SpeI) into pETBlue-2 vector 
which was digested with MluI and XhoI. Transformation into Top 10 E. coli strain was 
followed. A protein of the expected size was observed on SDS-PAGE gel.  The data is 
shown in Appendix D. Based on the experiment, we can conclude that our construction 
strategy and vector promoter is functional. However, further experiments need to be 
performed to confirm the hypothesis that the violacein sequence contains a similar 
sequence to the T7 terminator which can block the initiation of transcription by a T7 
promoter. 
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Scheme 5: Constructions of violacein cluster under the various promoters in Topo, 
pCC1FOS, and pETblue-2 vector. Construction M (T7/Native promoter in pETblue-2) 
used 3 different DNA fragments. 
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Scheme 5: continued 
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Scheme 5: continued 
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Scheme 5: continued 
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Scheme 5: continued 
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Purification and Characterization of Violacein (UV-VIS/MS/ HPLC/LCMS/NMR). 
Violacein was extracted as described in the experimental procedure section.  C. 
violaceum was grown in Nutrient Broth (Difco) (171) at 28C. The violacein-containing 
butanol phase was obtained by extraction with water-saturated butanol as previously 
described in the literature (157, 160, 161). The extract was scanned over the visible 
wavelengths of light; UV-VIS spectrum shows strong absorption at the visible region 
(585nm) due to resonance of violacein.  The UV-VIS spectrum of violacein after 
purification with preparative HPLC is shown in Figure 43. The UV-VIS spectrums of 
crude violacein expressed in E. coli and C. violaceum are shown in Appendix D. All 
UV-VIS data matched previously reported data (157, 160).  Crude violacein was subject 
to mass spectrometry as shown in Figure 44. 
 
 
Figure 43: UV-VIS spectrum of violacein. After ran HPLC with major peak at 6.83min. 
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Figure 44: Mass spectrometry data. (A)MS data of violacein from cell extract with ESI in 
positive mode. (Expressed in E. coli) (B) MS data of violacein, after purification of HPLC in 
Acetonitrile, with MALDI in positive mode.   
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MS data from methanol extraction shows the expected M+H peak, but sample dissolved 
in Acetonitrile following HPLC purification, shows M+ in positive mode with ESI Mass 
spectrometry.  To obtain the correct MS data from the sample dissolved in Acetonitrile, 
it was dried and resubjected to scan ESI MS in methanol. The data shows that the mass 
of the hydrogen in positive mode was still missing. Based on the MS data, HPLC 
solution was changed to Methanol or Acetone. The missing proton was detected by 
MALDI MS as shown in Figure 44 (B).  
UV-VIS and MS data confirmed the violet pigments are violacein. The methanol 
extract was further purified using reverse phase preparative HPLC.  
To optimize the HPLC condition, reported conditions were first applied (4, 6, 10, 13).  
Optimized conditions were applied to preparative HPLC. HPLC spectra of violacein are 
shown in Figure 45. Crude sample and pure sample were run on an analytical HPLC 
with detection at 220 nm and 575 nm. Due to the color of violacein, long wavelength 
was required to distinguish between violacein and deoxyviolacein. Violacein was eluted 
first and then a mixture of trace violacein and deoxyviolacein was eluted (Figure 45B). 
Each fraction was analyzed by LCMS. To further enrich samples for violacein, 
alternative solvents to dissolve violacein were tested. From tests with acetone and 4,5,5-
trimethylfuran-2-one (TMF), TMF was shown to be the best solvent to increase 
solubility of violacein. 
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Figure 45: HPLC spectrums of violacein crude sample (red trace) and violacein after preparative 
HPLC (black trace) column: Gemini C18, 150X4.6mm (MeOH/water) Gradient: 50%B (MeOH) 
to 100% in 15min, (A) the column effluent was monitored at 220nm. Violacein was eluted at 
9.53min. Peak around 4min most probable is a system peak, not from the sample itself. (B) the 
column effluent was monitored at 575nm.  More data are shown in Appendix D. 
 
 
A mixture of TMF and methanol was adapted as solvent to dissolve violacein and 
HPLC was run with MeOH/water gradient or acetone/water gradient. Acetone/water 
gradient eluted violacein earlier than methanol/water gradient because acetone is more 
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polar than methanol. More detailed data including LCMS data is shown in Appendix D. 
According to the literature (157), crystallized violacein was analyzed by analytical 
HPLC. Crystallized violacein contained more deoxyviolacein compared to the fraction 
after preparative HPLC.  Therefore preparative HPLC is required to isolate pure 
violacein.   
The samples obtained from preparative HPLC were combined and lyophilized to 
dryness after removal of the solvent by rotary evaporation. Dried violacein was 
dissolved in deuterated dimethylsulphoxide (DMSO-d6). DMSO is not easy to remove 
for the recovery of the sample.  Another concern is the hygroscopic property of DMSO. 
A very intense water peak was observed at 3.3 ppm. We attempted to use CDCl3, but 
solubility of violacein was poor.  
1
H and 
13
C NMR spectra were measured at 300 and 
500 MHz. NMR spectra were acquired on a Bruker ARX 500 instrument using a 3 mm 
Broad band (BB)/H probe with WALTZ decoupling for 
13
C experiment. To get high 
intensity data, 3mm NMR probe was used as well as 5mm NMR probe. Comparing our 
1
H NMR and 
13
C NMR spectra with the data in the literature (162, 171, 172), we 
obtained highly purified violacein. 
1
H NMR , 
13
C NMR, and 
13
C DEPT135  NMR  
spectra were shown in Figure 46.  Tabulated data of 
1
H NMR and 
13
C NMR spectra is 
shown in Table 5. In 
13
C DEPT (Distortionless Enhancement by Polarization Transfer), 
CH2 yields negative peaks, whereas CH and CH3 are positive. 
 
Two-dimensional 
1
H-
1
H 
Correlation Spectroscopy (2D
 1
H-
1
H COSY) NMR spectrum and more NMR spectra are 
shown in Appendix D.  
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Figure 46: NMR spectra of purified violacein using preparative HPLC. NMR spectra were 
acquired  on a Bruker ARX 500 instrument using a 3mm Broad band (BB)/H probe with 
WALTZ decoupling for 
13
C experiment.(A) NMR-
1
H spectrum of violacein dissolved in DMSO-
d6. (B) NMR-
13
C spectrum (C) 
13
C DEPT135 NMR spectrum: doublet (CH, positive peak) and 
triplet (CH2, negative peak). More NMR spectra and 2D 
1
H-
1
H COSY spectrum are shown in 
Appendix D. 
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Table 5: Identification of violacein using 
1
H NMR and 
13
C NMR spectroscopy (500MHz, 
DMSO-d6) 
Position 
1
H NMR 
  
13
C NMR 
  
  Sample 
violacein 
a 
violacein 
b Sample 
violacein 
a 
violacein 
b 
1 11.95 11.95 11.89 
   2 8.09 8.08 8.07 129.6 129.5 129.5 
3 
   
105.7 
 
105.8 
4 
   
125.5 
 
125.5 
5 7.25 7.25 7.24 104.6 104.5 104.5 
6 9.35 
 
9.35 152.9 
 
152.9 
7 6.79 6.79 6.78 113 113.2 113.2 
8 7.35 7.35 7.35 113.3 113.6 113.4 
9 
   
131.6 
 
131.5 
10 10.56 10.65 10.74 
   11 
   
171.6 
 
171.5 
12 
   
136.9 
 
136.9 
13 7.55 7.56 7.55 96.9 97.2 96.9 
14 
   
147.6 
 
147.5 
15 10.65 10.75 10.64 
   16 
   
170.1 
 
170.1 
17 
   
118.6 
 
118.7 
18 
   
122.4 
 
122.3 
19 8.93 8.93 8.93 126.2 126.3 126.3 
20 6.95 6.95 6.95 120.7 121 120.8 
21 7.2 7.2 7.2 129.2 129.1 129.3 
22 6.82 6.82 6.82 108.9 109 108.9 
23 
   
141.8 
 
141.8 
 
ESI MS m/z:  344.1033 
MW: 343.0957 (violacein) 
NMR data of violacein a in DMSO-d6 were cited from Nakamura, Y. et al. (172) and  
violacein b from Hoshino, T. et al.(171) 
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Evaluation of Violacein Production Levels under the Various Promoters. As 
mentioned above only six constructions in the Topo system expressed the violet-colored 
colonies: Lac/Native, Lac/Riboswitch, Lac/T7, Lac/ThiC/Riboswitch, ThiC/Riboswitch 
and Lac promoter. The expressed violet- colored colonies on Agar plates are shown in 
Figure 47.   
 
 
Figure 47: Constructions for the expression of violacein. 1 is original clone in Top10, 2 is 
streaked from 1, 3 is BL21 (DE3) strain.  Labeled constructions as A, C, D, F, P, and Q are 
matched with Table 1. (A) Lac/Native promoter construction with PCR product, (C) Lac 
promoter (D) Lac/T7 promoter (F) Lac/Riboswitch (P) Lac/ThiC/Riboswitch  (Q) 
ThiC/Riboswitch 
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The construction of thiC/Riboswitch promoter was shown to successfully express 
violacein. According to the results, we chose interesting constructions (such as 
Lac/Native, Native, Lac, T7, ThiC/Riboswitch and Lac/Riboswitch promoter) to 
evaluate violacein production. Native promoter and T7 promoter did not express 
violacein by itself in the E. coli system on agar plates. The constructions containing 
Native and T7 promoter were chosen because they cannot initiate the transcription of vio 
operon or production level is too low to detect by unaided eye. All chosen constructions 
were grown in LB including 10μg/ml kanamycin at 30C for 5 days. The longer 
incubation time is due to original Topo XL vector being a high copy number plasmid (as 
well as pETBlue-2) and violacein having antibiotic properties (149). Violacein from C. 
violaceum was purified with preparative HPLC and then used to make a standard curve 
for quantification of violacein production in E. coli by various promoters. Standard 
curve is shown in Appendix D.   
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Figure 48:  Violacein production by Lac/Native, Lac/Riboswitch, Native, ThiC/Riboswitch, Lac 
and T7 promoters. ThiC/Riboswitch promoter produced almost 3 times more violacein than 
other promoters. 
 
As shown in Figure 48, the production of violacein by various promoters increased as 
follows Native ≈ T7 < Lac < Lac/Riboswitch < Lac/Native < ThiC/Riboswitch. ThiC 
and Riboswitch had a synergistic effect on the production of violacein. Lac/Native 
promoter also showed a synergistic effect compared to their individual effects on the 
production of violacein.  Violacein production by Native promoter and T7 promoter was 
still too low to detect by HPLC. According to the standard curve, the minimum amount 
should be more than 0.03906mg/ml; the two promoter system might produce less than 
0.03906mg/ml of violacein.  Tabulated data is shown in Appendix D. This result 
suggests that the use of ThiC/Riboswitch promoter can be utilized as a general strategy 
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for improving the expression efficiency of a recombinant protein.  Therefore, the system 
was evaluated to express β-galactosidase from LacZ, a predicted flavin reductase (RutF) 
in a novel pyrimidine catabolism pathway, and β-lacto-Globulin (BLG) protein.  β-
galactosidase was successfully expressed in a LacZ/ThiC/Riboswitch system with high 
efficacy. RutF and BLG were expressed in ThiC/Riboswitch system, but high expression 
level was not obtained in the system. The details of the data will be disclosed in 
subsequent sections. 
 
Evaluate Metabolite Profiles under the ThiC/Riboswitch Promoter and 
Lac/Riboswitch Promoter. As mentioned above, translation of the vio operon under the 
ThiC/Riboswitch promoter control will be inhibited in the presence of high 
concentrations of TPP. 
Scheme 6 is a schematic representation of the proposed mechanism for TPP-
dependent deactivation of thiM translation. The conformation of TPP riboswitch will 
rearrange after TPP is bound.  Rearranged TPP riboswitch will not initiate the 
translation. 
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Scheme 6: Schematic representation of the proposed mechanism for TPP-dependent deactivation 
of thiM translation.  After Serganov, A. et al. (145) 
 
 
The production of violacein under the ThiC/Riboswitch promoter and Lac/Riboswitch 
promoter were evaluated by analytical HPLC.   Inhibition of violacein expression in E. 
coli under the ThiC/Riboswitch and the Lac/Riboswitch promoter was monitored in the 
presence of TPP.  TPP concentrations were 0mM, 0.5 mM, 1.0mM, 1.5 mM, 2.0 mM, 
2.5 mM, 3 mM and 5 mM as shown in Figure 49.  As a result of the construction 
containing ThiC/Riboswitch promoter the expression of violacein can be tuned by the 
concentration of TPP as expected.   
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Figure 49: Inhibition of violacein expression in E. coli due to the presence of thiamine 
pyrophosphate chloride (TPP salt).  A: under ThiC/Riboswitch promoter control B:  under 
Lac/Riboswitch promoter control.  
 
The effect of TPP on transcription was also monitored by HPLC analysis with the 
construction under Lac/Riboswitch. Violacein production was not detected in the 
presence of 2.25 mM TPP concentration.  Therefore, the transcription was terminated or 
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inhibited by TPP concentration. Based on these results, the function of ThiC/Riboswitch 
and riboswitch can be controlled by TPP concentration to express violacein.  The TPP 
riboswitch is believed to modulate gene expression primarily at the level of transcription 
where affinity for TPP is thought to vary as the RNA transcript is released from the 
RNA polymerase. Some modulation does occur at the translational level, where affinity 
for TPP varies as the protein emerges from the ribosome. The ability of the TPP 
riboswitch to accept heterologous templates was exemplified by its ability to modulate 
β-galactosidase expression. 
 
Investigation of Titratability of the Thiamin Riboswitch. ThiC/Riboswitch/β-
galactosidase system and Arabinose/β-galactosidase system were employed to 
investigate titrability of the thiamin riboswitch compared to the pBAD promoter.  The 
LacZ gene used in both systems was obtained from PCR and insertion was confirmed by 
sequencing. In the case of the ThiC/Riboswitch/ β-galactosidase system, ONPG/ β-
galactosidase assay was modified. After removing LB media containing various TPP 
concentrations, we again added TPP to permeabilized cells in Z-buffer. As a control 
experiment, we checked O.D at 450 nm with ONPG-treated permeabilized cells in Z-
buffer without TPP. When TPP was not included in the Z-buffer we obtained results 
which were not consistent. Therefore, ThiC/Riboswitch is very sensitive to the 
concentration of TPP. The results showed that the expression of β-galactosidase with the 
ThiC/Riboswitch promoter was inhibited by TPP as shown in Figure 50 (A). This result 
corresponds to the results of the expression of violacein controlled by TPP.  Violacein 
production and β-galactosidase production were controlled by the TPP concentration. 
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Therefore, it demonstrates that ThiC/Riboswitch promoter is titratable using TPP.  As 
many gene products are toxic, the use of the ThiC/Riboswitch is able to modulate gene 
expression pathways by varying the TPP concentration. 
The pBAD33 promoter was also monitored to check titratability using arabinose and 
glucose. Arabinose is the inducer and glucose is the repressor in the pBAD system. In 
the presence of 0.2% arabinose or 0.2% of glucose, gene expression can be fully induced 
or repressed as described in previously reported literature (141, 173). We investigated 
arabinose‟s effect on the expression of β-galactosidase with arabinose concentrations 
less than 0.2%. Results showed that β-galactosidase units increased proportional to the 
concentration of arabinose. The result is shown in Figure 50 (B). We did not check with 
high concentration of arabinose because 0.2% arabinose fully induces gene expression 
under the pBAD promoter (141, 173), and the pBAD33 promoter was monitored as a 
tunable promoter with lower concentration of arabinose.  However, the data obtained 
with glucose titration showed the pBAD33 promoter is not a titratable promoter as 
shown in Figure 50 (C). The result corresponds to the previously reported data in which 
0.2% glucose can fully repress the gene expression even though it is not titratable.  
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Figure 50: Titratability check with ThiC/Riboswitch promoter by TPP (A) pBAD33 promoter by 
arabinose (B) and glucose (C). 
 
Comparison of Expression Profiles of RutF Protein under the T5-Lac Promoter vs 
TPP/Riboswitch Promoter. RutF protein is a predicted flavin reductase in a novel 
pyrimidine catabolism pathway. It is an insoluble protein under standard conditions. 
RutF DNA was obtained from Prof. Tadhg Begley‟s group, Department of Chemistry, 
Texas A&M University.  The PCR product of RutF was ligated to the vector containing 
the ThiC/Riboswitch promoter as described in the experimental section. Transformation 
into Top 10 E. coli strain followed. RutF under a T5-Lac promoter of pCA24N vector 
was used as a control. The soluble and insoluble samples were loaded onto 12% SDS-
PAGE gel (Figure 51).  An 18kDa protein corresponding to the size of the RutF was 
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expressed by the construction under the ThiC/Riboswitch promoter. Compared to the 
T5-Lac promoter, the level of RutF protein expression was low and solubility of the 
protein was not increased under ThiC/Riboswitch promoter.  Interestingly, the solubility 
of RutF protein was improved by transformation into Top10 E. coli strain. This indicates 
that recombinant protein solubility depends on the host cell used.    
 
Figure 51: SDS-PAGE gel of RutF protein. Comparison of solubility of RutF under T5-Lac 
promoter vs RutF2 under TPP/Riboswitch promoter. 
 
Evaluate β-lactoglubin (BLG) Protein Expression by SDS/PAGE under 
TPP/Riboswitch Promoter. BLG protein was chosen as a complementary experiment for 
another project in the Watanabe group. The BLG gene was inserted into the vector under 
control of the TPP/Riboswitch promoter as described in experimental procedure. Protein 
expression was analyzed on SDS/PAGE gel as shown in Figure 51.  Phusion DNA 
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polymerase and Taq DNA polymerase were used to obtain the PCR product.  Both 
polymerases produced the desired PCR product which contained the BLG gene. PH 1 
protein was from the PCR product using phusion DNA polymerase.  The protein was 
expressed in Top 10 E. coli host strain as shown in Figure 52.  
 
 
Figure 52: SDS –PAGE gel of BLG protein. PH1 from the PCR product using phusion DNA 
polymerase, 9-4 and 9-5 from the PCR product using Taq DNA polymerase.  
 
In conclusion, the production of violacein was improved by employing the 
ThiC/Riboswitch as shown earlier. Violacein is commercially available from the 
Sigma/Aldrich Company, but the price is expensive at $249/mg, and purity is only 85%, 
with the remainder as deoxyviolacein. Our strategy can improve the production of 
violacein in E. coli and an optimized HPLC condition can be applied to purify violacein 
from deoxyviolacein.  
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We have successfully used the thiC riboswitch which is regulated by thiamin 
pyrophosphate concentration, to modulate gene expression of the natural product 
violacein. Additionally, the use of the ThiC/Riboswitch promoter as a titratable promoter 
was investigated with the LacZ system and compared to the pBAD promoter. Based on 
the data, we can conclude that the ThiC/Riboswitch promoter is tunable using varied 
thiamin pyrophosphate concentration, while the pBAD promoter is not tunable. 
The ThiC/Riboswitch promoter was also employed in an attempt to improve the 
solubility of proteins, however we did not observe improvement of in solubility. 
Solubility of recombinant protein is highly dependent on the specific protein sequences, 
some proteins would increase solubility but not in proteins used in this study. 
Therefore, the use of the ThiC/Riboswitch promoter is a general strategy for 
improving the expression efficiency of a recombinant protein or a metabolite, and for 
modulation of pathway gene expression by varying the TPP concentration. 
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CHAPTER VI 
 
CONCLUSIONS 
 
Current purification methods or cultivation conditions provide a limited source of 
marine microbial samples. We attemped to construct DNA libraries to clone and express 
non-culturable bacterial genomes using recombinant DNA technology instead of 
developing time consuming purification methods or manipulating cultivation conditions. 
Two different cDNA libraries from different microorganisms (Pup14A/B, Hon6) and 
five different fosmid libraries from environmental samples were successfully 
constructed. From cDNA libraries, we did not complete the screening of the libraries. 
Therefore, no useful clones of biosynthetic pathways have been detected so far. Fosmid 
libraries from marine environmental samples were created with 30 percent success (five 
libraries were constructed out of sixteen samples). Some samples originated from the 
deep depth of the ocean, so it might contain different organisms which may use different 
biosynthetic pathways compared to teresterial samples. However, the samples from 
marine environments contained too little DNA to construct libraries. DNA isolatation 
was the main obstacle in increasing the chance of successful construction of the libraries. 
In most cases, we failed to construct the library because of we could not isolate enough 
DNA.  
 For screening of the fosmid libraries, genetic selection is a practical and economic 
method. To evaluate the potential use of genetic selection in the elucidation of 
biosynthetic pathways from marine microbial consortia, we identified the biotin 
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biosynthetic genes within Hon6. As the statistical probability of observing heterologous 
expression of a single gene is much higher than that of an entire biosynthetic pathway, 
genetic selection could prove to be an important tool in the localization of novel 
biosynthetic pathways. Coupled with promoter replacement technologies, the approach 
could lead to the discovery of a new generation of bioactive natural products. In this 
regard, clones from the constructed libraries can be screened by genetic selection to 
reveal novel biosynthetic pathways, such as thiamine synthase (ThiC), pyrimidine 
synthase (NadA), heme (HemN), lipoyltransferase (LipB), and thiamine biosynthesis 
(ThiH), in marine microbial consortia. 
The utility of the ThiC riboswitch was evaluated to control violacein production 
using promoter replacement technology. The production of violacein was increased by 
the ThiC riboswitch promoter compared to other promoters. The “switch” function of the 
riboswitch was evaluated by changing the thiamin pyrophosphate concentration in E. 
coli. We have successfully used the ThiC riboswitch to regulate gene expression of the 
natural product violacein. Since this work has been very successful, we are now 
interested in pursuing this work further to develop it as a tool to carry out genetic 
knockouts of biosynthetic pathways like the violacein gene cluster, or to analyze the 
metabolic flux of pathways. The violacein gene cluster is composed of five genes (vioA, 
vioB, vioC, vioD, and vioE) as shown in scheme 4 in Chapter V. A different riboswitch 
can also be substituted to control the gene cluster. A variety of riboswitches are made 
available by nature such as lysine, flavin, adenine, etc. (shown in Figure 53) which could 
be further exploited for orthogonal production. 
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Figure 53: The chemical structures of riboswitch ligands and schematics of conserved secondary 
structure in riboswitches. There are 8 confirmed riboswitches with unique metabolite ligands. 
Many more conserved RNA motifs are currently under investigation. After Courtesy: Ron 
Breaker Lab (Yale University) (174)  
 
In conclusion, our research goals were achieved. First we successfully created cDNA 
libraries from Pup14A/B and Hon6 and fosmid libraries from environmental samples for 
the identification of the natural product biosynthetic genes. The construction of DNA 
libraries could be an alternative method to identify genes from unculturable 
microorganisms. Second, genetic selection of the biosynthetic pathways was applied to 
identify biotin biosynthetic genes in Hon6. Third, genetic manipulations of the 
production of a natural product were successfully investigated with violacein controlled 
by various promoters. DNA libraries can be screened by genetic selection coupled with 
promoter replacement technologies. ThiC riboswitch was a powerful promoter in the 
heterologous production of violacein in E. coli. The method could be applied to increase 
the production of other natural products in E. coli. Fourth, modulation of gene 
expression by the ThiC riboswitch promoter was achieved using TPP concentrations. As 
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many gene products are toxic, the use of the ThiC Riboswitch is able to modulate gene 
expression pathways by varing the TPP concentration. 
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APPENDIX A 
A: Pup16  1
st
  strand   
 
B: Pup16 2
nd
 strand 
 
 
Figure A.1: Phosphorimage A: Pup16 1
st
 strand B: Pup16 2
nd
 strand 
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A: Pup 14 
Pup14 (EC100) 
 
Pup14 (Zapper) before and after digestion 
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B: Hon 6 
Hon6 ( EC100) 
 
Hon 6 before and after digestion with NotI 
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C: Pup16 
Pup 16 (Zapper) before and after digestion 
    
 
 
 
Figure A.2: Insertion size 
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Control: pETBlue+Zapper 
1. pETBlue protein extract + Acetyl CoA enzyme(radioactive) + cofactors (NADPH, FAD,  
    SAM) 
2. pETBlue protein extract + SAM (radioactive) + cofactors (NADPH, FAD) 
3.pETBlue Lyophilized media + Acetyl CoA enzyme(radioactive) + cofactors (NADPH,     
    FAD, SAM) 
4. pETBlue Lyophilized media + SAM(radioactive) + cofactors (NADPH, FAD) 
 
A: cDNA protein extract + unactivated media + Acetyl CoA*+ NADPH+FAD+SAM 
B: cDNA protein extract +                           Cell + Acetyl CoA*+ NADPH+FAD+SAM 
C: cDNA protein extract + half-activated media + Acetyl CoA*+ NADPH+FAD+SAM 
D: cDNA protein extract +                          Cell + Acetyl CoA*+ NADPH+FAD+SAM 
E: cDNA protein extract + fully-activated media + Acetyl CoA*+ NADPH+FAD+SAM 
F: cDNA protein extract +                           Cell + Acetyl CoA*+ NADPH+FAD+SAM 
G: cDNA protein extract + unactivated media + SAM*+ NADPH+FAD 
H: cDNA protein extract +                           Cell + SAM*+ NADPH+FAD 
I: cDNA protein extract + half-activated media + SAM*+ NADPH+FAD 
J: cDNA protein extract +                             Cell + SAM*+ NADPH+FAD 
K: cDNA protein extract + fully-activated media + SAM*+ NADPH+FAD 
L: cDNA protein extract +                              Cell + SAM*+ NADPH+FAD 
 
Figure A.3: Phosphorous image of the cDNA protein Extract (Pup14) 
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A: SAM-dependent Methyltransferase  Pup14A 
 RX#1 ---expected PCR Product size (252bp) 
 RX#2 ---expected PCR Product size (540bp) 
 RX#3 ---expected PCR Product size (948bp) 
             RX#4 --- expected PCR Product size (258bp) 
 RX#5 --- expected PCR Product size (666bp) 
 RX#6 --- expected PCR Product size (378bp) 
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B : Reductase Pup14A 
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C: Pup 14B  SAM-dependent Methyltransferase 
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D: Pup 14B Reductase 
 
       
 
 
• PCR results 
– SAM-dependent Methyltransferase  
 Pup14A—Rx 1,4,5,6 
 Pup14B— Rx 5 
     Hon6— no hit 
– Reductase (Pup14A) 
             Pup14A— Rx 1,2,3,4,5,6 
 Pup14B— Rx 1,3,6 
     Hon6 — no hit 
 
Figure A.4: PCR  
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APPENDIX B 
Supplementary Data for Chapter III 
 
                
     DNA extract                                                                            C3 samples after   
                                                                                              dephosphorylation (25ng) 
Plasmid isolated from C3 fosmid library 
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Biotin biosynthetic pathway screening of C3 Fosmid library (plate#1): PCR  
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PCR with 16S rDNA 
 
C3 fosmid library 
• Extract PCR products 
• Subsequecing PCR results  
• Bahama samples from salt pond (Foward: No E.coli Reverse: E. coli) 
• C3 (Foward: No E. coli, Reverse: Containing 95~98% E. coli) 
• Meso (Forward: No E. coli, Reverse: Containing 95~98% E. coli) 
 
Figure B.1: Supplementary data of C3 Fosmid library  
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Biofilm NRPS and PKS Screening Conditions: 
Template (20 ng/ul)  1 ul 
Primer 1 (100 pmol/ul)  3 ul 
Primer 2 (100 pmol/ul)  3 ul 
Taq (1 U/ul)   1 ul 
ThermoPol Buffer (10X) 10 ul 
dNTP‟s (25 mM)  2 ul 
H2O    80 ul  
Total    100 ul 
 
Thermocycler settings: Touch-down program 
 
96 °C  2 min.________________ 
96 °C  30 sec  20 cycles 
55 °C -.5/cycle 30 sec 
68 °C  1 min________________ 
96 °C  30 sec  20 cycles 
50 °C  30 sec 
68 °C  1 min________________ 
68 °C  7 min 
4 °C  forever 
 
 
 
 
 
PCR reaction with PKS primers (Biofilm) 
PKSfrom BioRIGHT: 5‟-ACA CTG GCG GCC GTT ACT A-3‟  58.9C 
PKSfromBioLEFT: 5‟-CTG TCC AAC CCC ACT GTT G-3‟       56.1C 
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12 conditions for PCR 
#1: 1μl of DNA, 1μl of Forward primer, 1μl of Reverse primer, 0.5μl of Taq DNA polymerase,    
      5μl of 10x buffer, 0.5μl of dNTP, 41μl of H2O 
#2: 1μl of DNA, 1μl of Forward primer, 1μl of Reverse primer, 0.5μl of Taq DNA polymerase,    
      5μl of 10x buffer, 0.5μl of dNTP, 38μl of H2O, 3μl of MgCl2 
#3: 1μl of DNA, 1μl of Forward primer, 1μl of Reverse primer, 0.5μl of Taq DNA polymerase,    
      5μl of 10x buffer, 0.5μl of dNTP, 36μl of H2O, 5μl of MgCl2 
#4: 1μl of DNA, 1μl of Forward primer, 1μl of Reverse primer, 0.5μl of Taq DNA polymerase,    
      5μl of 10x buffer, 0.5μl of dNTP, 34μl of H2O, 7μl of MgCl2 
#5: 1μl of DNA, 1μl of Forward primer, 1μl of Reverse primer, 0.5μl of Taq DNA polymerase,    
      5μl of 10x buffer, 0.5μl of dNTP, 38.5μl of H2O, 2.5μ of glycerol 
#6: 1μl of DNA, 1μl of Forward primer, 1μl of Reverse primer, 0.5μl of Taq DNA polymerase,    
      5μl of 10x buffer, 0.5μl of dNTP, 35.5μl of H2O, 2.5μ of glycerol, 3μl of MgCl2 
#7: 1μl of DNA, 1μl of Forward primer, 1μl of Reverse primer, 0.5μl of Taq DNA polymerase,    
      5μl of 10x buffer, 0.5μl of dNTP, 33.5μl of H2O, 2.5μ of glycerol, 5μl of MgCl2 
#8: 1μl of DNA, 1μl of Forward primer, 1μl of Reverse primer, 0.5μl of Taq DNA polymerase,    
      5μl of 10x buffer, 0.5μl of dNTP, 31.5μl of H2O, 2.5μ of glycerol, 7μl of MgCl2 
#9: 1μl of DNA, 1μl of Forward primer, 1μl of Reverse primer, 0.5μl of Taq DNA polymerase,    
      5μl of 10x buffer, 0.5μl of dNTP, 38.5μl of H2O, 2.5μ of DMSO 
#10: 1μl of DNA, 1μl of Forward primer, 1μl of Reverse primer, 0.5μl of Taq DNA polymerase,    
      5μl of 10x buffer, 0.5μl of dNTP, 35.5μl of H2O, 2.5μ of DMSO, 3μl of MgCl2 
#11: 1μl of DNA, 1μl of Forward primer, 1μl of Reverse primer, 0.5μl of Taq DNA polymerase,    
      5μl of 10x buffer, 0.5μl of dNTP, 33.5μl of H2O, 2.5μ of DMSO, 5μl of MgCl2 
#12: 1μl of DNA, 1μl of Forward primer, 1μl of Reverse primer, 0.5μl of Taq DNA polymerase,    
      5μl of 10x buffer, 0.5μl of dNTP, 31.5μl of H2O, 2.5μ of DMSO, 7μl of MgCl2 
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Biofilm fosmid DNA from each plate before digestion 
 (#1-#11 shown in here total 13 plates) 
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Autoradiograph of Immobilized Biofilm Fosmid Library Probed With Radioactive 
PKS Fragment 
 
 
 
 
 
 
 
 
 
 
 
 
        
                 8hr developed image                                               overnight developed image 
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Best hit from Biofilm fosmid library by screening with 
32
P labeled hybridization 
probe: #4E10 
 
PCR Probe Primer Sequences: 
PKS and NRPS Primers 
PaltNRPS_for  GGYTTTCGYRTNGARYTRGGYGA 
PaltNRPS_rev  TGRCCYARYKSAAAAAARTYNGC 
PaltPKS_for  TWYVTNNNNRCNCAYGGYAC 
PaltPKS rev  CCRCCAAARCCAAADSWRTT 
 
 
• Digestion of #4E10 with series restriction enzyme with DMSO and w/o DMSO for 2 
hrs, 4hrs, 9hrs, 24hrs (Shown in here 2hrs and 4hrs) 
1. EcoRI             37C 
2. HpaI               37C  
3. PmlI                37C  
4. SfoI                 37C  
5. BamHI            37C  
6. BglII                37C  
7. EcoRV            37C  
8. KpnI                37C  
9. NotI                 37C  
10. PvuI                 37C  
 
 
 
 
 
 
  
191 
Screening of Biotin biosynthetic pathway with best hit of Biofilm Fosmid library 
 Used PCR conditions #9 : DMSO 2.5μl in total 50μl volume 
 Selected PCR product:  BioB: 1-8 (#3 1F-5R  678bp) 
                                        BioC: 9 (#9 6F-7R 324bp) 
                                        BioF: 10-12 (#12 10F-11R  225bp)                                                                                             
              
 
Determination of optimal amount of DNA for PCR reaction 
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Screening of biotin biosynthetic pathway using Biofilm fosmid library 
BioB PCR Product with Biofilm Fosmid library (678bp) 
     
      
 
Figure B.2: Supplementary data of Biofilm Fosmid library 
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Isolated plasmids from packaging and tittering method (transfection) 
 
         1
st
: Ladder 
        2
nd
: Big from dam-/dcm- (O.1) 
        3
rd
: Big from dam-/dcm- (O.1) 
        4
th
: Big from dam-/dcm- (O.5) 
        5
th
: Big from dam-/dcm- (O.5) 
        6
th
: Big from DH10B (0.1) 
        7
th
: Big from DH10B (0.1) 
        8
th
: Big from DH10B (0.5) 
        9
th
: Big from DH10B (0.5) 
 
Electroporation into EPI300 
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CD151 isolated plasmids from each plate before digestion(using transformation method) 
  
 
 
 
Figure B.3: Supplementary data of CD151 fosmid library 
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CD179 before and after digestion (Regular gel) 
 
 
 
 
 
 
Figure B.4: Supplementary data of CD179 fosmid library 
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APPENDIX C 
Supplementary Data for Chapter IV 
 
 
 
 
(A) High molecular weight genomic DNA isolated from Hon6. (B) Optimization of 
restriction enzyme digestion with Hind III (C)First size fraction with Hind III cut DNA (D) 
Second size selection to eliminate small fragments with altered CHEF gel conditions                         
 
 
Figure C.1: Representative gels on Hon6 library construction  
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Biotin biosynthetic pathway degenerate probes were designed using multiple sequence 
alignments to search for regions of high homology. Protein sequences were downloaded from the 
NCBI website (http://www.ncbi.nlm.nih.gov.). Sequences (10) were chosen for for BioA, 17 
sequences for BioB, 16 sequences for BioC, 16 sequences for BioD, 16 sequences for BioF, and 
16 sequences for BioH. Sequences were chosen from multiple species and strains, which were 
identified by BLAST search analysis (http://ncbi.nlm.nih.gov/blst/Blst.cgi). Multiple sequence 
alignment was performed on the Baylor College of Medicine Multiple sequence alignment tool 
using Clustal X (http://searchlauncher.bcm.tmc.edu/multi-align/multi-align.html). Highly 
conserved sequenced were identified and manually reverse-translated into degenerate codons. 
Sequences were chosen which minimized degeneracy and maximized specificity. 
Oligonucleotides were ordered from the GTL (Texas A&M University, Gene Technological 
Lab). These oligonucleotides were used as PCR primers. 
Gel pictures and expected size of PCR products 
BioA: 1F-2R 420bp 
BioB: 1F-5R 678bp 
BioC: 6F-7R 324bp 
BioD: 1F-3R 450bp 
BioF: 10F-11R 225bp 
 
BioA: 420bp (2
nd
 lane)(100bp ladder used) 
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BioB: 678bp (1kb ladder used) 
 
 
BioC: 324bp (5th lane) (100bp ladder used) 
 
BioD: 450bp (2
nd
 lane)(100bp ladder used) 
 
 
BioF:225bp (2
nd
 lane)(100bp ladder used) 
 
 
Figure C.2: Description of Biotin Degenerate Probe Design 
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Standards and samples Biotin Concentration(ng/L) O.D. 
STD #1 0 1.158 
STD #2 37 1.000 
STD #3 111 0.668 
STD #4 333 0.362 
STD #5 1000 0.165 
Hon6#2-1 753 0.215 
Hon6#2-2 732 0.224 
Hon6#2-3 667 0.256 
 
Biotin Elisa Standard curve
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Hon6 Superimposed on Biotin ELISA
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Figure C.3: Biotin ELISA Tabulated Results 
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NBioA1F: 5’-CAY ATH TGG CAY CCN TAY AC-3’ 
NBioA2R: 5’-CCR AAN GTR TCN CCR TGR TA-3’  
 
CACAGTGTGTGTTTGCAGAGTATGTCGGTGCGAGAACCGAAGTGGCAGCGGACCTGTCTGACGGCAGACGC
CAGTGACGGTATGCGTCCTGGTGGGCAGAGATCCACGACTACAATCACCCGCAGCTTAATGCGTTTATGAA
GTCGTCATTGATGCCATGTCGCATGTGATGTTTGAAGATATCACGCATGCGCCAGCCAATGAGCTACTCCG
CAAACTGGTGGAGATGACGCCGAACCGCGCGGGTGTGCGTTTTTCCTACCAGCACCAGATACCGTAGCACC
AGGAAGTGGCCGTTGAAAAATAAAGCAGCTCGCTTGCTTAGGCCAAAGACGACGCGGATAAACCGTTTGAG
GACCTTCCCAAAAGATTTTATAACGGGTGCCACAATTTGG 
                                                                  Score     E 
Sequences producing significant alignments:                       (Bits)  Value 
 
pdb|1DTY|A  Chain A, Crystal Structure Of Adenosylmethionine-8...  49.7    4e-13  
ref|ZP_01702231.1|  adenosylmethionine-8-amino-7-oxononanoate ...  48.5    8e-13 
ref|YP_668706.1|  adenosylmethionine-8-amino-7-oxononanoate am...  48.5    8e-13  
ref|YP_539789.1|  adenosylmethionine-8-amino-7-oxononanoate am...  48.5    8e-13  
ref|NP_752783.1|  adenosylmethionine--8-amino-7-oxononanoate t...  48.5    8e-13  
ref|YP_851870.1|  adenosylmethionine-8-amino-7-oxononanoate am...  48.5    8e-13  
gb|AAG60578.1|AF250776_2  DAPA-aminotransferase BioA [uncultured   48.5    8e-13 
ref|YP_407168.1|  7,8-diaminopelargonic acid synthetase [Shige...  48.5    8e-13  
ref|NP_286537.1|  adenosylmethionine--8-amino-7-oxononanoate t...  48.5    8e-13  
pdb|1S08|A  Chain A, Crystal Structure Of The D147n Mutant Of ...  48.5    8e-13  
pdb|1S07|A  Chain A, Crystal Structure Of The R253a Mutant Of ...  48.5    8e-13  
pdb|1S09|A  Chain A, Crystal Structure Of The Y144f Mutant Of ...  48.5    8e-13  
pdb|1S06|A  Chain A, Crystal Structure Of The R253k Mutant Of ...  48.5    8e-13  
pdb|1S0A|A  Chain A, Crystal Structure Of The Y17f Mutant Of 7...  48.5    8e-13  
ref|NP_308879.1|  adenosylmethionine--8-amino-7-oxononanoate t...  48.5    8e-13  
pdb|1QJ3|A  Chain A, Crystal Structure Of 7,8-Diaminopelargoni...  48.5    8e-13  
ref|NP_415295.1|  7,8-diaminopelargonic acid synthase, PLP-dep...  48.5    8e-13  
pdb|1MGV|A  Chain A, Crystal Structure Of The R391a Mutant Of ...  48.5    8e-13  
ref|ZP_00923501.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...  48.5    8e-13 
ref|ZP_00704996.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...  48.5    8e-13 
ref|ZP_00698063.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...  48.5    8e-13 
ref|ZP_00721164.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...  48.5    1e-12 
ref|NP_706652.1|  adenosylmethionine--8-amino-7-oxononanoate t...  48.5    2e-12  
ref|YP_402503.1|  7,8-diaminopelargonic acid synthetase [Shige...  48.5    2e-12  
ref|NP_836430.1|  adenosylmethionine--8-amino-7-oxononanoate t...  48.5    2e-12  
ref|ZP_00709063.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...  48.5    2e-12 
ref|ZP_00703082.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...  47.4    2e-12 
ref|ZP_00715008.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...  47.4    7e-12 
gb|AAA23514.1|  7,8-diamino-pelargonic acid aminotransferase       47.4    9e-12 
ref|ZP_00720007.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...  47.0    1e-11 
sp|P53656|BIOA_ESCVU  Adenosylmethionine-8-amino-7-oxononanoat...  45.1    8e-10 
ref|YP_151180.1|  adenosylmethionine--8-amino-7-oxononanoate t...  43.1    8e-10  
ref|NP_455335.1|  adenosylmethionine--8-amino-7-oxononanoate t...  43.1    8e-10  
ref|NP_459771.1|  adenosylmethionine--8-amino-7-oxononanoate t...  43.1    8e-10  
ref|YP_215778.1|  adenosylmethionine--8-amino-7-oxononanoate t...  43.1    2e-09  
gb|AAG53588.1|AF248314_3  DAPA aminotransferase BioA [uncultured   42.4    4e-09 
gb|AAG60558.1|  BioA-like protein [uncultured bacterium pCosFS1]   41.6    5e-09 
ref|YP_001175997.1|  adenosylmethionine-8-amino-7-oxononanoate...  41.2    8e-09  
gb|AAG60563.1|AF250770_1  DAPA-aminotransferase [uncultured bacte  41.2    1e-08 
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ref|ZP_01167088.1|  adenosylmethionine--8-amino-7-oxononanoate...  45.4    1e-08 
gb|AAF04396.1|AF191556_4  BioA [Xenorhabdus nematophila]           41.2    1e-08 
gb|ABR76235.1|  adenosylmethionine--8-amino-7-oxononanoate tra...  40.8    3e-08 
ref|ZP_00824685.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...  42.7    5e-08 
ref|ZP_01222495.1|  adenosylmethionine--8-amino-7-oxononanoate...  42.7    8e-08 
ref|NP_777893.1|  adenosylmethionine-8-amino-7-oxononanoate am...  42.0    1e-07  
ref|YP_130517.1|  adenosylmethionine--8-amino-7-oxononanoate t...  42.7    1e-07  
ref|ZP_01065427.1|  adenosylmethionine--8-amino-7-oxononanoate...  41.2    1e-07 
ref|YP_069716.1|  adenosylmethionine--8-amino-7-oxononanoate t...  40.8    1e-07  
ref|ZP_01497422.1|  hypothetical protein YpseI_02002586 [Yersi...  40.8    1e-07 
ref|NP_670332.1|  adenosylmethionine--8-amino-7-oxononanoate t...  40.8    1e-07  
ref|NP_404759.1|  adenosylmethionine--8-amino-7-oxononanoate t...  40.8    1e-07  
ref|ZP_01175286.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...  40.8    1e-07 
ref|ZP_00821421.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...  40.8    2e-07 
ref|YP_454582.1|  adenosylmethionine-8-amino-7-oxononanoate am...  40.4    2e-07  
ref|ZP_00829478.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...  39.7    2e-07 
ref|ZP_01535731.1|  adenosylmethionine-8-amino-7-oxononanoate ...  41.6    2e-07 
ref|YP_001131218.1|  adenosylmethionine-8-amino-7-oxononanoate...  40.8    2e-07  
ref|YP_206706.1|  adenosylmethionine--8-amino-7-oxononanoate t...  42.7    2e-07  
ref|ZP_00832231.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...  39.7    2e-07 
ref|YP_001007096.1|  adenosylmethionine-8-amino-7-oxononanoate...  38.9    3e-07  
ref|ZP_00530485.1|  Adenosylmethionine--8-amino-7-oxononanoate...  39.3    5e-07 
ref|ZP_00532661.1|  Adenosylmethionine--8-amino-7-oxononanoate...  39.3    5e-07 
ref|ZP_01224606.1|  putative adenosylmethionine-8-amino-7-oxon...  42.0    5e-07 
ref|ZP_01693278.1|  adenosylmethionine-8-amino-7-oxononanoate ...  42.0    7e-07 
ref|NP_240116.1|  adenosylmethionine-8-amino-7-oxononanoate am...  39.3    7e-07  
ref|ZP_00591569.1|  Adenosylmethionine--8-amino-7-oxononanoate...  38.9    7e-07 
ref|YP_691976.1|  7,8-diaminononanoate transaminase [Alcanivor...  40.4    7e-07  
ref|NP_928779.1|  adenosylmethionine--8-amino-7-oxononanoate t...  38.5    7e-07  
ref|ZP_01043920.1|  Adenosylmethionine-8-amino-7-oxononanoate ...  38.5    8e-07 
ref|YP_375950.1|  Adenosylmethionine--8-amino-7-oxononanoate a...  41.2    8e-07  
ref|YP_588695.1|  adenosylmethionine-8-amino-7-oxononanoate am...  38.5    1e-06  
ref|ZP_00588811.1|  Adenosylmethionine--8-amino-7-oxononanoate...  40.8    1e-06 
ref|ZP_01449474.1|  adenosylmethionine--8-amino-7-oxononanoate...  37.7    1e-06 
ref|ZP_01613057.1|  adenosylmethionine-8-amino-7-oxononanoate ...  37.7    1e-06 
gb|EDN14554.1|  adenosylmethionine-8-amino-7-oxononanoate amin...  39.3    1e-06 
gb|EDM55468.1|  adenosylmethionine-8-amino-7-oxononanoate amin...  39.3    1e-06 
gb|EAY41069.1|  adenosylmethionine-8-amino-7-oxononanoate amin...  39.3    1e-06 
ref|ZP_01679552.1|  adenosylmethionine-8-amino-7-oxononanoate ...  39.3    1e-06 
ref|NP_230756.1|  adenosylmethionine--8-amino-7-oxononanoate t...  39.3    1e-06  
ref|YP_662128.1|  adenosylmethionine-8-amino-7-oxononanoate am...  40.0    1e-06  
sp|P36568|BIOA_SERMA  Adenosylmethionine-8-amino-7-oxononanoat...  38.5    1e-06 
gb|EAZ75883.1|  adenosylmethionine-8-amino-7-oxononanoate amin...  39.3    1e-06 
ref|YP_340126.1|  adenosylmethionine-8-amino-7-oxononanoate am...  39.3    2e-06  
ref|YP_910611.1|  adenosylmethionine-8-amino-7-oxononanoate am...  38.9    2e-06  
gb|EAY34686.1|  adenosylmethionine-8-amino-7-oxononanoate amin...  38.9    2e-06 
ref|YP_001303271.1|  adenosylmethionine--8-amino-7-oxononanoat...  39.3    2e-06  
ref|ZP_00992911.1|  adenosylmethionine--8-amino-7-oxononanoate...  37.4    2e-06 
ref|ZP_01484255.1|  hypothetical protein VchoV5_02003173 [Vibrio   38.9    2e-06 
ref|YP_050917.1|  adenosylmethionine--8-amino-7-oxononanoate t...  40.0    2e-06  
ref|ZP_01787556.1|  adenosylmethionine--8-amino-7-oxononanoate...  39.7    2e-06 
ref|ZP_01785523.1|  adenosylmethionine--8-amino-7-oxononanoate...  39.7    2e-06 
ref|YP_249043.1|  adenosylmethionine--8-amino-7-oxononanoate t...  39.7    2e-06  
ref|NP_439703.1|  adenosylmethionine--8-amino-7-oxononanoate t...  39.7    2e-06  
ref|ZP_00155127.2|  COG0161: Adenosylmethionine-8-amino-7-oxon...  39.7    2e-06 
ref|ZP_00157150.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...  39.7    2e-06 
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ref|YP_001291543.1|  adenosylmethionine--8-amino-7-oxononanoat...  39.7    2e-06  
ref|YP_001290829.1|  adenosylmethionine--8-amino-7-oxononanoat...  39.7    2e-06  
ref|ZP_01797619.1|  adenosylmethionine--8-amino-7-oxononanoate...  39.7    2e-06 
ref|ZP_01794704.1|  adenosylmethionine--8-amino-7-oxononanoate...  39.7    2e-06 
ref|ZP_01793207.1|  adenosylmethionine--8-amino-7-oxononanoate...  39.7    2e-06 
 
TCTTCCGGCGCCGTTTGGGACCCGATGTGCGTGCGAGTTCGGTTGCGGTACTGAACTCTGTTTTATCGCGA
CTTCCACCGCTACGGTAACCGGACCCGCGAGAAAAACGCACTCCAGCACAAGCACCGTCAGCTTAATGCGT
TTGCGGCGTAGTCATTGACTCCATCATGGGTGATACCTTCGAACATCACATCCAACATGCAATCAATTTTG
CTACTTCATCGACTCATTAAGCTGAGGGTGATTGTAGCCGTGGATCGTTTCCTACCAGGACGACATACCGT
CAACCAGGCGTCTGCGGTCAGAAAAAATCAGCTCGCAACCTTCGGCGCTCACCACCGGATAAACCGGCAGA
GGGCAGGTCATGGATGTATACGGGTGCCAATTTTG 
         
                                                                  Score     E 
Sequences producing significant alignments:                       (Bits)  Value 
 
pdb|1DTY|A  Chain A, Crystal Structure Of Adenosylmethionine-8...   123    4e-27  
ref|NP_415295.1|  7,8-diaminopelargonic acid synthase, PLP-dep...   122    5e-27  
ref|ZP_00923501.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...   122    5e-27 
ref|YP_407168.1|  7,8-diaminopelargonic acid synthetase [Shige...   122    7e-27  
ref|ZP_00698063.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...   122    7e-27 
ref|ZP_01702231.1|  adenosylmethionine-8-amino-7-oxononanoate ...   121    2e-26 
ref|YP_851870.1|  adenosylmethionine-8-amino-7-oxononanoate am...   121    2e-26  
ref|YP_668706.1|  adenosylmethionine-8-amino-7-oxononanoate am...   121    2e-26  
ref|YP_539789.1|  adenosylmethionine-8-amino-7-oxononanoate am...   121    2e-26  
gb|AAG60578.1|AF250776_2  DAPA-aminotransferase BioA [uncultured    121    2e-26 
ref|NP_706652.1|  adenosylmethionine--8-amino-7-oxononanoate t...   121    2e-26  
ref|YP_402503.1|  7,8-diaminopelargonic acid synthetase [Shige...   121    2e-26  
ref|NP_836430.1|  adenosylmethionine--8-amino-7-oxononanoate t...   121    2e-26  
ref|NP_286537.1|  adenosylmethionine--8-amino-7-oxononanoate t...   121    2e-26  
ref|NP_752783.1|  adenosylmethionine--8-amino-7-oxononanoate t...   121    2e-26  
ref|NP_308879.1|  adenosylmethionine--8-amino-7-oxononanoate t...   121    2e-26  
ref|ZP_00704996.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...   121    2e-26 
ref|ZP_00703082.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...   121    2e-26 
ref|ZP_00709063.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...   121    2e-26 
ref|ZP_00721164.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...   120    3e-26 
ref|ZP_00720007.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...   119    7e-26 
pdb|1S08|A  Chain A, Crystal Structure Of The D147n Mutant Of ...   118    1e-25  
pdb|1S07|A  Chain A, Crystal Structure Of The R253a Mutant Of ...   118    1e-25  
pdb|1S09|A  Chain A, Crystal Structure Of The Y144f Mutant Of ...   118    1e-25  
pdb|1S06|A  Chain A, Crystal Structure Of The R253k Mutant Of ...   118    1e-25  
pdb|1QJ3|A  Chain A, Crystal Structure Of 7,8-Diaminopelargoni...   118    1e-25  
pdb|1MGV|A  Chain A, Crystal Structure Of The R391a Mutant Of ...   118    1e-25  
ref|ZP_00715008.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...   118    1e-25 
gb|AAA23514.1|  7,8-diamino-pelargonic acid aminotransferase        117    3e-25 
pdb|1S0A|A  Chain A, Crystal Structure Of The Y17f Mutant Of 7...   117    3e-25  
ref|YP_454582.1|  adenosylmethionine-8-amino-7-oxononanoate am...   115    6e-25  
ref|NP_459771.1|  adenosylmethionine--8-amino-7-oxononanoate t...   111    2e-23  
ref|YP_215778.1|  adenosylmethionine--8-amino-7-oxononanoate t...   110    3e-23  
ref|YP_151180.1|  adenosylmethionine--8-amino-7-oxononanoate t...   110    3e-23  
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ref|NP_455335.1|  adenosylmethionine--8-amino-7-oxononanoate t...   110    3e-23  
gb|ABR76235.1|  adenosylmethionine--8-amino-7-oxononanoate tra...   108    1e-22 
sp|P53656|BIOA_ESCVU  Adenosylmethionine-8-amino-7-oxononanoat...   108    1e-22 
gb|AAG53588.1|AF248314_3  DAPA aminotransferase BioA [uncultured    106    4e-22 
ref|NP_928779.1|  adenosylmethionine--8-amino-7-oxononanoate t...   106    4e-22  
ref|ZP_00829478.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...   106    4e-22 
ref|YP_001175997.1|  adenosylmethionine-8-amino-7-oxononanoate...   106    5e-22  
ref|ZP_00824685.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...   106    5e-22 
ref|ZP_00821421.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...   105    7e-22 
ref|YP_001007096.1|  adenosylmethionine-8-amino-7-oxononanoate...   104    1e-21  
gb|AAF04396.1|AF191556_4  BioA [Xenorhabdus nematophila]            104    1e-21 
ref|ZP_00832231.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...   104    2e-21 
ref|YP_588695.1|  adenosylmethionine-8-amino-7-oxononanoate am...   103    3e-21  
ref|YP_050917.1|  adenosylmethionine--8-amino-7-oxononanoate t...   100    2e-20  
ref|YP_069716.1|  adenosylmethionine--8-amino-7-oxononanoate t...   100    3e-20  
ref|NP_404759.1|  adenosylmethionine--8-amino-7-oxononanoate t...   100    3e-20  
ref|ZP_01175286.1|  COG0161: Adenosylmethionine-8-amino-7-oxon...   100    3e-20 
ref|ZP_01497422.1|  hypothetical protein YpseI_02002586 [Yersi...   100    3e-20 
ref|NP_670332.1|  adenosylmethionine--8-amino-7-oxononanoate t...   100    3e-20  
gb|AAG60558.1|  BioA-like protein [uncultured bacterium pCosFS1]   99.0    8e-20 
ref|ZP_01535731.1|  adenosylmethionine-8-amino-7-oxononanoate ...  97.8    2e-19 
sp|P36568|BIOA_SERMA  Adenosylmethionine-8-amino-7-oxononanoat...  97.1    3e-19 
ref|YP_691976.1|  7,8-diaminononanoate transaminase [Alcanivor...  95.1    1e-18  
gb|AAG60563.1|AF250770_1  DAPA-aminotransferase [uncultured bacte  94.4    2e-18 
ref|NP_660627.1|  adenosylmethionine-8-amino-7-oxononanoate am...  94.4    2e-18  
ref|ZP_01222495.1|  adenosylmethionine--8-amino-7-oxononanoate...  94.0    3e-18 
ref|YP_130517.1|  adenosylmethionine--8-amino-7-oxononanoate t...  94.0    3e-18  
ref|ZP_01898736.1|  adenosylmethionine-8-amino-7-oxononanoate ...  92.8    6e-18 
ref|ZP_01160450.1|  adenosylmethionine--8-amino-7-oxononanoate...  92.8    6e-18 
ref|ZP_00530485.1|  Adenosylmethionine--8-amino-7-oxononanoate...  92.8    6e-18 
ref|ZP_01043920.1|  Adenosylmethionine-8-amino-7-oxononanoate ...  92.4    8e-18 
ref|ZP_01235384.1|  adenosylmethionine--8-amino-7-oxononanoate...  92.0    1e-17 
ref|NP_240116.1|  adenosylmethionine-8-amino-7-oxononanoate am...  92.0    1e-17  
ref|ZP_00532661.1|  Adenosylmethionine--8-amino-7-oxononanoate...  92.0    1e-17 
ref|YP_001093844.1|  adenosylmethionine-8-amino-7-oxononanoate...  90.5    3e-17  
ref|NP_871455.1|  hypothetical protein WGLp452 [Wigglesworthia...  89.7    5e-17  
ref|ZP_01693278.1|  adenosylmethionine-8-amino-7-oxononanoate ...  89.4    6e-17 
ref|NP_874062.1|  adenosylmethionine--8-amino-7-oxononanoate t...  89.4    6e-17  
ref|YP_001131218.1|  adenosylmethionine-8-amino-7-oxononanoate...  89.4    6e-17  
ref|YP_001303271.1|  adenosylmethionine--8-amino-7-oxononanoat...  89.0    8e-17  
ref|YP_378405.1|  Adenosylmethionine--8-amino-7-oxononanoate a...  88.6    1e-16  
ref|YP_910611.1|  adenosylmethionine-8-amino-7-oxononanoate am...  88.6    1e-16  
ref|ZP_01224606.1|  putative adenosylmethionine-8-amino-7-oxon...  87.8    2e-16 
ref|ZP_01167088.1|  adenosylmethionine--8-amino-7-oxononanoate...  87.8    2e-16 
ref|ZP_00591569.1|  Adenosylmethionine--8-amino-7-oxononanoate...  87.8    2e-16 
ref|ZP_00511607.1|  Adenosylmethionine--8-amino-7-oxononanoate...  87.0    3e-16 
ref|ZP_01674408.1|  adenosylmethionine-8-amino-7-oxononanoate ...  86.7    4e-16 
ref|ZP_01473993.1|  hypothetical protein VEx2w_02003422 [Vibri...  86.3    5e-16 
ref|ZP_01385590.1|  adenosylmethionine-8-amino-7-oxononanoate ...  85.9    7e-16 
ref|YP_375950.1|  Adenosylmethionine--8-amino-7-oxononanoate a...  85.9    7e-16  
ref|YP_856026.1|  adenosylmethionine-8-amino-7-oxononanoate tr...  85.5    9e-16  
ref|ZP_01921353.1|  adenosylmethionine-8-amino-7-oxononanoate ...  85.1    1e-15 
ref|YP_206706.1|  adenosylmethionine--8-amino-7-oxononanoate t...  85.1    1e-15  
ref|NP_797491.1|  adenosylmethionine--8-amino-7-oxononanoate t...  85.1    1e-15  
ref|ZP_01065427.1|  adenosylmethionine--8-amino-7-oxononanoate...  85.1    1e-15 
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ref|ZP_01816621.1|  adenosylmethionine--8-amino-7-oxononanoate...  84.7    2e-15 
ref|ZP_00588811.1|  Adenosylmethionine--8-amino-7-oxononanoate...  84.3    2e-15 
ref|YP_750164.1|  adenosylmethionine-8-amino-7-oxononanoate am...  84.3    2e-15  
ref|ZP_01133854.1|  adenosylmethionine-8-amino-7-oxononanoate ...  84.0    3e-15 
ref|YP_870155.1|  adenosylmethionine-8-amino-7-oxononanoate am...  84.0    3e-15  
ref|XP_718351.1|  adenosylmethionine-8-amino-7-oxononanoate am...  84.0    3e-15  
ref|ZP_01597382.1|  adenosylmethionine-8-amino-7-oxononanoate ...  83.6    3e-15 
ref|YP_943296.1|  adenosylmethionine-8-amino-7-oxononanoate am...  83.6    3e-15  
ref|ZP_01260980.1|  adenosylmethionine--8-amino-7-oxononanoate...  83.6    3e-15 
ref|YP_562664.1|  adenosylmethionine-8-amino-7-oxononanoate am...  83.6    3e-15  
ref|ZP_00992911.1|  adenosylmethionine--8-amino-7-oxononanoate...  83.6    3e-15 
 
>> gb|CP000038.1|  Shigella sonnei Ss046, complete genome 
Length=4825265 
 
 Features in this part of subject sequence: 
   7,8-diaminopelargonic acid synthetase 
 
 Score =  230 bits (124),  Expect = 4e-57 
 Identities = 184/211 (87%), Gaps = 11/211 (5%) 
 Strand=Plus/Minus 
 
Query  55      TGTCTGACGGCAGACGCC-AG-TGACGGTATG-CGTCCTGGTGGGCAGAGATCCACGACT  111 
               ||||||||||||||||||  | |||||||||| ||||||||||||| | |||||||| || 
Sbjct  798228  TGTCTGACGGCAGACGCCTGGTTGACGGTATGTCGTCCTGGTGGGCGGCGATCCACGGCT  798169 
 
Query  112     ACAATCACCCGCAGCTTAATGCGTTTATGAAGTCGTC--ATTGATGCCATGTCGCATGTG  169 
               |||||||||||||||||||||||   ||||||||| |  ||||||||||||||||||||| 
Sbjct  798168  ACAATCACCCGCAGCTTAATGCGGCGATGAAGTCG-CAAATTGATGCCATGTCGCATGTG  798110 
 
Query  170     ATGTTTGAAGATATCACGCATGCGCCAGCCAATGAGCTACT-CCGCAAACTGGTGGAGAT  228 
               |||||||  | |||||| ||||||||||||| ||||||  | |||||||||||||| ||| 
Sbjct  798109  ATGTTTGGCGGTATCACCCATGCGCCAGCCATTGAGCTG-TGCCGCAAACTGGTGGCGAT  798051 
 
Query  229     GACGCCG-AACCGCGCGGGTGTGCGTTTTTC  258 
               ||||||| ||||||  ||  ||||||||||| 
Sbjct  798050  GACGCCGCAACCGCT-GGA-GTGCGTTTTTC  798022 
 
 
> gb|CP000036.1|  Shigella boydii Sb227, complete genome 
Length=4519823 
 
 Features in this part of subject sequence: 
   7,8-diaminopelargonic acid synthetase 
 
 Score =  219 bits (118),  Expect = 9e-54 
 Identities = 169/192 (88%), Gaps = 9/192 (4%) 
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 Strand=Plus/Minus 
 
Query  55      TGTCTGACGGCAGACGCC--AGTGACGGTATG-CGTCCTGGTGGGCAGAGATCCACGACT  111 
               ||||||||||||||||||  | |||||||||| ||||||||||||| | |||||||| || 
Sbjct  675164  TGTCTGACGGCAGACGCCTGATTGACGGTATGTCGTCCTGGTGGGCGGCGATCCACGGCT  675105 
 
Query  112     ACAATCACCCGCAGCTTAATGCGTTTATGAAGTCGTC--ATTGATGCCATGTCGCATGTG  169 
               |||||||||||||||||||||||   ||||||||| |  ||||||||||||||||||||| 
Sbjct  675104  ACAATCACCCGCAGCTTAATGCGGCGATGAAGTCG-CAAATTGATGCCATGTCGCATGTG  675046 
 
Query  170     ATGTTTGAAGATATCACGCATGCGCCAGCCAATGAGCTACT-CCGCAAACTGGTGGAGAT  228 
               |||||||  | |||||| ||||||||||||| ||||||  | |||||||||||||| ||| 
Sbjct  675045  ATGTTTGGCGGTATCACCCATGCGCCAGCCATTGAGCTG-TGCCGCAAACTGGTGGCGAT  674987 
 
Query  229     GACGCCG-AACC  239 
               ||||||| |||| 
Sbjct  674986  GACGCCGCAACC  674975 
 
 
BioB 
BioB1F: 5’-GAR GAY TGY AAR TAY TGY CC-3’ 
BioB5R: 5’-CCN GCC ATR AAR CAC ATN GCY TG-3’ 
 
ATCTCGGATGAACATACGTCTGCCGCCAGGAGGGTGACGTAAGTGTTAGATGATGATGCCCGCCAAGTGGT
GCGATAAAATCAAAGGCATCGACATCATCGTTATCGGCAAGCGGCGTGCTTTCACCTTCACCAGCATGTTG
ATTGGCACGCTTTCCGGCGCGCGGAGGGTTGGAGGTGAGCAATAATCCGGCACGATCTTTTACCGTTACGC
CTAAGCCCACAATGCCGCCAGAACAGACTTTGATCCCGGCATCGTGCACTTTTTCCAGCGTATCGAGGCGT
TCCTGATAAGCGCATGTCTTTGATGATATTGCCGTAAAACTCCGGCAAGAGGTCCAGGTTGTGGTTGAAGT
AATCCAGCTGGGCGTTCGGGAGGCGTTGGGAAAAAGATAAACTCAACGTGCCCAGCATTATACACGCTTCC
AGCCCCATCGCTGCTGCCGGAAGCGCTACTTATTCAAGGTACGGCGTATGGGAAAGGTACCCCGCTTTGCC
AATCACCGTGCATACAGTAGCTCGGAGTTTATGCGGATAATTGTTGGGGCGGGGACTCTAGTACCAGCTCA
CTTACGATCAATTTCTCGCGGACCAGCGCGGTTTTACCGAACAGACTTAGGCATTATGCTTAGGGACTCCT
TAAA 
                                                                  Score     E 
Sequences producing significant alignments:                       (Bits)  Value 
 
pdb|1R30|A  Chain A, The Crystal Structure Of Biotin Synthase,...  94.4    7e-37  
gb|AAA23515.1|  biotin synthetase                                  94.4    7e-37 
ref|YP_402502.1|  biotin synthesis [Shigella dysenteriae Sd197...  94.4    7e-37  
ref|NP_706653.1|  biotin synthesis, sulfur insertion? [Shigell...  94.4    7e-37  
ref|NP_415296.1|  biotin synthase [Escherichia coli K12] >ref|...  94.4    7e-37  
ref|NP_752785.1|  Biotin synthase [Escherichia coli CFT073] >r...  92.8    2e-36  
ref|ZP_00721165.1|  COG0502: Biotin synthase and related enzym...  92.8    2e-36 
ref|NP_308880.1|  biotin synthetase [Escherichia coli O157:H7 ...  94.4    4e-36  
gb|AAG60579.1|AF250776_3  biotin synthase BioB [uncultured bacter  94.4    7e-36 
ref|ZP_00698064.1|  COG0502: Biotin synthase and related enzym...  94.4    7e-36 
ref|NP_286538.1|  biotin synthesis, sulfur insertion? [Escheri...  94.4    2e-35  
sp|Q47862|BIOB_ESCVU  Biotin synthase (Biotin synthetase) >gb|...  93.2    7e-35 
gb|ABR76236.1|  biotin synthesis, sulfur insertion? [Klebsiell...  91.7    1e-34 
ref|YP_215779.1|  biotin synthetase [Salmonella enterica subsp...  90.5    4e-34  
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ref|YP_151179.1|  biotin synthetase [Salmonella enterica subsp...  90.5    4e-34  
ref|NP_459772.1|  biotin synthetase [Salmonella typhimurium LT...  90.5    4e-34  
ref|NP_455336.1|  biotin synthetase [Salmonella enterica subsp...  90.5    4e-34  
ref|YP_001175998.1|  biotin synthase [Enterobacter sp. 638] >g...  90.1    2e-33  
gb|AAG53589.1|AF248314_4  biotin synthase BioB [uncultured bacter  82.0    7e-32 
sp|P36569|BIOB_SERMA  Biotin synthase (Biotin synthetase) >dbj...  90.5    1e-31 
ref|YP_001007095.1|  biotin synthase [Yersinia enterocolitica ...  84.7    7e-31  
ref|ZP_00824684.1|  COG0502: Biotin synthase and related enzym...  84.7    7e-31 
ref|ZP_01535732.1|  biotin synthase [Serratia proteamaculans 5...  84.3    2e-30 
ref|ZP_00829477.1|  COG0502: Biotin synthase and related enzym...  83.2    3e-30 
gb|AAG60559.1|  BioB-like protein [uncultured bacterium pCosFS1]   82.0    6e-30 
ref|ZP_00821420.1|  COG0502: Biotin synthase and related enzym...  83.6    7e-30 
ref|ZP_00832232.1|  COG0502: Biotin synthase and related enzym...  84.7    1e-29 
ref|YP_050916.1|  biotin synthase [Erwinia carotovora subsp. a...  85.5    2e-29  
ref|NP_928780.1|  biotin synthetase (biotin synthase) [Photorh...  79.7    5e-29  
ref|NP_404760.1|  biotin synthase [Yersinia pestis CO92] >ref|...  80.1    2e-28  
ref|ZP_01497421.1|  hypothetical protein YpseI_02002585 [Yersi...  80.1    2e-28 
ref|YP_454583.1|  biotin synthase BioB [Sodalis glossinidius s...  80.1    9e-26  
ref|NP_797492.1|  biotin synthase [Vibrio parahaemolyticus RIM...  71.6    4e-24  
ref|ZP_01661930.1|  Biotin synthase [Ralstonia pickettii 12J] ...  74.7    1e-23 
ref|ZP_01914987.1|  probable biotin synthase protein [Limnobac...  77.4    1e-23 
gb|EDN42426.1|  biotin synthase [Ralstonia pickettii 12D]          74.7    2e-23 
ref|ZP_00967143.1|  COG0502: Biotin synthase and related enzym...  68.9    2e-23 
gb|EDN56181.1|  biotin synthase [Vibrio sp. Ex25]                  70.9    2e-23 
gb|AAT51401.1|  PA0500 [synthetic construct]                       68.9    2e-23 
ref|YP_788670.1|  biotin synthase [Pseudomonas aeruginosa UCBP...  68.9    2e-23  
ref|NP_249191.1|  biotin synthase [Pseudomonas aeruginosa PAO1...  68.9    2e-23  
ref|ZP_01260979.1|  biotin synthase [Vibrio alginolyticus 12G0...  70.9    2e-23 
ref|ZP_01473994.1|  hypothetical protein VEx2w_02003423 [Vibrio s  70.9    2e-23 
ref|ZP_01640775.1|  biotin synthase [Pseudomonas putida W619] ...  69.3    4e-23 
ref|YP_001189567.1|  biotin synthase [Pseudomonas mendocina ym...  68.9    4e-23  
ref|ZP_01293752.1|  hypothetical protein PaerP_01004394 [Pseud...  68.2    4e-23 
ref|YP_001174331.1|  biotin synthase [Pseudomonas stutzeri A15...  68.6    4e-23  
ref|ZP_01869259.1|  biotin synthase [Vibrio shilonii AK1] >gb|...  71.2    5e-23 
ref|ZP_01484254.1|  hypothetical protein VchoV5_02003172 [Vibr...  70.1    6e-23 
ref|NP_230757.1|  biotin synthase [Vibrio cholerae O1 biovar e...  70.1    6e-23  
ref|YP_001265745.1|  biotin synthase [Pseudomonas putida F1] >...  69.3    8e-23  
ref|NP_518387.1|  PROBABLE BIOTIN SYNTHASE PROTEIN [Ralstonia ...  68.6    1e-22  
ref|NP_742529.1|  biotin synthetase [Pseudomonas putida KT2440...  69.3    1e-22  
ref|ZP_01235385.1|  putative biotin synthase [Vibrio angustum ...  71.6    1e-22 
ref|ZP_01160449.1|  putative biotin synthase [Photobacterium s...  71.6    1e-22 
ref|YP_588696.1|  biotin synthase [Baumannia cicadellinicola s...  73.2    1e-22  
ref|YP_262751.1|  biotin synthetase [Pseudomonas fluorescens P...  64.7    2e-22  
ref|NP_790343.1|  biotin synthetase [Pseudomonas syringae pv. ...  65.5    2e-22  
ref|YP_610533.1|  biotin synthetase [Pseudomonas entomophila L...  69.3    2e-22  
ref|ZP_01816622.1|  biotin synthase [Vibrionales bacterium SWA...  70.5    2e-22 
ref|NP_934120.1|  biotin synthase [Vibrio vulnificus YJ016] >d...  68.9    3e-22  
ref|ZP_01065426.1|  biotin synthase [Vibrio sp. MED222] >gb|EA...  70.1    3e-22 
ref|NP_761747.1|  Biotin synthase [Vibrio vulnificus CMCP6] >g...  68.9    3e-22  
ref|ZP_01717084.1|  biotin synthase [Pseudomonas putida GB-1] ...  68.6    4e-22 
ref|YP_276822.1|  biotin synthase [Pseudomonas syringae pv. ph...  66.2    4e-22  
ref|YP_237752.1|  Biotin synthase [Pseudomonas syringae pv. sy...  66.2    4e-22  
ref|ZP_00992912.1|  biotin synthase [Vibrio splendidus 12B01] ...  70.5    4e-22 
gb|EAY41068.1|  biotin synthase [Vibrio cholerae MZO-3]            67.4    4e-22 
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ref|ZP_00418345.1|  Biotin synthase [Azotobacter vinelandii Av...  66.6    4e-22 
ref|YP_350904.1|  Biotin synthase [Pseudomonas fluorescens PfO...  65.1    8e-22  
ref|ZP_00943498.1|  Biotin synthase [Ralstonia solanacearum UW...  65.9    1e-21 
ref|YP_269309.1|  biotin synthase [Colwellia psychrerythraea 3...  69.7    1e-21  
ref|YP_130516.1|  putative biotin synthase [Photobacterium pro...  72.0    1e-21  
ref|YP_001142637.1|  biotin synthase [Aeromonas salmonicida su...  69.3    2e-21  
ref|YP_943295.1|  biotin synthase [Psychromonas ingrahamii 37]...  67.4    2e-21  
ref|ZP_01510809.1|  biotin synthase [Burkholderia phytofirmans...  68.6    2e-21 
ref|YP_556786.1|  Biotin synthase [Burkholderia xenovorans LB4...  68.6    2e-21  
ref|ZP_01224751.1|  biotin synthetase [marine gamma proteobact...  63.5    4e-21 
ref|YP_528608.1|  Biotin synthase [Saccharophagus degradans 2-...  62.0    4e-21  
ref|ZP_01222496.1|  putative biotin synthase [Photobacterium p...  70.1    5e-21 
ref|YP_155713.1|  Biotin synthase [Idiomarina loihiensis L2TR]...  65.5    5e-21  
ref|YP_856027.1|  biotin synthase [Aeromonas hydrophila subsp....  67.0    6e-21  
ref|ZP_01921354.1|  biotin synthase [Shewanella sediminis HAW-...  60.5    6e-21 
ref|ZP_01597380.1|  biotin synthase [Marinomonas sp. MWYL1] >g...  68.6    8e-21 
ref|ZP_01167078.1|  biotin synthase; contains an iron-sulfur c...  69.7    9e-21 
ref|ZP_00987655.1|  COG0502: Biotin synthase and related enzym...  65.5    9e-21 
ref|ZP_01540454.1|  biotin synthase [Shewanella woodyi ATCC 51...  58.2    1e-20 
ref|YP_934320.1|  biotin synthase [Azoarcus sp. BH72] >emb|CAL...  67.4    1e-20  
ref|ZP_01499695.1|  biotin synthase [Burkholderia phymatum STM...  66.6    2e-20 
ref|NP_871456.1|  hypothetical protein WGLp453 [Wigglesworthia...  63.9    2e-20  
ref|YP_562665.1|  biotin synthase [Shewanella denitrificans OS...  63.2    2e-20  
ref|YP_001093845.1|  biotin synthase [Shewanella loihica PV-4]...  61.6    2e-20  
ref|YP_734487.1|  biotin synthase [Shewanella sp. MR-4] >ref|Y...  59.7    2e-20  
ref|YP_113595.1|  biotin synthetase [Methylococcus capsulatus ...  69.7    2e-20  
ref|NP_881326.1|  biotin synthase [Bordetella pertussis Tohama...  68.6    2e-20  
ref|ZP_01569499.1|  biotin synthase [Burkholderia multivorans ...  65.5    2e-20 
ref|YP_927315.1|  Biotin synthase [Shewanella amazonensis SB2B...  60.8    2e-20  
ref|ZP_01115221.1|  biotin synthetase [Reinekea sp. MED297] >g...  70.1    2e-20 
ref|YP_963054.1|  biotin synthase [Shewanella sp. W3-18-1] >re...  59.7    2e-20  
ref|NP_718324.1|  biotin synthase [Shewanella oneidensis MR-1]...  59.3    2e-20  
 
 
CAGCTTTTCGTTAATCTCCTCGGCCGGCTGAAGGCCACGTAAGAGGCTGGATCATGATCCGGCGCCCTATG
GTGCGATAAAATCAAAGGCATCGACATCATCGTTATCGGCAAGCGGTGTGCTTTCACCTTCACCAGCATGT
TGATTGGCACGCTTTCCGGCGCGTCGCAGGGTTGCAAGTTGCAGCAATAATCCGGCGCGATCTTTTACCGT
TTCGCCTAAGCCCACAATGCCGCCAGAACAGACTTTGATCCCGGCATCGGGACTTTTTCCAGGGGTTATCG
GGGGCGTTCCTGATAAGTGCGTGTGGTATGAGATGAATATTGCCGTAAAACTCCGGCGAGGTGTCCAGGTT
GTGGTTGAAGTAATCCAGCCCGGCGTTCGCGAGGCGTTGCCCAAAAGATTAACTCAACGTGCCCAGCGTCA
TACACGCCTCCAGCCCCATCGCTTTTCCCCATGCCCATTTGTTCAAGGTACGGCAAATCGCGAACGTGGGG
ATTCTCCCACGCCGACCAATACAGAACCGCGCATTCTTCCGCTTTCGCTTTGCGCGCGGCTCTGGACCTGT
TCATTCCACAACGCTGGGTCCAGCCGGTTTTGTGCCCAGTTTTGCGGTAGATTTCGATCTTAA 
                                                                  Score     E 
Sequences producing significant alignments:                       (Bits)  Value 
 
ref|NP_308880.1|  biotin synthetase [Escherichia coli O157:H7 ...  89.4    7e-35  
pdb|1R30|A  Chain A, The Crystal Structure Of Biotin Synthase,...  89.0    9e-35  
gb|AAA23515.1|  biotin synthetase                                  89.0    9e-35 
ref|YP_402502.1|  biotin synthesis [Shigella dysenteriae Sd197...  89.0    9e-35  
ref|NP_706653.1|  biotin synthesis, sulfur insertion? [Shigell...  89.0    9e-35  
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ref|NP_415296.1|  biotin synthase [Escherichia coli K12] >ref|...  89.0    9e-35  
ref|ZP_00721165.1|  COG0502: Biotin synthase and related enzym...  89.4    2e-34 
sp|Q47862|BIOB_ESCVU  Biotin synthase (Biotin synthetase) >gb|...  87.4    2e-34 
ref|NP_752785.1|  Biotin synthase [Escherichia coli CFT073] >r...  89.0    3e-34  
ref|NP_286538.1|  biotin synthesis, sulfur insertion? [Escheri...  87.0    3e-34  
gb|AAG60579.1|AF250776_3  biotin synthase BioB [uncultured bacter  86.3    6e-34 
ref|ZP_00698064.1|  COG0502: Biotin synthase and related enzym...  86.3    6e-34 
ref|YP_215779.1|  biotin synthetase [Salmonella enterica subsp...  89.0    1e-33  
ref|NP_459772.1|  biotin synthetase [Salmonella typhimurium LT...  89.0    1e-33  
ref|NP_455336.1|  biotin synthetase [Salmonella enterica subsp...  87.8    3e-33  
gb|ABR76236.1|  biotin synthesis, sulfur insertion? [Klebsiell...  85.1    3e-33 
ref|YP_151179.1|  biotin synthetase [Salmonella enterica subsp...  86.3    8e-33  
ref|YP_001175998.1|  biotin synthase [Enterobacter sp. 638] >g...  84.7    3e-32  
sp|P36569|BIOB_SERMA  Biotin synthase (Biotin synthetase) >dbj...  79.3    6e-31 
ref|ZP_01535732.1|  biotin synthase [Serratia proteamaculans 5...  81.3    7e-31 
gb|AAG60559.1|  BioB-like protein [uncultured bacterium pCosFS1]   82.0    2e-30 
ref|YP_001007095.1|  biotin synthase [Yersinia enterocolitica ...  78.6    1e-29  
gb|AAG53589.1|AF248314_4  biotin synthase BioB [uncultured bacter  81.6    2e-29 
ref|ZP_00821420.1|  COG0502: Biotin synthase and related enzym...  78.6    3e-29 
ref|ZP_00824684.1|  COG0502: Biotin synthase and related enzym...  77.0    4e-29 
ref|ZP_00832232.1|  COG0502: Biotin synthase and related enzym...  76.6    5e-29 
ref|ZP_00829477.1|  COG0502: Biotin synthase and related enzym...  78.6    8e-29 
ref|NP_928780.1|  biotin synthetase (biotin synthase) [Photorh...  79.0    3e-28  
ref|YP_050916.1|  biotin synthase [Erwinia carotovora subsp. a...  74.3    5e-28  
ref|YP_454583.1|  biotin synthase BioB [Sodalis glossinidius s...  76.6    1e-27  
ref|NP_404760.1|  biotin synthase [Yersinia pestis CO92] >ref|...  76.6    1e-27  
ref|ZP_01497421.1|  hypothetical protein YpseI_02002585 [Yersi...  76.3    2e-27 
ref|NP_797492.1|  biotin synthase [Vibrio parahaemolyticus RIM...  78.6    2e-25  
gb|EAY41068.1|  biotin synthase [Vibrio cholerae MZO-3]            77.8    7e-25 
ref|YP_001189567.1|  biotin synthase [Pseudomonas mendocina ym...  73.9    9e-25  
ref|ZP_01640775.1|  biotin synthase [Pseudomonas putida W619] ...  73.2    9e-25 
ref|ZP_01484254.1|  hypothetical protein VchoV5_02003172 [Vibr...  77.8    9e-25 
ref|NP_230757.1|  biotin synthase [Vibrio cholerae O1 biovar e...  77.8    9e-25  
gb|EDN56181.1|  biotin synthase [Vibrio sp. Ex25]                  77.0    1e-24 
ref|ZP_01260979.1|  biotin synthase [Vibrio alginolyticus 12G0...  77.0    1e-24 
ref|ZP_01473994.1|  hypothetical protein VEx2w_02003423 [Vibrio s  77.0    1e-24 
ref|ZP_01869259.1|  biotin synthase [Vibrio shilonii AK1] >gb|...  76.3    1e-24 
ref|YP_001174331.1|  biotin synthase [Pseudomonas stutzeri A15...  74.3    1e-24  
ref|ZP_00418345.1|  Biotin synthase [Azotobacter vinelandii Av...  76.3    1e-24 
ref|ZP_01293752.1|  hypothetical protein PaerP_01004394 [Pseud...  72.8    2e-24 
gb|AAT51401.1|  PA0500 [synthetic construct]                       72.8    2e-24 
ref|ZP_00967143.1|  COG0502: Biotin synthase and related enzym...  72.8    2e-24 
ref|YP_788670.1|  biotin synthase [Pseudomonas aeruginosa UCBP...  72.8    2e-24  
ref|NP_249191.1|  biotin synthase [Pseudomonas aeruginosa PAO1...  72.8    2e-24  
ref|YP_001265745.1|  biotin synthase [Pseudomonas putida F1] >...  72.0    2e-24  
ref|NP_742529.1|  biotin synthetase [Pseudomonas putida KT2440...  71.6    2e-24  
ref|ZP_01717084.1|  biotin synthase [Pseudomonas putida GB-1] ...  70.5    5e-24 
ref|YP_610533.1|  biotin synthetase [Pseudomonas entomophila L...  70.5    5e-24  
ref|NP_934120.1|  biotin synthase [Vibrio vulnificus YJ016] >d...  75.9    7e-24  
ref|NP_761747.1|  Biotin synthase [Vibrio vulnificus CMCP6] >g...  75.9    7e-24  
ref|ZP_01914987.1|  probable biotin synthase protein [Limnobac...  68.9    7e-24 
ref|YP_350904.1|  Biotin synthase [Pseudomonas fluorescens PfO...  73.6    9e-24  
ref|YP_262751.1|  biotin synthetase [Pseudomonas fluorescens P...  73.9    1e-23  
ref|ZP_01816622.1|  biotin synthase [Vibrionales bacterium SWA...  73.9    1e-23 
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ref|NP_790343.1|  biotin synthetase [Pseudomonas syringae pv. ...  72.0    2e-23  
ref|ZP_01065426.1|  biotin synthase [Vibrio sp. MED222] >gb|EA...  73.9    2e-23 
ref|YP_155713.1|  Biotin synthase [Idiomarina loihiensis L2TR]...  74.3    2e-23  
ref|YP_276822.1|  biotin synthase [Pseudomonas syringae pv. ph...  71.2    3e-23  
ref|YP_237752.1|  Biotin synthase [Pseudomonas syringae pv. sy...  71.2    3e-23  
ref|ZP_00992912.1|  biotin synthase [Vibrio splendidus 12B01] ...  72.8    3e-23 
ref|ZP_01115221.1|  biotin synthetase [Reinekea sp. MED297] >g...  69.7    3e-23 
ref|YP_588696.1|  biotin synthase [Baumannia cicadellinicola s...  68.2    4e-23  
ref|ZP_01102888.1|  biotin synthase [gamma proteobacterium KT ...  74.7    6e-23 
ref|ZP_01235385.1|  putative biotin synthase [Vibrio angustum ...  70.5    6e-23 
ref|ZP_01160449.1|  putative biotin synthase [Photobacterium s...  70.1    8e-23 
ref|ZP_00987655.1|  COG0502: Biotin synthase and related enzym...  77.8    8e-23 
ref|YP_693940.1|  biotin synthase [Alcanivorax borkumensis SK2...  70.5    1e-22  
ref|ZP_01569499.1|  biotin synthase [Burkholderia multivorans ...  76.6    2e-22 
emb|CAB56476.1|  biotin synthetase [Pseudomonas stutzeri]          73.2    2e-22 
gb|EDN42426.1|  biotin synthase [Ralstonia pickettii 12D]          68.6    3e-22 
ref|ZP_01661930.1|  Biotin synthase [Ralstonia pickettii 12J] ...  68.6    3e-22 
ref|ZP_01558074.1|  biotin synthase [Burkholderia ambifaria MC...  77.8    3e-22 
ref|ZP_01224751.1|  biotin synthetase [marine gamma proteobact...  70.9    4e-22 
ref|YP_130516.1|  putative biotin synthase [Photobacterium pro...  65.1    4e-22  
ref|YP_744320.1|  biotin synthase [Granulibacter bethesdensis ...  72.0    4e-22  
ref|YP_774873.1|  biotin synthase [Burkholderia cepacia AMMD] ...  77.8    5e-22  
ref|ZP_00943498.1|  Biotin synthase [Ralstonia solanacearum UW...  72.0    8e-22 
ref|YP_001093845.1|  biotin synthase [Shewanella loihica PV-4]...  74.7    8e-22  
ref|ZP_00980828.1|  COG0502: Biotin synthase and related enzym...  76.3    8e-22 
ref|ZP_01043921.1|  Biotin synthase [Idiomarina baltica OS145]...  68.9    1e-21 
ref|YP_927315.1|  Biotin synthase [Shewanella amazonensis SB2B...  73.6    1e-21  
ref|ZP_01222496.1|  putative biotin synthase [Photobacterium p...  65.1    1e-21 
ref|YP_370516.1|  Biotin synthase [Burkholderia sp. 383] >gb|A...  75.9    2e-21  
ref|YP_001120855.1|  biotin synthase [Burkholderia vietnamiens...  75.9    2e-21  
ref|YP_934320.1|  biotin synthase [Azoarcus sp. BH72] >emb|CAL...  69.7    2e-21  
ref|ZP_01510809.1|  biotin synthase [Burkholderia phytofirmans...  70.9    2e-21 
ref|YP_001142637.1|  biotin synthase [Aeromonas salmonicida su...  68.6    2e-21  
ref|YP_856027.1|  biotin synthase [Aeromonas hydrophila subsp....  67.8    2e-21  
ref|NP_518387.1|  PROBABLE BIOTIN SYNTHASE PROTEIN [Ralstonia ...  71.6    2e-21  
ref|NP_871456.1|  hypothetical protein WGLp453 [Wigglesworthia...  64.7    3e-21  
ref|YP_269309.1|  biotin synthase [Colwellia psychrerythraea 3...  63.5    3e-21  
ref|YP_192423.1|  Biotin synthase [Gluconobacter oxydans 621H]...  73.2    3e-21  
ref|YP_556786.1|  Biotin synthase [Burkholderia xenovorans LB4...  70.9    4e-21  
ref|YP_562665.1|  biotin synthase [Shewanella denitrificans OS...  74.3    4e-21  
ref|ZP_01921354.1|  biotin synthase [Shewanella sediminis HAW-...  73.2    4e-21 
 
BioC 
BioC6F: 5’-TNG CNG TNC ART GGT GYG G-3’ 
BioC7R: 5’-GTN GCN CCD ATN CCY TT -3’ 
 
AAAAGTATGGACTGACGCATCATCAAACCCAGCGTGATGGGCTGAATATGATGTTGATAATGCACGCCGTT
CAGCGACTGTTCGATTTCATCTGGCGGTAAAAAGCGATTAGCATGCGGACGCTCGTCCACCGCCTGCCACG
CCTGATGCAGTTCGGGTAACGATCCCTGCACCAGCGTGGTAAACGCGACCACGCCTTTGGGGCGCACCACC
CGATACAGCTCGCGGAGTGCCGCGGATAAATTACCGCACCACTGCTCCGCCACACAATTGTACAGCTTGCT
TCCTTGCTGGCCTCACTCCCCAACGATAACTCCCAAAAATGCCCCGCCGATTAACTAACCACTTCCCTAGC
AAATACCCCCCCCAATTTGCCCCCAGGTGCCCAAATACCTCTCTTTCACAGCGACGACCTGCTCTGACTCC
TTATCATCTCCTCCTTCGTCTACGATGCAGCCGCGACTAACCCCCGCCCGTTCAACCTGCCTTG 
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                                                                  Score     E 
Sequences producing significant alignments:                       (Bits)  Value 
 
ref|NP_415298.1|  predicted methltransferase, enzyme of biotin...   162    8e-39  
gb|AAA23517.1|  bioC                                                159    4e-38 
ref|ZP_00703085.1|  COG0500: SAM-dependent methyltransferases ...   159    5e-38 
ref|YP_309740.1|  biotin biosynthesis protein [Shigella sonnei...   159    5e-38  
gb|AAG60581.1|AF250776_5  biotin biosynthesis protein BioC [uncul   159    7e-38 
ref|ZP_00721167.1|  COG0500: SAM-dependent methyltransferases ...   157    2e-37 
ref|NP_286540.1|  biotin biosynthesis; reaction prior to pimel...   156    5e-37  
ref|YP_402500.1|  biotin biosynthesis protein [Shigella dysent...   155    6e-37  
ref|YP_539792.1|  biotin synthesis protein BioC [Escherichia c...   154    1e-36  
ref|ZP_00709066.1|  COG0500: SAM-dependent methyltransferases ...   154    2e-36 
ref|NP_752787.1|  Biotin synthesis protein bioC [Escherichia c...   152    5e-36  
ref|NP_836433.1|  biotin biosynthesis protein BioC [Shigella f...   145    6e-34  
ref|YP_151177.1|  biotin synthesis protein BioC [Salmonella en...   106    5e-22  
ref|NP_455338.1|  biotin synthesis protein BioC [Salmonella en...   106    5e-22  
ref|YP_215781.1|  biotin biosynthesis; reaction prior to pimel...   105    1e-21  
ref|NP_459774.1|  biotin biosynthetic protein [Salmonella typh...   105    1e-21  
ref|YP_001176000.1|  biotin biosynthesis protein BioC [Enterob...   102    1e-20  
sp|O06898|BIOC_ESCVU  Biotin synthesis protein bioC >gb|AAB529...  97.8    2e-19 
gb|ABR76238.1|  biotin biosynthesis; reaction prior to pimeloy...  91.7    1e-17 
gb|AAG53591.1|AF248314_6  biotin biosynthesis BioC-like protei...  89.7    5e-17 
gb|AAG60557.1|AF250768_2  biotin biosynthesis protein BioC [uncul  82.4    8e-15 
ref|NP_404762.1|  biotin synthesis protein BioC [Yersinia pest...  82.4    8e-15  
ref|YP_069719.1|  biotin synthesis protein BioC [Yersinia pseu...  82.0    1e-14  
ref|ZP_01497419.1|  hypothetical protein YpseI_02002583 [Yersi...  82.0    1e-14 
ref|ZP_00824682.1|  COG0500: SAM-dependent methyltransferases ...  80.5    3e-14 
ref|YP_050914.1|  biotin synthesis protein [Erwinia carotovora...  79.7    5e-14  
ref|NP_928782.1|  biotin synthesis protein [Photorhabdus lumin...  79.7    5e-14  
ref|ZP_00832234.1|  COG0500: SAM-dependent methyltransferases ...  79.0    9e-14 
ref|ZP_00821418.1|  COG0500: SAM-dependent methyltransferases ...  77.4    3e-13 
ref|YP_001007093.1|  biotin synthesis protein BioC [Yersinia e...  76.3    6e-13  
ref|ZP_01535734.1|  biotin biosynthesis protein BioC [Serratia...  75.9    8e-13 
ref|YP_454585.1|  biotin synthesis protein BioC [Sodalis gloss...  75.9    8e-13  
ref|NP_761745.1|  Biotin synthesis protein [Vibrio vulnificus ...  75.1    1e-12  
sp|P36571|BIOC_SERMA  Biotin synthesis protein bioC >dbj|BAA04...  75.1    1e-12 
ref|YP_130514.1|  putative biotin synthesis protein BioC [Phot...  73.9    3e-12  
ref|ZP_00829475.1|  COG0500: SAM-dependent methyltransferases ...  73.9    3e-12 
ref|ZP_01222498.1|  putative biotin synthesis protein BioC [Ph...  73.6    4e-12 
ref|ZP_01235387.1|  putative biotin synthesis protein BioC [Vi...  71.2    2e-11 
ref|ZP_00418348.1|  probable biotin synthesis protein BioC [Az...  71.2    2e-11 
ref|ZP_01160447.1|  putative biotin synthesis protein BioC [Ph...  70.9    3e-11 
ref|YP_276819.1|  biotin biosynthesis protein BioC [Pseudomona...  70.1    4e-11  
ref|ZP_01307867.1|  biotin synthesis protein BioC [Oceanobacte...  69.3    7e-11 
ref|YP_588698.1|  biotin biosynthesis protein BioC [Baumannia ...  68.9    1e-10  
ref|YP_001189564.1|  biotin biosynthesis protein BioC [Pseudom...  67.0    4e-10  
ref|YP_237749.1|  biotin synthesis protein BioC [Pseudomonas s...  67.0    4e-10  
ref|YP_610530.1|  biotin biosynthesis protein BioC [Pseudomona...  66.2    6e-10  
gb|EAY41077.1|  biotin synthesis protein BioC [Vibrio cholerae MZ  65.1    1e-09 
ref|NP_790346.1|  biotin synthesis protein BioC [Pseudomonas s...  64.7    2e-09  
gb|EDM52799.1|  biotin synthesis protein BioC [Vibrio cholerae MZ  64.3    2e-09 
gb|EDN14557.1|  biotin synthesis protein BioC [Vibrio cholerae AM  63.9    3e-09 
gb|EDL74527.1|  biotin synthesis protein BioC [Vibrio cholerae 62  63.9    3e-09 
  
211 
ref|YP_001142635.1|  biotin synthesis protein BioC [Aeromonas ...  63.9    3e-09  
ref|ZP_01678573.1|  biotin synthesis protein BioC [Vibrio chol...  63.9    3e-09 
ref|ZP_01597377.1|  Methyltransferase type 11 [Marinomonas sp....  63.9    3e-09 
ref|NP_230759.1|  biotin synthesis protein BioC [Vibrio choler...  63.9    3e-09  
ref|NP_871458.1|  hypothetical protein WGLp455 [Wigglesworthia...  63.5    4e-09  
ref|ZP_01484411.1|  hypothetical protein VchoV5_02003001 [Vibr...  63.5    4e-09 
ref|ZP_01717081.1|  biotin biosynthesis protein BioC [Pseudomo...  62.8    7e-09 
ref|NP_742532.1|  biotin biosynthesis protein BioC [Pseudomona...  62.8    7e-09  
ref|ZP_01898733.1|  Biotin synthesis protein [Moritella sp. PE...  62.4    9e-09 
gb|EAY34736.1|  biotin synthesis protein BioC [Vibrio cholerae 15  62.4    9e-09 
ref|ZP_01293749.1|  hypothetical protein PaerP_01004391 [Pseud...  62.4    9e-09 
gb|AAT51029.1|  PA0503 [synthetic construct]                       62.4    9e-09 
ref|YP_001265748.1|  biotin biosynthesis protein BioC [Pseudom...  62.4    9e-09  
ref|ZP_01473996.1|  hypothetical protein VEx2w_02003425 [Vibri...  62.4    9e-09 
ref|YP_788673.1|  putative biotin synthesis protein BioC [Pseu...  62.4    9e-09  
ref|NP_249194.1|  probable biotin synthesis protein BioC [Pseu...  62.4    9e-09  
ref|YP_262748.1|  biotin synthesis protein BioC [Pseudomonas f...  62.0    1e-08  
ref|ZP_01640772.1|  Biotin biosynthesis protein BioC [Pseudomo...  61.6    2e-08 
ref|ZP_01816624.1|  biotin synthesis protein BioC [Vibrionales...  61.2    2e-08 
ref|YP_856029.1|  biotin biosynthesis protein BioC [Aeromonas ...  61.2    2e-08  
ref|YP_155711.1|  Biotin synthesis protein [Idiomarina loihien...  60.8    3e-08  
ref|ZP_00992914.1|  biotin synthesis protein BioC [Vibrio sple...  60.8    3e-08 
ref|YP_113598.1|  biotin synthesis protein BioC [Methylococcus...  60.5    3e-08  
ref|NP_797494.1|  biotin synthesis protein BioC [Vibrio paraha...  60.1    4e-08  
ref|ZP_01065424.1|  biotin synthesis protein BioC [Vibrio sp. ...  60.1    4e-08 
ref|YP_001174328.1|  biotin synthesis protein BioC [Pseudomona...  59.7    6e-08  
ref|YP_350901.1|  Biotin biosynthesis protein BioC [Pseudomona...  59.7    6e-08  
ref|YP_206704.1|  biotin synthesis protein BioC [Vibrio fische...  58.9    1e-07  
ref|ZP_01260977.1|  biotin synthesis protein BioC [Vibrio algi...  58.5    1e-07 
ref|ZP_01869261.1|  biotin synthesis protein BioC [Vibrio shil...  57.8    2e-07 
ref|YP_392245.1|  Biotin biosynthesis protein BioC [Thiomicros...  57.4    3e-07  
ref|YP_943293.1|  biotin biosynthesis protein BioC [Psychromon...  56.6    5e-07  
ref|ZP_01133857.1|  desthiobiotin biosynthesis; reaction prior...  56.6    5e-07 
ref|ZP_01613054.1|  desthiobiotin biosynthesis; reaction prior...  55.5    1e-06 
ref|ZP_01167075.1|  biotin synthesis protein BioC [Oceanospiri...  54.7    2e-06 
ref|YP_344088.1|  Biotin biosynthesis protein BioC [Nitrosococ...  53.9    3e-06  
ref|YP_269311.1|  biotin biosynthesis protein bioC [Colwellia ...  53.9    3e-06  
ref|ZP_01127180.1|  biotin synthesis protein [Nitrococcus mobi...  53.9    3e-06 
ref|NP_777890.1|  biotin synthesis protein BioC [Buchnera aphi...  53.1    5e-06  
ref|ZP_01737942.1|  biotin synthesis protein [Marinobacter sp....  52.8    7e-06 
ref|YP_903510.1|  biotin biosynthesis protein BioC [Candidatus...  52.8    7e-06  
ref|YP_286099.1|  Biotin biosynthesis protein BioC [Dechloromo...  52.0    1e-05  
ref|YP_314080.1|  Biotin biosynthesis protein BioC [Thiobacill...  51.6    2e-05  
ref|YP_960016.1|  biotin biosynthesis protein BioC [Marinobact...  51.2    2e-05  
ref|YP_001219097.1|  biotin biosynthesis protein BioC [Candida...  50.8    3e-05  
ref|YP_743263.1|  biotin biosynthesis protein BioC [Alkalilimn...  50.8    3e-05  
ref|ZP_01216783.1|  biotin synthesis protein BioC [Psychromona...  50.8    3e-05 
ref|ZP_01895249.1|  biotin synthesis protein BioC [Marinobacte...  49.7    6e-05 
ref|YP_748322.1|  biotin biosynthesis protein BioC [Nitrosomon...  49.7    6e-05  
 
 
 
BioD 
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BioD1F: 5’-GAY ACN GAR GTN GGN AA-3’ 
BioD3R: 5’-GCR TGR TTD ATR CAN CC-3’ 
 
TTGTTGTATACGACTCCTATAGGGCGAACTGGGCCCTCTAGATGCAAGCTCGAGCGGCCGCCAGTGTGATG
GATATCTGCAGAATTCGCCCTTGATACAGAAGTGGGGAAAACCGTCGCCAGCAGCGCCTTGCTGCAGGCCG
CCAACCGGGCGGGCTACCGCAGCGCCGGCTATAAGCCGGTGGCCTCCGGCAGCGAGATGACCGCCGAGGGG
CTGCGCAACGGCGACGCGCTGGCGCTGCAGGCCAACAGCGGTGTGGCGCTGGATTACGACGAAGTGAACCC
TTACGTATTTGCCGAACCGACCTCGCCGCATATCGTCAGCGCCGATGAAGGCCGGCCGATCGACGCGGAGC
GGCTGTCCAACGGCCTGCGCCGGCTGGAGCAGCGCGCCGACTGGGTGCTGGTCGAGGGGGGCGCGGCGGGG
TGGTTTACCCCGTTGTCGGCGGAGTACACCCTTCGCCGACTGGGTGCGGCAAGAGCAACTGCCGGTGATCC
TGGTGGTGGGGCATCAAGCTGGGCTGCATCAACCACGCAAGGGCGAATTCCAGCACACTGGCGGCCGGTTA
CTATGGAATCCGAGCTCGGGTACCAGCTTGGCGTAATCATGGTCAT 
                                                                  Score     E 
Sequences producing significant alignments:                       (Bits)  Value 
 
sp|P36572|BIOD_SERMA  Dethiobiotin synthetase (Dethiobiotin sy...   223    8e-64 
ref|ZP_01535735.1|  dethiobiotin synthase [Serratia proteamacu...   199    2e-56 
gb|AAA23518.1|  dethiobiotin synthetase                             180    3e-50 
gb|AAG60582.1|AF250776_6  dethiobiotin synthetase BioD [unculture   180    3e-50 
gb|ABR76239.1|  dithiobiotin synthetase [Klebsiella pneumoniae...   181    8e-50 
ref|ZP_01702227.1|  dethiobiotin synthase [Escherichia coli B]...   177    1e-49 
ref|NP_415299.1|  dethiobiotin synthetase [Escherichia coli K1...   177    1e-49  
ref|ZP_00705000.1|  COG0132: Dethiobiotin synthetase [Escheric...   177    1e-49 
pdb|1DBS|   Chain  , Dethiobiotin Synthetase (E.C.6.3.3.3) >pd...   177    1e-49  
pdb|1DTS|   Chain  , Dethiobiotin Synthase (E.C.6.3.3.3)            177    1e-49  
ref|ZP_00734066.1|  COG0132: Dethiobiotin synthetase [Escherichia   177    1e-49 
ref|YP_539793.1|  dethiobiotin synthetase [Escherichia coli UT...   177    2e-49  
ref|NP_286541.1|  dithiobiotin synthetase [Escherichia coli O1...   177    2e-49  
ref|YP_668710.1|  dethiobiotin synthetase [Escherichia coli 53...   176    3e-49  
ref|YP_402499.1|  dethiobiotin synthetase [Shigella dysenteria...   176    3e-49  
ref|YP_309741.1|  dethiobiotin synthetase [Shigella sonnei Ss0...   176    5e-49  
ref|ZP_00698067.1|  COG0132: Dethiobiotin synthetase [Shigella bo   175    8e-49 
ref|ZP_00721168.1|  COG0132: Dethiobiotin synthetase [Escherichia   174    1e-48 
ref|YP_407172.1|  dethiobiotin synthetase [Shigella boydii Sb2...   174    1e-48  
ref|ZP_00709067.1|  COG0132: Dethiobiotin synthetase [Escherichia   176    1e-48 
ref|NP_836434.1|  dithiobiotin synthetase [Shigella flexneri 2...   172    4e-48  
sp|O06899|BIOD_ESCVU  Dethiobiotin synthetase (Dethiobiotin sy...   172    1e-47 
ref|NP_459775.1|  dithiobiotin synthetase [Salmonella typhimur...   172    1e-47  
gb|AAG53592.1|AF248314_7  dethiobiotin synthase BioD [uncultured    174    2e-47 
ref|YP_001176001.1|  dethiobiotin synthase [Enterobacter sp. 6...   172    2e-47  
ref|YP_215782.1|  dithiobiotin synthetase [Salmonella enterica...   172    3e-47  
ref|YP_151176.1|  dithiobiotin synthetase [Salmonella enterica...   171    4e-47  
ref|NP_455339.1|  dithiobiotin synthetase [Salmonella enterica...   171    4e-47  
ref|YP_050913.1|  dithiobiotin synthetase [Erwinia carotovora ...   168    2e-46  
ref|NP_752788.1|  dithiobiotin synthetase [Escherichia coli CF...   166    3e-46  
ref|ZP_00824681.1|  COG0132: Dethiobiotin synthetase [Yersinia...   165    8e-46 
ref|ZP_01497418.1|  hypothetical protein YpseI_02002582 [Yersi...   163    4e-45 
ref|NP_670328.1|  dithiobiotin synthetase [Yersinia pestis KIM...   162    6e-45  
ref|NP_404763.1|  dithiobiotin synthetase [Yersinia pestis CO9...   162    6e-45  
ref|ZP_00832235.1|  COG0132: Dethiobiotin synthetase [Yersinia...   164    8e-45 
ref|ZP_00821417.1|  COG0132: Dethiobiotin synthetase [Yersinia...   160    2e-44 
ref|NP_928783.1|  dithiobiotin synthetase [Photorhabdus lumine...   159    2e-43  
ref|ZP_00829474.1|  COG0132: Dethiobiotin synthetase [Yersinia...   155    5e-43 
ref|YP_454586.1|  dethiobiotin synthase [Sodalis glossinidius ...   155    1e-37  
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ref|YP_588699.1|  dethiobiotin synthase [Baumannia cicadellini...   144    1e-37  
ref|YP_001007092.1|  dethiobiotin synthetase [Yersinia enteroc...   137    2e-37  
ref|ZP_01235388.1|  dithiobiotin synthetase [Vibrio angustum S...   132    3e-33 
ref|ZP_01160446.1|  putative dethiobiotin synthetase [Photobac...   131    3e-33 
ref|YP_130513.1|  dithiobiotin synthetase [Photobacterium prof...   121    1e-29  
ref|YP_206703.1|  dithiobiotin synthetase [Vibrio fischeri ES1...   118    3e-29  
ref|ZP_01222499.1|  dithiobiotin synthetase [Photobacterium pr...   117    7e-29 
ref|ZP_01869262.1|  dithiobiotin synthetase [Vibrio shilonii A...   113    4e-28 
ref|NP_761744.1|  dithiobiotin synthetase [Vibrio vulnificus C...   111    2e-27  
gb|EDN56178.1|  dethiobiotin synthase [Vibrio sp. Ex25]             110    5e-27 
ref|ZP_01473997.1|  hypothetical protein VEx2w_02003426 [Vibrio s   110    5e-27 
ref|NP_240114.1|  dethiobiotin synthetase [Buchnera aphidicola...   114    5e-27  
ref|NP_797495.1|  dithiobiotin synthetase [Vibrio parahaemolyt...   108    8e-27  
sp|Q87QN3|BIOD_VIBPA  Dethiobiotin synthetase (Dethiobiotin sy...   108    8e-27 
ref|ZP_01260976.1|  dithiobiotin synthetase [Vibrio alginolyti...   107    2e-26 
ref|NP_230760.1|  dithiobiotin synthetase [Vibrio cholerae O1 ...   106    5e-26  
ref|ZP_01478768.1|  hypothetical protein VchoM_02002132 [Vibri...   106    5e-26 
gb|EAY37851.1|  dethiobiotin synthase [Vibrio cholerae MAK 757]     106    5e-26 
gb|EDN14558.1|  dethiobiotin synthetase [Vibrio cholerae AM-19226   106    6e-26 
gb|EDL74522.1|  dethiobiotin synthetase [Vibrio cholerae 623-39]    106    6e-26 
ref|ZP_00820371.1|  COG0132: Dethiobiotin synthetase [Yersinia...   100    6e-26 
gb|EAY34705.1|  dethiobiotin synthase [Vibrio cholerae 1587]        106    6e-26 
ref|NP_669423.1|  hypothetical protein y2111 [Yersinia pestis ...   100    1e-25  
gb|AAL14974.1|AF418982_11  putative dethiobiotin synthase [Yersin   100    1e-25 
ref|NP_405805.1|  putative dethiobiotin synthetase [Yersinia p...   100    1e-25  
ref|ZP_01065423.1|  dithiobiotin synthetase [Vibrio sp. MED222...   106    1e-25 
ref|YP_001142634.1|  dethiobiotin synthetase [Aeromonas salmon...   104    1e-25  
ref|YP_856030.1|  dethiobiotin synthase [Aeromonas hydrophila ...   104    2e-25  
ref|ZP_01816625.1|  dithiobiotin synthetase [Vibrionales bacte...   105    3e-25 
ref|YP_365467.1|  dithiobiotin synthetase [Xanthomonas campest...   101    4e-25  
ref|YP_662124.1|  dethiobiotin synthase [Pseudoalteromonas atl...   110    5e-25  
ref|YP_001174327.1|  dethiobiotin synthase [Pseudomonas stutze...   111    6e-25  
ref|ZP_00992915.1|  dithiobiotin synthetase [Vibrio splendidus...   103    7e-25 
ref|YP_001008378.1|  putative dethiobiotin synthetase [Yersini...  97.4    7e-25  
ref|ZP_00827097.1|  COG0132: Dethiobiotin synthetase [Yersinia...  97.4    7e-25 
ref|YP_199406.1|  dithiobiotin synthetase [Xanthomonas oryzae ...  99.4    1e-24  
ref|YP_449726.1|  dethiobiotin synthetase [Xanthomonas oryzae ...  99.0    2e-24  
ref|ZP_01167074.1|  dethiobiotin synthase [Oceanospirillum sp....   109    2e-24 
ref|NP_790347.1|  dithiobiotin synthetase [Pseudomonas syringa...   110    2e-24  
ref|ZP_00834859.1|  COG0132: Dethiobiotin synthetase [Yersinia...  95.5    2e-24 
ref|YP_943292.1|  dethiobiotin synthase [Psychromonas ingraham...   105    3e-24  
ref|YP_788674.1|  dethiobiotin synthase [Pseudomonas aeruginos...   109    3e-24  
ref|NP_837279.1|  dithiobiotin synthetase [Shigella flexneri 2...  97.4    4e-24  
ref|NP_460449.1|  dithiobiotin synthetase [Salmonella typhimur...  97.4    5e-24  
ref|YP_150621.1|  dithiobiotin synthetase [Salmonella enterica...  97.1    7e-24  
ref|ZP_01293748.1|  hypothetical protein PaerP_01004390 [Pseud...   108    7e-24 
ref|ZP_01216784.1|  dethiobiotin synthetase [Psychromonas sp. ...   103    7e-24 
ref|ZP_00828727.1|  COG0132: Dethiobiotin synthetase [Yersinia...  94.4    9e-24 
ref|YP_403190.1|  hypothetical protein SDY_1563 [Shigella dyse...  95.9    1e-23  
ref|ZP_00717407.1|  COG0132: Dethiobiotin synthetase [Escherichia  95.9    1e-23 
ref|NP_288028.1|  dithiobiotin synthetase [Escherichia coli O1...  95.9    1e-23  
ref|NP_455990.1|  dithiobiotin synthetase [Salmonella enterica...  96.3    1e-23  
ref|NP_310326.2|  dithiobiotin synthetase [Escherichia coli O1...  95.9    1e-23  
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ref|NP_777889.1|  dethiobiotin synthetase [Buchnera aphidicola...   100    2e-23  
ref|YP_244707.1|  dithiobiotin synthetase [Xanthomonas campest...  95.9    2e-23  
ref|YP_310505.1|  hypothetical protein SSON_1571 [Shigella son...  95.1    2e-23  
ref|NP_753879.1|  dithiobiotin synthetase [Escherichia coli CF...  95.1    2e-23  
ref|YP_669445.1|  putative dethiobiotin synthetase [Escherichi...  95.1    2e-23  
gb|AAT50325.1|  PA0504 [synthetic construct]                        106    2e-23 
ref|NP_249195.1|  dithiobiotin synthetase [Pseudomonas aerugin...   106    2e-23  
ref|YP_216494.1|  dithiobiotin synthetase [Salmonella enterica...  95.1    3e-23  
 
 
BioF 
BioF10F: 5’-ATG GTN GAY GAY GCN CAY GG -3’ 
BioF11R: 5’-GCY TCN GCN GGN GGC AT-3’ 
 
ACGATGCAGCTTGCTCCGGCTCGGACCCTAGTAACGGCCGCCAGTGTGCTGGAATTCGCCCTTATGGTTGA
AGACGCGCATGGCATCGGCGTGCGCGGCGAACAAGGCCGCGGCAGCTGCTGGCAGCAGGGCGTGCGCCCTG
AACTGCTGGTGGCGACCTTCGGCAAGGCGTTCGGCGTCAGCGGCGCGGCGGTGCTGTGCGATGAGGCGACC
GCCGAGTATCTGCTGCAGTTCGCCCGCCATCTGATCTACAGCACCGCGATGCCCCCAGCACAGGCAAGGGC
GAATTCTGCAGATATCCATCACACTGGCGGCCGCTCGAGCAGGCATCTAGAGGGCCCAATTCGCCCTATAG
TGAGTCGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAAC
TTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCT
TCCCAACAGTTGCGCAGCCTGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTG
GTGGTT 
                                                                  Score     E 
Sequences producing significant alignments:                       (Bits)  Value 
 
sp|P36570|BIOF_SERMA  8-amino-7-oxononanoate synthase (AONS) (...   150    4e-35 
gb|AAG60556.1|AF250768_1  KAPA-synthetase [uncultured bacterium p   148    2e-34 
ref|ZP_01535733.1|  8-amino-7-oxononanoate synthase [Serratia ...   147    3e-34 
emb|CAA71575.1|  fused-ccdB [Cloning vector pZeRO-2T]               136    8e-31 
gb|AAS78488.1|  LacZ alpha & ccdB lethal fusion protein [Cloni...   136    8e-31 
ref|NP_928781.1|  8-amino-7-oxononanoate synthase [Photorhabdu...   135    1e-30  
ref|YP_215780.1|  8-amino-7-oxononanoate synthase [Salmonella ...   134    4e-30  
ref|YP_151178.1|  8-amino-7-oxononanoate synthase [Salmonella ...   134    4e-30  
ref|NP_455337.1|  8-amino-7-oxononanoate synthase [Salmonella ...   134    4e-30  
ref|YP_069718.1|  8-amino-7-oxononanoate synthase [Yersinia ps...   133    5e-30  
ref|ZP_01497420.1|  hypothetical protein YpseI_02002584 [Yersi...   133    5e-30 
ref|ZP_00829476.1|  COG0156: 7-keto-8-aminopelargonate synthet...   133    7e-30 
gb|ABR76237.1|  8-amino-7-oxononanoate synthase [Klebsiella pn...   132    9e-30 
ref|ZP_00832233.1|  COG0156: 7-keto-8-aminopelargonate synthet...   132    1e-29 
emb|CAA67127.1|  ccdB [synthetic construct]                         132    1e-29 
ref|NP_404761.1|  8-amino-7-oxononanoate synthase [Yersinia pe...   132    1e-29  
ref|NP_459773.1|  8-amino-7-oxononanoate synthase [Salmonella ...   130    3e-29  
gb|AAA53120.1|  beta-galactosidase-complementation protein          116    7e-29 
emb|CAA75108.1|  beta-galactosidase [Phagemid cloning vector pTZ1   116    7e-29 
ref|YP_050915.1|  8-amino-7-oxononanoate synthase [Erwinia car...   129    7e-29  
gb|AAR19394.1|  modified lacZ' [Cloning vector pTA6]                114    3e-28 
gb|AAF61634.1|  lacZ [Cloning vector pTG8]                          114    3e-28 
gb|ABI35978.1|  LacZ alpha peptide [Cloning vector pYESW29']        114    3e-28 
gb|AAP44986.1|  LacZalpha [Shuttle vector pNG168]                   114    3e-28 
gb|AAG34547.1|  beta-galactosidase [Cloning vector pUG7]            114    3e-28 
gb|AAG34526.1|  beta-galactosidase [Cloning vector pUG26]           114    3e-28 
gb|AAA53118.1|  beta-galactosidase-complementation protein          114    3e-28 
ref|YP_539791.1|  8-amino-7-oxononanoate synthase [Escherichia...   127    4e-28  
gb|AAG60580.1|AF250776_4  KAPA synthetase BioF [uncultured bacter   127    4e-28 
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ref|YP_402501.1|  8-amino-7-oxononanoate synthase [Shigella dy...   127    4e-28  
ref|YP_309739.1|  8-amino-7-oxononanoate synthase [Shigella so...   127    4e-28  
ref|NP_706654.1|  8-amino-7-oxononanoate synthase [Shigella fl...   127    4e-28  
ref|NP_752786.1|  8-amino-7-oxononanoate synthase [Escherichia...   127    4e-28  
ref|NP_415297.1|  8-amino-7-oxononanoate synthase [Escherichia...   127    4e-28  
pdb|1DJ9|A  Chain A, Crystal Structure Of 8-Amino-7-Oxonanoate...   127    4e-28  
ref|ZP_00721166.1|  COG0156: 7-keto-8-aminopelargonate synthet...   127    4e-28 
ref|ZP_00734064.1|  COG0156: 7-keto-8-aminopelargonate synthet...   127    4e-28 
ref|ZP_00715006.1|  COG0156: 7-keto-8-aminopelargonate synthet...   127    4e-28 
ref|ZP_00703084.1|  COG0156: 7-keto-8-aminopelargonate synthet...   127    4e-28 
ref|ZP_00709065.1|  COG0156: 7-keto-8-aminopelargonate synthet...   127    4e-28 
ref|ZP_00704998.1|  COG0156: 7-keto-8-aminopelargonate synthet...   127    4e-28 
ref|ZP_00821419.1|  COG0156: 7-keto-8-aminopelargonate synthet...   127    5e-28 
gb|AAS77680.1|  LacZ-alpha [Shuttle vector pELS100] >gb|AAS776...   126    6e-28 
gb|AAS77687.2|  LacZ-alpha [Shuttle vector pLPV111]                 126    6e-28 
gb|AAD31805.1|AF128862_1  LacZ [Cloning vector pHIND2.2]            126    6e-28 
emb|CAB76939.1|  alpha-peptide [Cloning vector pPW78]               126    6e-28 
ref|NP_286539.1|  8-amino-7-oxononanoate synthase [Escherichia...   126    8e-28  
ref|NP_308881.1|  8-amino-7-oxononanoate synthase [Escherichia...   126    8e-28  
ref|ZP_00698065.1|  COG0156: 7-keto-8-aminopelargonate synthet...   126    8e-28 
ref|ZP_00824683.1|  COG0156: 7-keto-8-aminopelargonate synthet...   125    1e-27 
gb|AAA56741.1|  lacZ alpha peptide                                  114    5e-27 
gb|AAA56738.1|  lacZ alpha peptide                                  114    5e-27 
ref|YP_001007094.1|  8-amino-7-oxononanoate synthase [Yersinia...   122    1e-26  
gb|AAF86670.1|AF178449_1  beta-galactosidase alpha peptide [In...   122    2e-26 
gb|AAF86672.1|AF178450_1  beta-galactosidase alpha peptide [In...   122    2e-26 
gb|AAG53590.1|AF248314_5  7-KAPA synthetase [uncultured bacterium   119    1e-25 
sp|Q47829|BIOF_ENTAG  8-amino-7-oxononanoate synthase (AONS) (...   119    1e-25 
ref|YP_001175999.1|  8-amino-7-oxononanoate synthase [Enteroba...   117    4e-25  
gb|EDM59207.1|  8-amino-7-oxononanoate synthase [Vibrio paraha...   115    1e-24 
ref|ZP_01222497.1|  8-amino-7-oxononanoate synthase [Photobact...   115    1e-24 
ref|YP_130515.1|  8-amino-7-oxononanoate synthase [Photobacter...   115    1e-24  
ref|NP_797493.1|  8-amino-7-oxononanoate synthase [Vibrio para...   115    1e-24  
gb|AAK73367.1|AF327711_1  LacZ [Cloning vector pDN19] >emb|CAA...   114    2e-24 
ref|ZP_01160448.1|  8-amino-7-oxononanoate synthase [Photobact...   114    2e-24 
gb|EDL74524.1|  8-amino-7-oxononanoate synthase [Vibrio cholerae    114    3e-24 
ref|ZP_01235386.1|  8-amino-7-oxononanoate synthase [Vibrio an...   114    4e-24 
gb|EDN14556.1|  8-amino-7-oxononanoate synthase [Vibrio cholerae    113    5e-24 
gb|EDM52798.1|  8-amino-7-oxononanoate synthase [Vibrio cholerae    113    5e-24 
gb|EAY41082.1|  8-amino-7-oxononanoate synthase [Vibrio cholerae    113    5e-24 
gb|AAA75561.1|  LacOPZ-alpha peptide from pUC9; putative [unid...   113    5e-24 
ref|NP_230758.1|  8-amino-7-oxononanoate synthase [Vibrio chol...   113    5e-24  
emb|CAC14450.1|  alfa-peptide [Cloning vector pBPSCat2] >emb|C...   113    5e-24 
ref|ZP_01478821.1|  hypothetical protein VchoM_02001980 [Vibri...   113    5e-24 
gb|EAY34702.1|  8-amino-7-oxononanoate synthase [Vibrio cholerae    113    7e-24 
gb|AAC43252.1|  lacZ alpha peptide [Cloning vector Pk184]           113    7e-24 
gb|AAC48874.1|  lacZ-alpha [Cloning vector pAL-Z] >gb|AAC53715...   113    7e-24 
ref|YP_454584.1|  8-amino-7-oxononanoate synthase [Sodalis glo...   113    7e-24  
 
 
Figure C.4: Sequence Alignment Data for Biotin from Hon6 
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APPENDIX D 
Supplementary data of Chapter V 
Topo XL vector  
 
 
pETBlue-2 vector 
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pCC1FOS vector 
 
 
 
 
Figure D.1: Vector Map 
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Reaction condition of Synthesis of linker 
PNK 10X buffer     1μl 
2mmol ATP             1μl 
Oligo                        2μl 
PNK                      0.1μl 
Deionized water   5.9μl 
Total 10μl  incubation at 37C for 1 hr then mix all oligo  incubation at 95C for 5 min 
cooling it down to R.T. 
 
Ligation condition with vector and linker 
Vector                         2μl 
10mmol ATP             1μl 
Oligo linker                5μl 
T4 DNA ligase           1μl 
10X buffer                 1μl 
Total 10μl -> incubation at 16C for overnight. 
 
Expected PCR product size 
VioE-R - VioE-F 550bp 
VioD-R - VioD-F 1060bp 
VioC-R - VioC-F 1230bp 
VioB-R - VioB-F 2920bp 
VioA-R - VioA-F 1190bp 
VioA-R – 3275R 2130bp 
 3269-F - VioE-F 1700bp 
VioE-R - VioD-F 1650bp 
VioD-R - VioC-F 2350bp 
VioC-R - VioB-F 4230bp 
VioB-RX – VioA-F 1865bp 
VioB-RX – 3275R  2840bp 
VioB-R - VioA-F   4270bp 
VioB-R – 3275R  5230bp 
3269-F - VioC-F  4400bp 
3369-F - VioBCF 4550bp 
VioB-R – 3275RLR  4900bp (Seq: VioBCR – 3275RLS) 
3369LFR - VioBCF 4450bp (Seq: VioCF – 3269LFS) 
3275RLR-3269LFR 9100bp (Seq: 3269LFS-3275RLS) 
3275RLR-3269RLF 8920bp (Seq: 3269LFS-3275RLS) 
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PCR conditions: 
VioA: 1 μl of C. Violacein genomic DNA or PCR product, 1 μl of VioA F primer, 1 μl of VioA 
R primer, 0.5 μl of Taq polymerase, 5 μl of 10× thermal solution, 0.5 μl of dNTP, 2.5 μl of 
glycerol, and 38.5 μl of deionized water. 
 
 VioC: 1 μl of C. Violacein genomic DNA or PCR product, 1 μl of VioC F primer, 1 μl of VioC 
R primer, 0.5 μl of Taq polymerase, 5 μl of 10× thermal solution, 0.5 μl of dNTP, 2.5 μl of 
DMSO and 38.5 μl of deionized water. 
 
VioD: 1 μl of C. Violacein genomic DNA or PCR product, 1 μl of VioD F primer, 1 μl of VioD 
R primer, 0.5 μl of Taq polymerase, 5 μl of 10× thermal solution, 0.5 μl of dNTP, 2.5 μl of 
DMSO and 38.5 μl of deionized water. 
 
VioE: 1 μl of C. Violacein genomic DNA or PCR product, 1 μl of VioE F primer, 1 μl of VioE R 
primer, 0.5 μl of Taq polymerase, 5 μl of 10× thermal solution, 0.5 μl of dNTP, 2.5 μl of DMSO 
and 38.5 μl of deionized water. 
 
TPP+P+Riboswitch: 1 μl of DH10B plasmid DNA, 1 μl of TPP+Riboswitch F primer, 1 μl of 
TPP+Riboswitch R primer, 0.5 μl of Taq polymerase, 5 μl of 10× thermal solution, 0.5 μl of 
dNTP, 2.5 μl of glycerol, and 38.5 μl of deionized water. 
 
BLG: 1 μl of pETBlue plasmid DNA, 0.4μl of BLGThiCRibo(f) SpeI F primer, 0.4 μl of 
BLGThiCRibo(R) XhoI R primer, 0.4 μl of phusion polymerase, 4 μl of 5× Buffer, 0.5 μl of 
dNTP, and 13.3 μl of deionized water. 
                
 
Figure D.2: Reaction conditions and PCR conditions 
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Riboswitch sequence  
sequence from Cheah et al. (165) 
TAATTTCTTGTCGGAGTGCCTTAACTGGCTGAGACCGTTTATTCGGGATCCGCGGAACCTGATCAGGCTA 
ATACCTGCGAAGGGAACAAGAGTTA 
 
TPP riboswitch aptamer sequence (Gene/Homolog:ThiC, ID:Eco2) 
E.coli str. K12 substr.DH10B (CP000948) 
   thiamin phosphate synthase (thiamin phosphate pyrophospho... 
   thiamin (pyrimidine moiety) biosynthesis protein 
4291923-4293818 
Sequence was found comparison of TPP riboswitch sequence from Cheah et al (165)  
  4291921 catcacgctt cctccttacg caggtagatt tctccgcctc tggcacggaa gttctccgac 
  4291981 atatccgcca ttcccatttc aatagtttgc gtggcggcgt aatcacgcac ttcctggctg 
  4292041 attttcatcg agcagaattt cggcccacac atggagcaaa aatgggcgac tttacctgac 
  4292101 tcttgcggca gggtttcatc gtgataagcg cgggcggtaa acgggtcgag ggccagatta 
  4292161 aactggtctt cccagcgaaa ttcgaagcgg gctttcgaca tggcgttatc gcgaatttgc 
  4292221 gcgcccggat gccctttcgc caggtcagcg gcgtgggcag caatcttata ggtgataagc 
  4292281 ccctgcttaa catcttcttt attgggcaga cccagatgct cttttggcgt tacgtaacag 
  4292341 agcatcgcgc agccaaacca gccaatcatc gccgcaccaa tccccgacgt gaagtggtca 
  4292401 tagcccggcg caatatcggt agttagcggc cccagagtgt aaaacggcgc ttcgtggcag 
  4292461 tgctctaact cctcggtcat attgcggcgg atcatctgca tcggcacgtg gcctgggcct 
  4292521 tcaatcatca cctgcacgtc atattcccag gcaattttgg tcagttcgcc cagcgtatgc 
  4292581 agctcggcaa actgcgcttc atcgttggcg tcctgaatag aaccggggcg cagaccgtcg 
  4292641 cccagcgaca gcgaaacgtc ataagcggca cagatttcac aaatttcgcg gaagtgttga 
  4292701 tagaggaaat tttcctgatg atgggagagg caccatttcg ccataatcga accgccgcga 
  4292761 gagacgatac cggtcaggcg tttcgcggtc atcggcacat agcgcagcag tacgcccgca 
  4292821 tggatagtga agtaatccac accttgctcg gcctgttcca gcagcgtgtc gcggaacgct 
  4292881 tcccaggtaa gatcttcggc gatcccgtta accttctcca gcgcctggta gatcggcact 
  4292941 gtaccgatcg gcaccgggct gttacgcaaa atccactcgc gggtttcgtg aatatagcga 
  4293001 ccggtggaga gatccatcac cgtatccgct ccccagcgcg tggaccatac cagcttttcc 
  4293061 acttcttctt cgatggaaga ggtgaccgcc gagttgccga tattggcgtt aacttttacc 
  4293121 aggaaattgc gaccaataat catcggctcc gattccggat gattaatgtt ggccgggata 
  4293181 atcgcacgtc cggcagcaac ttcatcacgg acaaattccg cagtgatatt ttccggcaga 
  4293241 tgtgcgccaa agctcattcc cggatgctgg tggcgtaaaa cctcgctacg gatgcgctcg 
  4293301 cggcccatat tctcgcggat ggcgatgaat tccatttccg gcgtgatgat gccctggcgg 
  4293361 gcgtagtgca gttgggtgac acggcgtcct gctttggcgc gttttggtgt tagtacgccg 
  4293421 ctaaaacgca gttcgtcgag gccatcatct gccagccgcg ctttagtgta atcggaactg 
  4293481 cgcacggtaa gttcttcggt atcgccgcgc gcatcgatcc acggctggcg tagttttgcc 
  4293541 agcccttgct gcacgttaat ggcaatctgc ggatcaccat acgggccgga ggtgtcgtag 
  4293601 accggaatcg cttcgttttc ttcgtactgc ggctgttctt tgctaccgcc aattagcgtc 
  4293661 gggctaagct ggatctcacg catcggcacg cgcacgccgg ggtgtgtgcc agtgatataa 
  4293721 atgcgttttg agttgggaaa ggcggtgcct tccagggtgt cgataaaatg ttgggcccgg 
  4293781 gcgcgttgtt cgcggcgggt cagttttgtt gcagacatag ctcattccaa aaagttaagg 
  4293841 acgtggcttg tcagacgacg gatgaagcaa gagacgatcg ccgcaggggc gatgcgatag 
  4293901 cagattaact cttgttccct tcgcaggtat tagcctgatc aggttccgcg gatcccgaat 
  4293961 aaacggtctc agccagttaa ggcactccga caagaaatta gccccgcaaa tggggcattg 
 
Complementary DNA Sequence: Bold and underlined sequences are Riboswitch part. 
LOCUS       nameless                2100 bp                                    
ORIGIN       
   1 CAATGCCCCA TTTGCGGGGC TAATTTCTTG TCGGAGTGCC TTAACTGGCT GAGACCGTTT 
  61 ATTCGGGATC CGCGGAACCT GATCAGGCTA ATACCTGCGA AGGGAACAAG AGTTAATCTG 
 121 CTATCGCATC GCCCCTGCGG CGATCGTCTC TTGCTTCATC CGTCGTCTGA CAAGCCACGT 
 181 CCTTAACTTT TTGGAATGAG CTATGTCTGC AACAAAACTG ACCCGCCGCG AACAACGCGC 
 241 CCGGGCCCAA CATTTTATCG ACACCCTGGA AGGCACCGCC TTTCCCAACT CAAAACGCAT 
 301 TTATATCACT GGCACACACC CCGGCGTGCG CGTGCCGATG CGTGAGATCC AGCTTAGCCC 
 361 GACGCTAATT GGCGGTAGCA AAGAACAGCC GCAGTACGAA GAAAACGAAG CGATTCCGGT 
 421 CTACGACACC TCCGGCCCGT ATGGTGATCC GCAGATTGCC ATTAACGTGC AGCAAGGGCT 
 481 GGCAAAACTA CGCCAGCCGT GGATCGATGC GCGCGGCGAT ACCGAAGAAC TTACCGTGCG 
 541 CAGTTCCGAT TACACTAAAG CGCGGCTGGC AGATGATGGC CTCGACGAAC TGCGTTTTAG 
 601 CGGCGTACTA ACACCAAAAC GCGCCAAAGC AGGACGCCGT GTCACCCAAC TGCACTACGC 
 661 CCGCCAGGGC ATCATCACGC CGGAAATGGA ATTCATCGCC ATCCGCGAGA ATATGGGCCG 
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 721 CGAGCGCATC CGTAGCGAGG TTTTACGCCA CCAGCATCCG GGAATGAGCT TTGGCGCACA 
 781 TCTGCCGGAA AATATCACTG CGGAATTTGT CCGTGATGAA GTTGCTGCCG GACGTGCGAT 
 841 TATCCCGGCC AACATTAATC ATCCGGAATC GGAGCCGATG ATTATTGGTC GCAATTTCCT 
 901 GGTAAAAGTT AACGCCAATA TCGGCAACTC GGCGGTCACC TCTTCCATCG AAGAAGAAGT 
 961 GGAAAAGCTG GTATGGTCCA CGCGCTGGGG AGCGGATACG GTGATGGATC TCTCCACCGG 
1021 TCGCTATATT CACGAAACCC GCGAGTGGAT TTTGCGTAAC AGCCCGGTGC CGATCGGTAC 
1081 AGTGCCGATC TACCAGGCGC TGGAGAAGGT TAACGGGATC GCCGAAGATC TTACCTGGGA 
1141 AGCGTTCCGC GACACGCTGC TGGAACAGGC CGAGCAAGGT GTGGATTACT TCACTATCCA 
1201 TGCGGGCGTA CTGCTGCGCT ATGTGCCGAT GACCGCGAAA CGCCTGACCG GTATCGTCTC 
1261 TCGCGGCGGT TCGATTATGG CGAAATGGTG CCTCTCCCAT CATCAGGAAA ATTTCCTCTA 
1321 TCAACACTTC CGCGAAATTT GTGAAATCTG TGCCGCTTAT GACGTTTCGC TGTCGCTGGG 
1381 CGACGGTCTG CGCCCCGGTT CTATTCAGGA CGCCAACGAT GAAGCGCAGT TTGCCGAGCT 
1441 GCATACGCTG GGCGAACTGA CCAAAATTGC CTGGGAATAT GACGTGCAGG TGATGATTGA 
1501 AGGCCCAGGC CACGTGCCGA TGCAGATGAT CCGCCGCAAT ATGACCGAGG AGTTAGAGCA 
1561 CTGCCACGAA GCGCCGTTTT ACACTCTGGG GCCGCTAACT ACCGATATTG CGCCGGGCTA 
1621 TGACCACTTC ACGTCGGGGA TTGGTGCGGC GATGATTGGC TGGTTTGGCT GCGCGATGCT 
1681 CTGTTACGTA ACGCCAAAAG AGCATCTGGG TCTGCCCAAT AAAGAAGATG TTAAGCAGGG 
1741 GCTTATCACC TATAAGATTG CTGCCCACGC CGCTGACCTG GCGAAAGGGC ATCCGGGCGC 
1801 GCAAATTCGC GATAACGCCA TGTCGAAAGC CCGCTTCGAA TTTCGCTGGG AAGACCAGTT 
1861 TAATCTGGCC CTCGACCCGT TTACCGCCCG CGCTTATCAC GATGAAACCC TGCCGCAAGA 
1921 GTCAGGTAAA GTCGCCCATT TTTGCTCCAT GTGTGGGCCG AAATTCTGCT CGATGAAAAT 
1981 CAGCCAGGAA GTGCGTGATT ACGCCGCCAC GCAAACTATT GAAATGGGAA TGGCGGATAT 
2041 GTCGGAGAAC TTCCGTGCCA GAGGCGGAGA AATCTACCTG CGTAAGGAGG AAGCGTGATG 
 
Thiamin biosynthesis protein ThiC sequence 
>gi|169887498:4291721-4294220 Escherichia coli str. K12 substr. DH10B, complete genome 
ATAAACAATCGCGCGTTATAGCGGCGGCCCAGCGCAATTGCCGCCACGACATCGGCTTCCACCTCTTCAT 
CGCGCCGATCTTTGATGCGTAGCTGGAGAGTACGTACGCCTGCATCCAACAGACGTTCGATCCACTGTAC 
GCTGTCCACCACCGGGTACAGTCCTGAACGAAAAGGTACAGGAGGAAAATCAGGCTGATACATCACGCTT 
CCTCCTTACGCAGGTAGATTTCTCCGCCTCTGGCACGGAAGTTCTCCGACATATCCGCCATTCCCATTTC 
AATAGTTTGCGTGGCGGCGTAATCACGCACTTCCTGGCTGATTTTCATCGAGCAGAATTTCGGCCCACAC 
ATGGAGCAAAAATGGGCGACTTTACCTGACTCTTGCGGCAGGGTTTCATCGTGATAAGCGCGGGCGGTAA 
ACGGGTCGAGGGCCAGATTAAACTGGTCTTCCCAGCGAAATTCGAAGCGGGCTTTCGACATGGCGTTATC 
GCGAATTTGCGCGCCCGGATGCCCTTTCGCCAGGTCAGCGGCGTGGGCAGCAATCTTATAGGTGATAAGC 
CCCTGCTTAACATCTTCTTTATTGGGCAGACCCAGATGCTCTTTTGGCGTTACGTAACAGAGCATCGCGC 
AGCCAAACCAGCCAATCATCGCCGCACCAATCCCCGACGTGAAGTGGTCATAGCCCGGCGCAATATCGGT 
AGTTAGCGGCCCCAGAGTGTAAAACGGCGCTTCGTGGCAGTGCTCTAACTCCTCGGTCATATTGCGGCGG 
ATCATCTGCATCGGCACGTGGCCTGGGCCTTCAATCATCACCTGCACGTCATATTCCCAGGCAATTTTGG 
TCAGTTCGCCCAGCGTATGCAGCTCGGCAAACTGCGCTTCATCGTTGGCGTCCTGAATAGAACCGGGGCG 
CAGACCGTCGCCCAGCGACAGCGAAACGTCATAAGCGGCACAGATTTCACAAATTTCGCGGAAGTGTTGA 
TAGAGGAAATTTTCCTGATGATGGGAGAGGCACCATTTCGCCATAATCGAACCGCCGCGAGAGACGATAC 
CGGTCAGGCGTTTCGCGGTCATCGGCACATAGCGCAGCAGTACGCCCGCATGGATAGTGAAGTAATCCAC 
ACCTTGCTCGGCCTGTTCCAGCAGCGTGTCGCGGAACGCTTCCCAGGTAAGATCTTCGGCGATCCCGTTA 
ACCTTCTCCAGCGCCTGGTAGATCGGCACTGTACCGATCGGCACCGGGCTGTTACGCAAAATCCACTCGC 
GGGTTTCGTGAATATAGCGACCGGTGGAGAGATCCATCACCGTATCCGCTCCCCAGCGCGTGGACCATAC 
CAGCTTTTCCACTTCTTCTTCGATGGAAGAGGTGACCGCCGAGTTGCCGATATTGGCGTTAACTTTTACC 
AGGAAATTGCGACCAATAATCATCGGCTCCGATTCCGGATGATTAATGTTGGCCGGGATAATCGCACGTC 
CGGCAGCAACTTCATCACGGACAAATTCCGCAGTGATATTTTCCGGCAGATGTGCGCCAAAGCTCATTCC 
CGGATGCTGGTGGCGTAAAACCTCGCTACGGATGCGCTCGCGGCCCATATTCTCGCGGATGGCGATGAAT 
TCCATTTCCGGCGTGATGATGCCCTGGCGGGCGTAGTGCAGTTGGGTGACACGGCGTCCTGCTTTGGCGC 
GTTTTGGTGTTAGTACGCCGCTAAAACGCAGTTCGTCGAGGCCATCATCTGCCAGCCGCGCTTTAGTGTA 
ATCGGAACTGCGCACGGTAAGTTCTTCGGTATCGCCGCGCGCATCGATCCACGGCTGGCGTAGTTTTGCC 
AGCCCTTGCTGCACGTTAATGGCAATCTGCGGATCACCATACGGGCCGGAGGTGTCGTAGACCGGAATCG 
CTTCGTTTTCTTCGTACTGCGGCTGTTCTTTGCTACCGCCAATTAGCGTCGGGCTAAGCTGGATCTCACG 
CATCGGCACGCGCACGCCGGGGTGTGTGCCAGTGATATAAATGCGTTTTGAGTTGGGAAAGGCGGTGCCT 
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TCCAGGGTGTCGATAAAATGTTGGGCCCGGGCGCGTTGTTCGCGGCGGGTCAGTTTTGTTGCAGACATAG 
CTCATTCCAAAAAGTTAAGGACGTGGCTTGTCAGACGACGGATGAAGCAAGAGACGATCGCCGCAGGGGC 
GATGCGATAGCAGATTAACTCTTGTTCCCTTCGCAGGTATTAGCCTGATCAGGTTCCGCGGATCCCGAAT 
AAACGGTCTCAGCCAGTTAAGGCACTCCGACAAGAAATTAGCCCCGCAAATGGGGCATTGAATGTAAATT 
ACGCGTTAACAGCGCAGAACTCAAGCAGGATGTTTGACGCGGGCGGCGTCAAGCACCAGCAGAATCAGCT 
TATCTTCCAGCACAAAGCGCGCTTCCAGCGCCTCGCCGATGTCAGATAAAACCTGTTGAAACTCAAGGTA 
ATTATCATGATCGATGGCGGTTTCCAGACTGGAATCGTAGTAATCCATAA 
 
4291721-4294220 Escherichia coli str. K12 substr. DH10B 
Complementary DNA sequence: Blue: -35 and -10 promoter region, Red: riboswitch, Pink: start 
codon for transcription, Green: transcriptional part for thiamine biosynthetic protein 
 
TTATGGATTACTACGATTCCAGTCTGGAAACCGCCATCGATCATGATAATTACCTTGAGTTTCAACAGGTT
TTATCTGACATCGGCGAGGCGCTGGAAGCGCGCTTTGTGCTGGAAGATAAGCTGATTCTGCTGGTGCTTGA
CGCCGCCCGCGTCAAACATCCTGCTTGAGTTCTGCGCTGTTAACGCGTAATTTACATTCAATGCCCCATTT
GCGGGGCTAATTTCTTGTCGGAGTGCCTTAACTGGCTGAGACCGTTTATTCGGGATCCGCGGAACCTGATC
AGGCTAATACCTGCGAAGGGAACAAGAGTTAATCTGCTATCGCATCGCCCCTGCGGCGATCGTCTCTTGCT
TCATCCGTCGTCTGACAAGCCACGTCCTTAACTTTTTGGAATGAGCTATGTCTGCAACAAAACTGACCCGC
CGCGAACAACGCGCCCGGGCCCAACATTTTATCGACACCCTGGAAGGCACCGCCTTTCCCAACTCAAAACG
CATTTATATCACTGGCACACACCCCGGCGTGCGCGTGCCGATGCGTGAGATCCAGCTTAGCCCGACGCTAA
TTGGCGGTAGCAAAGAACAGCCGCAGTACGAAGAAAACGAAGCGATTCCGGTCTACGACACCTCCGGCCCG
TATGGTGATCCGCAGATTGCCATTAACGTGCAGCAAGGGCTGGCAAAACTACGCCAGCCGTGGATCGATGC
GCGCGGCGATACCGAAGAACTTACCGTGCGCAGTTCCGATTACACTAAAGCGCGGCTGGCAGATGATGGCC
TCGACGAACTGCGTTTTAGCGGCGTACTAACACCAAAACGCGCCAAAGCAGGACGCCGTGTCACCCAACTG
CACTACGCCCGCCAGGGCATCATCACGCCGGAAATGGAATTCATCGCCATCCGCGAGAATATGGGCCGCGA
GCGCATCCGTAGCGAGGTTTTACGCCACCAGCATCCGGGAATGAGCTTTGGCGCACATCTGCCGGAAAATA
TCACTGCGGAATTTGTCCGTGATGAAGTTGCTGCCGGACGTGCGATTATCCCGGCCAACATTAATCATCCG
GAATCGGAGCCGATGATTATTGGTCGCAATTTCCTGGTAAAAGTTAACGCCAATATCGGCAACTCGGCGGT
CACCTCTTCCATCGAAGAAGAAGTGGAAAAGCTGGTATGGTCCACGCGCTGGGGAGCGGATACGGTGATGG
ATCTCTCCACCGGTCGCTATATTCACGAAACCCGCGAGTGGATTTTGCGTAACAGCCCGGTGCCGATCGGT
ACAGTGCCGATCTACCAGGCGCTGGAGAAGGTTAACGGGATCGCCGAAGATCTTACCTGGGAAGCGTTCCG
CGACACGCTGCTGGAACAGGCCGAGCAAGGTGTGGATTACTTCACTATCCATGCGGGCGTACTGCTGCGCT
ATGTGCCGATGACCGCGAAACGCCTGACCGGTATCGTCTCTCGCGGCGGTTCGATTATGGCGAAATGGTGC
CTCTCCCATCATCAGGAAAATTTCCTCTATCAACACTTCCGCGAAATTTGTGAAATCTGTGCCGCTTATGA
CGTTTCGCTGTCGCTGGGCGACGGTCTGCGCCCCGGTTCTATTCAGGACGCCAACGATGAAGCGCAGTTTG
CCGAGCTGCATACGCTGGGCGAACTGACCAAAATTGCCTGGGAATATGACGTGCAGGTGATGATTGAAGGC
CCAGGCCACGTGCCGATGCAGATGATCCGCCGCAATATGACCGAGGAGTTAGAGCACTGCCACGAAGCGCC
GTTTTACACTCTGGGGCCGCTAACTACCGATATTGCGCCGGGCTATGACCACTTCACGTCGGGGATTGGTG
CGGCGATGATTGGCTGGTTTGGCTGCGCGATGCTCTGTTACGTAACGCCAAAAGAGCATCTGGGTCTGCCC
AATAAAGAAGATGTTAAGCAGGGGCTTATCACCTATAAGATTGCTGCCCACGCCGCTGACCTGGCGAAAGG
GCATCCGGGCGCGCAAATTCGCGATAACGCCATGTCGAAAGCCCGCTTCGAATTTCGCTGGGAAGACCAGT
TTAATCTGGCCCTCGACCCGTTTACCGCCCGCGCTTATCACGATGAAACCCTGCCGCAAGAGTCAGGTAAA
GTCGCCCATTTTTGCTCCATGTGTGGGCCGAAATTCTGCTCGATGAAAATCAGCCAGGAAGTGCGTGATTA
CGCCGCCACGCAAACTATTGAAATGGGAATGGCGGATATGTCGGAGAACTTCCGTGCCAGAGGCGGAGAAA
TCTACCTGCGTAAGGAGGAAGCGTGATGTATCAGCCTGATTTTCCTCCTGTACCTTTTCGTTCAGGACTGT
ACCCGGTGGTGGACAGCGTACAGTGGATCGAACGTCTGTTGGATGCAGGCGTACGTACTCTCCAGCTACGC
ATCAAAGATCGGCGCGATGAAGAGGTGGAAGCCGATGTCGTGGCGGCAATTGCGCTGGGCCGCCGCTATAA
CGCGCGATTGTTTAT 
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pBAD33 Sequence 
source          1..5376 
ORIGIN     BASE COUNT     1355 a   1365 c   1276 g   1380 t 
   1 atcgatgcat aatgtgcctg tcaaatggac gaagcaggga ttctgcaaac cctatgctac 
  61 tccgtcaagc cgtcaattgt ctgattcgtt accaattatg acaacttgac ggctacatca 
 121 ttcacttttt cttcacaacc ggcacggaac tcgctcgggc tggccccggt gcatttttta 
 181 aatacccgcg agaaatagag ttgatcgtca aaaccaacat tgcgaccgac ggtggcgata 
 241 ggcatccggg tggtgctcaa aagcagcttc gcctggctga tacgttggtc ctcgcgccag 
 301 cttaagacgc taatccctaa ctgctggcgg aaaagatgtg acagacgcga cggcgacaag 
 361 caaacatgct gtgcgacgct ggcgatatca aaattgctgt ctgccaggtg atcgctgatg 
 421 tactgacaag cctcgcgtac ccgattatcc atcggtggat ggagcgactc gttaatcgct 
 481 tccatgcgcc gcagtaacaa ttgctcaagc agatttatcg ccagcagctc cgaatagcgc 
 541 ccttcccctt gcccggcgtt aatgatttgc ccaaacaggt cgctgaaatg cggctggtgc 
 601 gcttcatccg ggcgaaagaa ccccgtattg gcaaatattg acggccagtt aagccattca 
 661 tgccagtagg cgcgcggacg aaagtaaacc cactggtgat accattcgcg agcctccgga 
 721 tgacgaccgt agtgatgaat ctctcctggc gggaacagca aaatatcacc cggtcggcaa 
 781 acaaattctc gtccctgatt tttcaccacc ccctgaccgc gaatggtgag attgagaata 
 841 taacctttca ttcccagcgg tcggtcgata aaaaaatcga gataaccgtt ggcctcaatc 
 901 ggcgttaaac ccgccaccag atgggcatta aacgagtatc ccggcagcag gggatcattt 
 961 tgcgcttcag ccatactttt catactcccg ccattcagag aagaaaccaa ttgtccatat 
1021 tgcatcagac attgccgtca ctgcgtcttt tactggctct tctcgctaac caaaccggta 
1081 accccgctta ttaaaagcat tctgtaacaa agcgggacca aagccatgac aaaaacgcgt 
1141 aacaaaagtg tctataatca cggcagaaaa gtccacattg attatttgca cggcgtcaca 
1201 ctttgctatg ccatagcatt tttatccata agattagcgg atcctacctg acgcttttta 
1261 tcgcaactct ctactgtttc tccatacccg tttttttggg ctagcgaatt cgagctcggt 
1321 acccggggat cctctagagt cgacctgcag gcatgcaagc ttggctgttt tggcggatga 
1381 gagaagattt tcagcctgat acagattaaa tcagaacgca gaagcggtct gataaaacag 
1441 aatttgcctg gcggcagtag cgcggtggtc ccacctgacc ccatgccgaa ctcagaagtg 
1501 aaacgccgta gcgccgatgg tagtgtgggg tctccccatg cgagagtagg gaactgccag 
1561 gcatcaaata aaacgaaagg ctcagtcgaa agactgggcc tttcgtttta tctgttgttt 
1621 gtcggtgaac gctctcctga gtaggacaaa tccgccggga gcggatttga acgttgcgaa 
1681 gcaacggccc ggagggtggc gggcaggacg cccgccataa actgccaggc atcaaattaa 
1741 gcagaaggcc atcctgacgg atggcctttt tgcgtttcta caaactcttt tgtttatttt 
1801 tctaaataca ttcaaatatg tatccgctca tgagacaata accctgataa atgcttcaat 
1861 aatattgaaa aaggaagagt atgagtattc aacatttccg tgtcgccctt attccctttt 
1921 ttgcggcatt ttgccttcct gtttttgctc acccagaaac gctggtgaaa gtaaaagatg 
1981 ctgaagatca gttgggtgca ctgcgcaaac tattaactgg cgaactactt actctagctt 
2041 cccggcaaca attaatagac tggatggagg cggataaagt tgcaggacca cttctgcgct 
2101 cggcccttcc ggctggctgg tttattgctg ataaatctgg agccggtgag cgtgggtctc 
2161 gcggtatcat tgcagcactg gggccagatg gtaagccctc ccgtatcgta gttatctaca 
2221 cgacggggag tcaggcaact atggatgaac gaaatagaca gatcgctgag ataggtgcct 
2281 cactgattaa gcattggtaa ctgtcagacc aagtttactc atatatactt tagattgatt 
2341 tacgcgccct gtagcggcgc attaagcgcg gcgggtgtgg tggttacgcg cagcgtgacc 
2401 gctacacttg ccagcgccct agcgcccgct cctttcgctt tcttcccttc ctttctcgcc 
2461 acgttcgccg gctttccccg tcaagctcta aatcgggggc tccctttagg gttccgattt 
2521 agtgctttac ggcacctcga ccccaaaaaa cttgatttgg gtgatggttc acgtagtggg 
2581 ccatcgccct gatagacggt ttttcgccct ttgacgttgg agtccacgtt ctttaatagt 
2641 ggactcttgt tccaaacttg aacaacactc aaccctatct cgggctattc ttttgattta 
2701 taagggattt tgccgatttc ggcctattgg ttaaaaaatg agctgattta acaaaaattt 
2761 aacgcgaatt ttaacaaaat attaacgttt acaatttaaa aggatctagg tgaagatcct 
2821 ttttgataat ctcatgacca aaatccctta acgtgagttt tcgttccact gagcgtcaga 
2881 ccccgtagaa aagatcaaag gatcttcttg agatcctttt tttctgcgcg taatctgctg 
2941 cttgcaaaca aaaaaaccac cgctaccagc ggtggtttgt ttgccggatc aagagctacc 
3001 aactcttttt ccgaaggtaa ctggcttcag cagagcgcag ataccaaata ctgtccttct 
3061 agtgtagccg tagttaggcc accacttcaa gaactctgta gcaccgccta catacctcgc 
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3121 tctgctaatc ctgttaccag tggctgcctc aggcatttga gaagcacacg gtcacactgc 
3181 ttccggtagt caataaaccg gtaaaccagc aatagacata agcggctatt taacgaccct 
3241 gccctgaacc gacgaccggg tcgaatttgc tttcgaattt ctgccattca tccgcttatt 
3301 atcacttatt caggcgtagc accaggcgtt taagggcacc aataactgcc ttaaaaaaat 
3361 tacgccccgc cctgccactc atcgcagtac tgttgtaatt cattaagcat tctgccgaca 
3421 tggaagccat cacagacggc atgatgaacc tgaatcgcca gcggcatcag caccttgtcg 
3481 ccttgcgtat aatatttgcc catggtgaaa acgggggcga agaagttgtc catattggcc 
3541 acgtttaaat caaaactggt gaaactcacc cagggattgg ctgagacgaa aaacatattc 
3601 tcaataaacc ctttagggaa ataggccagg ttttcaccgt aacacgccac atcttgcgaa 
3661 tatatgtgta gaaactgccg gaaatcgtcg tggtattcac tccagagcga tgaaaacgtt 
3721 tcagtttgct catggaaaac ggtgtaacaa gggtgaacac tatcccatat caccagctca 
3781 ccgtctttca ttgccatacg gaattccgga tgagcattca tcaggcgggc aagaatgtga 
3841 ataaaggccg gataaaactt gtgcttattt ttctttacgg tctttaaaaa ggccgtaata 
3901 tccagctgaa cggtctggtt ataggtacat tgagcaactg actgaaatgc ctcaaaatgt 
3961 tctttacgat gccattggga tatatcaacg gtggtatatc cagtgatttt tttctccatt 
4021 ttagcttcct tagctcctga aaatctcgat aactcaaaaa atacgcccgg tagtgatctt 
4081 atttcattat ggtgaaagtt ggaacctctt acgtgccgat caacgtctca ttttcgccaa 
4141 aagttggccc agggcttccc ggtatcaaca gggacaccag gatttattta ttctgcgaag 
4201 tgatcttccg tcacaggtat ttattcggcg caaagtgcgt cgggtgatgc tgccaactta 
4261 ctgatttagt gtatgatggt gtttttgagg tgctccagtg gcttctgttt ctatcagctg 
4321 tccctcctgt tcagctactg acggggtggt gcgtaacggc aaaagcaccg ccggacatca 
4381 gcgctagcgg agtgtatact ggcttactat gttggcactg atgagggtgt cagtgaagtg 
4441 cttcatgtgg caggagaaaa aaggctgcac cggtgcgtca gcagaatatg tgatacagga 
4501 tatattccgc ttcctcgctc actgactcgc tacgctcggt cgttcgactg cggcgagcgg 
4561 aaatggctta cgaacggggc ggagatttcc tggaagatgc caggaagata cttaacaggg 
4621 aagtgagagg gccgcggcaa agccgttttt ccataggctc cgcccccctg acaagcatca 
4681 cgaaatctga cgctcaaatc agtggtggcg aaacccgaca ggactataaa gataccaggc 
4741 gtttccccct ggcggctccc tcgtgcgctc tcctgttcct gcctttcggt ttaccggtgt 
4801 cattccgctg ttatggccgc gtttgtctca ttccacgcct gacactcagt tccgggtagg 
4861 cagttcgctc caagctggac tgtatgcacg aaccccccgt tcagtccgac cgctgcgcct 
4921 tatccggtaa ctatcgtctt gagtccaacc cggaaagaca tgcaaaagca ccactggcag 
4981 cagccactgg taattgattt agaggagtta gtcttgaagt catgcgccgg ttaaggctaa 
5041 actgaaagga caagttttgg tgactgcgct cctccaagcc agttacctcg gttcaaagag 
5101 ttggtagctc agagaacctt cgaaaaaccg ccctgcaagg cggttttttc gttttcagag 
5161 caagagatta cgcgcagacc aaaacgatct caagaagatc atcttattaa tcagataaaa 
5221 tatttctaga agcgctcatg agcccgaagt ggcgagcccg atcttcccca tcggtgatgt 
5281 cggcgatata ggcgccagca accgcacctg tggcgccggt gatgccggcc acgatgcgtc 
5341 cggcgtagag gatctgctca tgtttgacag cttatc 
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Protein Sequences for Expression and solubility  
 
RutF sequence  
>fig|83333.1.peg.995 [Escherichia coli K12] [Predicted flavin reductase RutF in novel 
pyrimidine catabolism pathway] 
ATGAACATTGTCGATCAACAAACTTTTCGCGATGCGATGTCCTGCATGGGCGCGGCGGTCAATATTATCAC
CACGGACGGTCCAGCCGGGCGCGCCGGGTTCACCGCCAGCGCCGTCTGCAGTGTGACCGATACGCCGCCCA
CATTACTGGTGTGCCTGAATCGTGGGGCGTCCGTCTGGCCGGCATTCAATGAAAATCGAACGCTGTGTGTA
AATACACTTAGCGCCGGGCAGGAGCCGCTTTCAAACCTTTTTGGCGGCAAAACGCCCATGGAACACCGCTT
TGCCGCCGCCCGCTGGCAGACGGGGGTGACCGGATGCCCGCAACTGGAAGAGGCTCTGGTTTCGTTTGACT
GCCGTATCAGCCAGGTGGTGAGCGTCGGCACCCACGACATTCTGTTTTGCGCCATCGAAGCGATTCATCGT
CACACCACACCCTACGGGCTGGTGTGGTTCGATCGCAGTTATCACGCGCTGATGCGCCCTGCTTGTTAA 
 
BLG sequence 
ATGAAATGTCTGCTGCTGGCGCTGGCCCTGACCTGCGGTGCGCAGGCCCTGATTGTGACCCAGACCATGAA
AGGCCTGGATATTCAGAAAGTGGCGGGTACCTGGTATAGCCTGGCCATGGCGGCGAGCGATATTAGCCTGC
TGGATGCGCAGAGCGCGCCGCTGCGTGTGTATGTTGAAGAACTGAAACCGACCCCGGAAGGCGATCTGGAA
ATTCTGCTGCAGAAATGGGAAAACGGCGAATGCGCGCAGAAAAAAATTATCGCGGAAAAAACCAAAATTCC
GGCGGTGTTTAAAATTGATGCGCTGAATGAAAACAAAGTGCTGGTGCTGGATACCGATTATAAAAAATATC
TGCTGTTTTGCATGGAAAATAGCGCGGAACCGGAACAGAGCCTGGCGTGCCAGTGTCTGGTGCGCACCCCG
GAAGTGGATGATGAAGCCCTGGAAAAATTTGATAAAGCGCTGAAAGCGCTGCCGATGCATATTCGCCTGAG
CTTTAATCCGACCCAGCTGGAAGAACAGTGTCACATTTAA 
 
 
 
Figure D.3: Sequences used in Chapter V 
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• 10kb A  PCR product (Whole vio opron) 
–  VioA: 97% identity 3e-45 
–  CV3269 92% identity, 7e-126 E value 
• ~5kb PCR product 
–  vioA  98% identity 4e-46 
–  cv3269 84% identity 1e-8 
–  VioBCF 91% identity 7e-17 (vioC 82%, VioB 97%) 
–  vioB  97% identity 2e-172  
• ~10kb size from ~5kb+~5kb (Whole vio operon) 
– Cv3269 97% identity 2e-120 
– VioA 97% identity 2e-55 
• Original violet colored colony (mini-prep) (Lac+Native) 
– Oriv3269LFS : CV3269: 93% Identity 4e-122 
– O3276RLS: VioA, 90% identity 1e-96 
• V1(best results) (Lac+Native) 
– V13269LFS: CV3269, 99% Identity 1e-122 
– V13275RLS: vioA, 99% Identity 8e-91 
• V2 (Lac+Native) 
– V23269LFS: CV3269, 99% Identity 3e-120 
– V23275RLS: vioA, 73% Identity 9e-67 
• V5 violet colored colony (mini-prep) (Lac+Native) 
– AF :vioA, 99% Identity 4e-122 
– BF: vioB, 99% Identity 1e-122 
– BR: vioB, 99% Identity 8e-91 
– CF: vioC, 99% Identity 3e-120 
– CR: vioC, 99% Identity 9e-67 
– DF: vioD, 99% Identity 1e-122 
– DR: vioD, 99% Identity 8e-91 
– EF: vioE, % Identity 3e-120 
– ER: vioE, % Identity 9e-67 
– All operon was in the vector (TOPO) 
• RV8: colored clone from riboswitch in TOPO plasmid without native promoter (lac promoter + 
riboswitch) 
– M13R: 3e-152  96% Identity VioA  
– M13F: 2e-153  99% Identity CV3269  
– VioAF: 1e-138  99% Identity VioA  
– CV3269: 8e-120 98% Identity VioA  
• V4D1 (pETBlue-2 + vio operon) 
– vioAF: 2e-118  99% identity   VioA  
– CV3269 : 4e-118 99% identity  CV3269 in chromobacterium violaceum ATCC12472 
• RutF 
– FRutF: 98% identity 
– RRutF: 94% identity 
• Riboswitch 
– 100% Identity  
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Riboswitch sequence (100% match) 
 
 
 
Figure D.4: Sequencing results with PCR products 
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At 585nm 
 
 
 
 
  
 
Figure D.5: UV-Vis DATA 
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V7 MS crude cell extract (E. coli)  
 
 
V5 MS crude cell extract (E. coli) 
 
 
 
 
 
 
Figure D.6: MS Spectra data of Violacein 
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Sampled was dissolved in 10% Acetnitile (ACN) 
Detected at 168-575nm 
Gradient 4 min 10% ACN 90% Water  88% ACN in 30min then 100% CAN 
Flow rate 0.5ml/min 
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Anlytical vs prep HPLC 
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Figure D.7: HPLC spectra of violacein 
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(1) TIC (ESI-APCI-Positive mode) (red trace)  UV 220NM ( pink trace)  
       A: 0.2% Formic acid water  B: 0.14% formic acid Acetonitrile 
       Gradient 5 100% B in 45min  
03_M2_VIO.D: TIC +All MS
03_M2_VIO.D: UV Chromatogram, 218-222 nm
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Figure D.8: LCMS spectra of violacein 
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Figure D.9: MALDI MS spectra of violacein 
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1
H  NMR 500MHz  (used 5mm BB/H probe) 
 
 
1
H  NMR 500MHz  (used 3mm BB/H probe) >7ppm  
 
 
1
H-
1
H COSY 2D NMR (used 3mm tube) >7ppm 
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Figure D.10: NMR spectra of violacein 
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Standard Curve 
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Figure D.11: Violacein production supplementary data 
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Figure D.12: Tabulated data of violacein production under various promoter 
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ThiC+Ribo  3121740  3.198  
0.5mM TPP  2637494  2.713  
1.0mM TPP  2388635  2.464  
1.5mM TPP  887811  0.964  
2.0mM TPP  616711  0.693  
2.5mM TPP  430717  0.507  
3.0mM TPP  499072  0.575  
5.0mM TPP  155624  0.231  
ThiC+Ribo  3089760  3.166  
0.5mM TPP  2526476  2.602  
1.0mM TPP  2184841  2.261  
1.5mM TPP  1577464  1.653  
2.0mM TPP  477161  0.553  
2.5mM TPP  473124  0.549  
3.0mM TPP  529531  0.605  
5.0mM TPP  417570  0.493  
 
 
 
 
Figure D.13: Tabulated Data for violacein production under ThiC/Riboswitch in 
the presence of TPP 
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Insertion check 
 
 
pV4(MluI-SpeI)Topo construction 
: (Lac promoter + Violacein without native promoter part) 
 
 
SpeI-XhoI violacein operon (no Native promoter region)  
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Lac+Riboswitch construction: 
A: Riboswitch insert after MluI-SpeI digestion B: After ligation with Riboswitch and MluI-SpeI 
digested Topo XL vector which containing violacein operon to remove native promoter part 
(MluI-SpeI) 
A:                                                                 B: 
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Vector manipulation for different construction with various promoters 
 
 
 
 
TPP+Riboswitch+Vio operon (no Native promoter) 
 
 
                                                                                                       After gel extraction 
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IPTG effect check with Lac+Native and Lac+Riboswitch systems 
 
 
 
 
 
Expression of violacein in E.coli with Lac+Native promoter 
 
 
 
      
 
 
 
  
244 
 
β-Galactosidase PCR product and DNA recovery after gel extraction 
 
 
 
  After transformation into Top 10 
 
              
 
 
Sequencing results 
• pBAD33+LacZ 
– 20ul PCR reaction :~60% identity 
– 3ul PCR reaction: 99% identity 
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BLG protein  
 
PCR 
 
 
 
 
 
Figure D.14: Supplementary data of Gene manipulation 
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Predicted flavin reductase RutF in novel pyrimidine catabolism pathway 
 
 
 
 
            
 
15%  SDS-PAGE gel 
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 Western blot gel 
 
 
 
Figure D.15: Supplementary Data for Gene manipulations of the Insoluble Proteins 
RutF 
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– Violacein operon has been checked  for T7 terminator 
• Found similar T7 terminator sequence (7932-7978) after native 
promotor (MluI~SpeI site) 
 
 
 
Looks like hair-pin shape: 
 
 
 
Figure D.16: Evaluation of T7 Promoter function with RutF protein 
  
250 
VITA 
 
 
Name:                 Eun Jin Kim 
Address:               Chemistry Department, Texas A&M University, College Station, TX  
                             77843  Mail stop 3255 
Email Address:     kejin11@hotmail.com 
Education:      B. S.  Chemical Education, Korea National Univeristy of Education,   
                              1993 
                              M. S. Chemistry, Korea National University of Education, 1995 
    M. S. Chemistry, Texas A&M University, 2004 
       Ph. D.  Chemistry, Texas A&M University, 2009 
 
 
 
 
